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Abstract
Asthma is a chronic inflammatory disease of the airways, resulting in significant
morbidity and premature deaths. Rhinoviruses, agents of the common cold,
have been identified as the most frequent viruses inducing asthma exacerbations.
However the mechanisms involved in this process, especially in moderate-to-severe
asthmatics, are not clear. IL-17, a protein secreted by Th17 and IL-17+γδ T
cells, is found to be up-regulated in asthmatics and correlates with severity of
disease. Observations from a clinical study of rhinovirus infection showed increased
induction of IL-17 in nasal lavage fluid from asthmatics following experimental
rhinovirus infection compared to healthy controls. Using mouse models, this
thesis addresses the interactions of rhinovirus with IL-17 in the context of allergic
airways disease.
Primary infection of C57BL/6 mice did not induce IL-17 responses as seen
in human subjects; this may be explained by the apparent lack of induction
of IL-23 following primary infection in mice. Supplementation of rhinovirus
infection with recombinant IL-17 showed significant, selective increases in neu-
trophil chemokines with subsequent increases in both neutrophil recruitment and
activation, as defined by myeloperoxidase activity. In an existing Th2-driven
model of allergic airways disease, rhinovirus was seen to selectively expand Th2
responses while not increasing allergen-induced Th17, IL-17+γδ T cells or IL-17.
However, rhinovirus infection in a Th17-driven model of allergic airways disease
showed a significant increase of neutrophil numbers with a concomitant increase
in airway hyperresponsiveness.
This work augments existing knowledge on rhinovirus exacerbation of Th2-
mediated asthma with the interactions between Th17 and rhinovirus, which may
play a significant role in moderate-to-severe asthma exacerbations. This supports
current research on therapeutic targeting of the IL-17 pathway in asthmatics.
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PMA Phorbol-Myristate-Acetate
qPCR (Quantitative) real time PCR
RANTES Regulated on Activation, Normal T cell Expressed and Secreted
(chemokine)
RAR Retinoic Acid Receptor
rIL-17 Recombinant Interleukin 17
RNA Riboxynucleic acid
RORγt RAR-related Orphan Receptor Gamma (Thymus orphan recep-
tor)
rpm Revolutions per minute
RPMI Roswell Park Memorial Institute media
RSV Respiratory Syncytial Virus
RV(1B) Rhinovirus (serotype 1B)
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Abbreviations
SABA Short-Acting β2 Agonist
SAM Synthetic Absorptive Matrix
SD Standard Deviation
SEM Standard Error of the Mean
SFB Segmented Filamentous Bacteria
SOC Super Optimal broth with Catabolite repression
SSC Side Scatter
STAT Signal Transducers and Activator of Transcription
Te Expiratory Time
Treg Regulatory T cell
Tr Relaxation Time
TAMRA Tetramethylrhodamin
TARC Thymus and Activation-Related Chemokine
TCID50 50% Tissue-Culture Infective Dose
TCR T Cell Receptor
TGFβ Transforming Growth Factor β
Th1, Th2, Th17 T Helper cell type 1, type 2, type 17
TLR Toll-Like Receptors
TMB 3,3’,5,5’-Tetramethylbenzidine
TNFα Tumour Necrosis Factor α
TSLP Thymic Stromal Lymphopoietin
U Units (of enzymatic activity)
UV Ultraviolet light
UV-RV UV-inactivated Rhinovirus
v/v Volume by Volume
VP Viral Protein
w/v Weight by Volume
WBP Whole Body Plethysmography
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1 Introduction
1.1 Asthma
1.1.1 Prevalence
Asthma affects approximately 300 million individuals worldwide, and has been
estimated to cause the loss of 15 million disability-adjusted life years (DALYs)
and 250,000 lives annually. Asthma prevalence is not uniform between countries;
the greatest incidence occurs in industrialised nations. However this variation
is reducing as numbers increase in developing areas of Asia, Africa and Latin
America, possibly as a result of greater awareness and diagnosis, as well as a
poorly understood influence of industrialisation on the incidence of allergic disease
(Global Initiative for Asthma, 2012). Yet prevalence of asthma does not correlate
with mortality rates, with over 80% of deaths occurring in low and lower-middle
income countries, in part due to worse access to essential drugs and healthcare
(World Health Organisation, 2011). It is estimated that up to 90% of these
deaths are preventable, caused by a failure of both long term care and assistance
during the final exacerbation (Global Initiative for Asthma, 2012). In addition to
morbidity and mortality, asthma also affects the daily lives of patients with loss
of sleep and curtailing of physical activities, with severe asthmatics describing
their disease with the words ‘breathlessness’, ‘suffocation’ and ‘fear’ (European
Federation of Allergy and Airway Diseases Patients’ Associations, 2004).
The UK has one of the highest incidences of asthma in the world, with 5.4
million people having a diagnosis, although the rate of increase plateaued during
the 1990s. 1,143 deaths from asthma occurred in 2010, of which 16 were of
individuals aged 14 or under (Asthma UK, 2013). The costs of asthma treatment
are estimated at approximately £1 billion a year to the NHS, consisting of £850
million for drugs and £61 million for emergency adult admissions, of which there
were 49,054 in 2010/11 (NHS, 2011). The cost of treatment for a patient who
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suffers at least one asthma exacerbation per year is estimated at over 3.5 times
that for a patient that does not (Hoskins et al., 2000). In 2008/09, 1.1 million
working days were lost due to breathing or lung problems (Asthma UK, 2013).
1.1.2 Definition and diagnosis
As the heterogeneity of asthmatic disease is becoming recognised, asthma is
understood to be an umbrella term for a range of diseases that have different
underlying causes but with the same clinical outcome. It is defined by the Global
Initiative for Asthma (GINA):
“Asthma is a chronic inflammatory disorder of the airways in which
many cells and cellular elements play a role. The chronic inflammation
is associated with airway hyperresponsiveness that leads to recurrent
episodes of wheezing, breathlessness, chest tightness, and coughing,
particularly at night or in the early morning. These episodes are
usually associated with widespread, but variable, airflow obstruction
within the lung that is often reversible either spontaneously or with
treatment.”
(Bateman et al., 2008)
Currently, diagnosis of asthma is made mainly on the basis of clinical pre-
sentation and patient history, with lung function measured by spirometry or
peak expiratory flow (PEF) (Map of Medicine, 2013). Patients present with
intermittent exacerbations and worsening of otherwise mild symptoms, showing
a tendency to be worse in the morning with cough at night. History includes
personal and familial history of atopic conditions such as eczema and allergic
rhinitis (as well as asthma), occupation and housing conditions where exposure
to allergen or irritants may occur. Spirometry, allowing the measurement of
forced expiratory volume in one second (FEV1), is used to assess the presence
and severity of airways obstruction and to exclude differential diagnoses such as
chronic obstructive pulmonary disease (COPD), which is defined by non-reversible,
progressive loss of lung function.
1.1.3 Pathogenesis
Typically, asthma is an atopic condition driven by immune responses to inhaled
allergens. It has been classically seen as a T helper type 2 (Th2) driven disease,
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typified by the Th2 cytokines in the airways (IL-4, IL-5, IL-13) which lead to
increased eosinophilia and goblet cell numbers in the lung with high circulating
IgE antibody, both total and allergen-specific. Even at baseline, these mediators
are present and contribute to chronic inflammation of the lung.
Upon inhalation of allergen, IgE mediates signalling through crosslinking of
IgE receptors on mucosa-resident mast cells, which rapidly release pre-formed
histamine and other mediators, such as leukotrienes. Histamine quickly causes
dilation of blood vessels and tissue oedema, leading to swelling and obstruction of
the airways and reduction in lung function. Leukotrienes promote inflammation
and contraction of the smooth muscles in the airways, adding to the effects of
histamine. Additional eosinophils are also recruited into the lung tissue and
airways, where they release mediators that again increase inflammation as well
as damaging the epithelium and contributing to remodelling of the airways,
involving goblet cell hyperplasia, basement membrane thickening and smooth
muscle hyperplasia (Hamid et al., 2003). Goblet cells secrete mucins which
compound airway obstruction, and in severe cases can lead to full occlusion with
mucus plugs, a common finding in fatal asthma exacerbations (Carroll et al.,
2002).
However, not all asthmatics are seen to be atopic, as even studies with the
highest detection rates still show only 72% (mean 54%) or 89% (mean 50%) of
asthmatics are atopic by skin prick test or total serum IgE, respectively (Pearce
et al., 1999). Additionally, neutrophils are also seen in association with asthma,
especially in those with more severe and steroid refractory disease (MacDowell
and Peters, 2007). Taken together, it is becoming clear that although atopy and
Th2 responses are important in many asthmatics, other mechanisms are at play
in different subsets of patients.
The Th1/Th2 hypothesis of adaptive T cell responses has been a mainstay
in immunology for many years, but in the past decade it has become clear that
additional subsets exist with their own distinct cytokines and roles. Th17 cells,
which are identified by their ability to secrete IL-17, appear to fill a gap in
the normal immune defence against fungi, which are poorly controlled by Th1
and Th2 responses, through promotion of neutrophil responses (cf. Th2 and
eosinophil responses; Curtis and Way 2009). Thus, the existence of neutrophilic
asthmatics has led to the investigation of Th17 cells in asthma pathogenesis. IL-17
has been shown to be higher in the lungs of asthmatics (Al-Ramli et al., 2009;
Doe et al., 2010) by immunohistochemistry staining and mRNA expression, and
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circulating Th17 are higher in peripheral blood (Zhao et al., 2010), in both cases
correlating with severity of disease. Levels of sputum IL-17 also correlate with
airway hyperresponsiveness in asthmatics (Barczyk et al., 2003). This growing
body of evidence demonstrates asthma as a more complex, heterogeneous disease
than previously thought, especially with regards severe and neutrophilic asthmatic
patients.
1.1.4 Classification of asthmatic disease
Asthmatic patients can be subdivided by several different systems for both clinical
and scientific requirements. Upon presentation and before beginning treatment,
patients can be stratified by severity into intermittent, mild persistent, moderate
persistent or severe persistent. A more useful clinical categorisation is based on
current symptoms and lung function, defining controlled, partially controlled or
uncontrolled asthmatics. This system can assist in achieving good control of
symptoms and reduction of future exacerbations (Global Initiative for Asthma,
2012).
Further testing can be undertaken both for diagnosis as well as screening for
clinical studies. Commonly, identification of the allergens to which a patient
is sensitised will be assessed by skin prick tests. Clinically this can help with
avoidance of exacerbation triggers; however response to a known allergen is
only seen in approximately 72% of asthmatics (Pearce et al., 1999), leading to
distinction between extrinsic (atopic) and intrinsic (non-atopic) asthmatics. The
level of airway hyperresponsiveness (AHR) can be assessed by challenge with
bronchoconstrictants such as methacholine or histamine, with the dose required
to reduce FEV1 to 20% below baseline, expressed as provocative concentration
(PC20). Classification can also be made by counting cell types in induced sputum,
with eosinophils being the ‘classical’ asthma inflammatory cell. However, the
heterogeneity of patients had led to a suggested classification into eosinophilic,
neutrophilic, mixed granulocytic and paucigranulocytic subtypes (Simpson et al.,
2006).
1.1.5 Aetiology
Asthma, like other atopic conditions, has a strong genetic linkage estimated to
be between 35% and 95%. In agreement with the major role of Th2 responses in
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asthma, many of the genes differentially-expressed in asthmatics are associated
with Th2 cells including IL-33, TSLP and ST2 (a subunit of the IL-33 receptor)
(Ober and Yao, 2011). Genome-wide association studies (GWAS) have also
highlighted other genetic associations not directly related to known pathogenic
mechanisms in asthma, such as ORMDL3 which did not have a known function
when first identified (Moffatt et al., 2007). In concert, environmental factors are
also known to play a role in precipitating asthma. Exposure to allergen in early
life is likely to sensitise a susceptible individual to subsequent challenge. Many
environmental allergens are well studied, such as pollens, cat dander and house
dust mite faeces, as well as occupational allergens such as flour (bakers) and
toluene (factory workers) (Nicholson PJ, 2010).
In trying to explain the dramatic rise in atopic diseases (including asthma) in
developed compared to developing nations over the past decades, the notable
difference in exposure to parasites and other infectious agents has led to the
‘hygiene hypothesis’ (Okada et al., 2010; Strachan, 1989). This states that the
lack of chronic parasite infections, which can suppress Th2 cells as a defence
mechanism, leads to overpronounced Th2 reponses to innocuous enviromental
antigens. Additionally, the lack of pathogen exposure in early life may cause poor
development of both regulatory T cell (Treg) and CD8
+ T cell responses which are
unable to suppress these Th2 responses (Noble, 2009). The hypothesis is supported
by the documented protective effect of parasite infection against development
of allergies (Feary et al., 2011). Even in developed countries, there is a marked
decrease in the incidence of atopic disease in children growing up on farms versus
urban areas (Kabesch and Lauener, 2004) and a negative correlation of atopic
prevalence with environmentally-derived LPS exposure (Braun-Fahrla¨nder et al.,
2002).
Over the last few decades it has also become clear that severe respiratory viral
infections in childhood predispose to development of asthma in later life, and in
atopic individuals viral infection increases the risk of subsequent asthma over
10-fold (Holt and Sly, 2012). Respiratory syncytial virus (RSV) was initially
shown to be an important causative agent in early life wheeze and subsequent
asthma (reviewed in Mohapatra and Boyapalle, 2008), however later investigations
have shown that rhinovirus also has an important role in asthma induction, to
a similar degree as RSV (Holt et al., 2012). The mechanisms involved in these
early life events remain incompletely understood.
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1.1.6 Current asthma therapy
Treatments for asthma are aimed at controlling airways inflammation and reversing
bronchoconstriction when it occurs. The aim for newly diagnosed patients is
to achieve control of symptoms and reduce frequency of exacerbations as far as
possible on the minimum drug doses and frequencies necessary. There is currently
no cure for asthma.
Asthma is managed on a step-wise scale of increasing drug regime. Patients
are initially treated on the most suitable step for their severity at presentation,
which is then reduced to the lowest step giving control of symptoms (The British
Thoracic Society, 2008). For patients presenting with intermittent disease an
inhaled short-acting β2 agonist (SABA) is prescribed for use when needed. For
moderate disease a regular inhaled glucocorticosteroid is given in addition to a
SABA, to which a long acting β2 agonist (LABA) may be added. Persistent loss
of control can be addressed by further supplemental drugs such as leukotriene
inhibitors and oral steroids.
1.1.7 Future therapeutic approaches
While current therapy is aimed at non-specific, symptomatic treatment, emerging
therapies are attempting to target specific underlying mechanisms of asthma, with
the seeming importance of Th2 pathways making this an attractive target. The
prostaglandin receptor, CRTH2, is expressed on Th2 cells, eosinophils, basophils
(Quirce et al., 2012) and type 2 innate lymphoid cells (ILC2), and mediates
their activation. An antagonist of this receptor is able to improve lung function
measured by FEV1 and quality of life (Barnes et al., 2012). Monoclonal antibodies
or receptor antagonists are increasingly used to block the effects of mediators in
disease, and for asthma clinical trials have been conducted for blocking antibodies
to IgE (Tan and Corren, 2011), IL-4 (Borish et al., 2001; Hart et al., 2002),
IL-5 (Liu et al., 2013) and IL-13 (Corren et al., 2011). However when assessed
in undifferentiated groups of asthmatics, these have met with limited success,
with significant effects only seen in subgroups as defined by asthma phenotype.
The anti-IL-5 antibody Mepolizumab was effective at reducing eosinophilia and
subsequent exacerbations in the eosinophilic asthmatic subpopulation only, and
the IL-13 antibody Lebrikizumab was seen to improve lung function (by FEV 1)
in patients defined as periostin high. These studies demonstrate that, unlike
treatment with existing therapies such as steroids, it is important to stratify
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asthmatic patients by their underlying pathology when treating with mechanism-
specific therapies to ensure efficacy. Future trials are more likely to take this into
account and thus achieve significance in one or more asthma phenotypes.
1.1.8 Viral exacerbations
Although asthma is considered a response to environmental allergens, as early as
a century ago it was recorded that “Chronic cases [of bronchial asthma], in which
the attacks recur year after year, gradually become associated with emphysema,
and every fresh ‘cold’ induces a paroxysm.” (Osler, 1892). The discovery of
viruses as the cause of the common cold led to their being linked to exacerbation
of respiratory diseases such as chronic bronchitis and asthma (Carlsen et al., 1984;
Horn and Gregg, 1973; Lambert and Stern, 1972; Stott et al., 1968)
However, it was not until the ability to detect respiratory viruses reliably (and
cheaply) by PCR in clinical studies, that it was possible to objectively show
their correlation with asthma exacerbations, with PCR detection rates being
three times higher than culture alone (Johnston et al., 1993). Figure 1.1 (from
Johnston et al., 1995) shows the results from one asthmatic child over 13 months,
with culture and/or PCR detecting a rhinovirus from a sample taken within 48
hours of each objectively reported exacerbation; overall 80% of exacerbations
were associated with a viral infection, of which the majority were rhinoviruses. In
support, it has also been shown that asthmatics do not suffer from more frequent
rhinovirus infections than non-atopics when monitored for infections at 2-weekly
intervals, but do endure longer, more severe lower respiratory tract infections
(LRTI) than healthy controls (Corne et al., 2002).
The link between viruses and exacerbations is now firmly established, with
40-90% of exacerbations showing a concomitant respiratory viral infection. Rhi-
novirus is the most commonly isolated of these, being found in 55% (range 42-82%)
of exacerbations in children and 29% (8-65%) in adults (Papadopoulos et al.,
2011).
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Figure 1.1: Example chart of peak flow recordings, respiratory symptom scores
and virus isolations for an asthmatic child over 13 months. (Adapted from
Johnston et al., 1995)
1.2 Rhinovirus
1.2.1 Discovery
The cause of the common cold was for a long time unknown and, as the name
suggests, was thought to be an environmental effect (Cheney, 1928). In agreement,
studies showed close correlation between the onset of colds and temperature; this
idea persisted well into the 20th century (Simpson, 1958). However, early on
it was also shown that the common cold was transmissible in nasal secretions
between volunteers (Dochez et al., 1930). Filtering of the secretions did not
prevent infection, excluding bacteria and leading to the proposition that a virus
was the cause. Methods for the culture of viruses from nasal secretions were
developed from those in use for the related enteroviruses (Parsons and Tyrrell,
1961). Concerted work with these techniques and the use of human volunteers,
much of it carried out at the MRC Common Cold Unit, led to the isolation of a
number of related viruses that caused the common cold and the classification of
a new genus of picornaviruses, named Rhinovirus (Tyrrell and Chanock, 1963).
1.2.2 Virology
Rhinovirus species are now placed in the family Picornaviridae and genus En-
terovirus, and are divided into three species named human rhinovirus (HRV)-A,
-B and -C based on their genomic sequences (Palmenberg et al., 2010). Further
division is made into serotypes by antibody neutralisation, leading to greater
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Figure 1.2: The structure of rhinovirus. (a) Arrangement and cleavage inter-
mediates of the rhinovirus genome. (b) Arrangement of the structural proteins
to form the rhinovirus viral capsid. Taken from http://viralzone.expasy.org/
(Hulo et al., 2011)
than 150 distinct viruses (Harvala et al., 2012). Rhinoviruses are small (30nm),
non-enveloped, positive-sense RNA viruses with a genome of approximately 7
kilobases encoding 4 structural and 7 non-structural genes (figure 1.2a). The
structural genes (VP1-4) form protomers, 60 of which make up the viral capsid
(figure 1.2b). While VP1-3 are exposed on the outside of the capsid, VP4 is
internal and associated with RNA (Arden and Mackay, 2001).
Rhinoviruses bind to cell surface receptors to initiate cell invasion. Most HRV-A
and all HRV-B rhinoviruses bind to ICAM-1 (CD54) and are called the major
group, whereas a subset of HRV-A, named the minor group, bind the low density
lipoprotein receptor (LDL-R); the receptor(s) for HRV-C are currently unknown,
but they have been shown to infect sinus organ culture and differentiated human
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airway epithelial cells (Hao et al., 2012).
Receptor binding and cell invasion leads to the virus particle uncoating, with the
RNA genome being released into the cytosol. A virus-encoded RNA-dependent
RNA polymerase synthesises further copies of RNA, both negative strand tem-
plates and further positive strand genomes. Host ribosomes are hijacked to
translate viral proteins, initially as a single polyprotein which is then cleaved
by viral proteases (figure 1.2a). The viral protease 2APRO cleaves itself from the
polyprotein and further cleaves the structural proteins from the non-structural.
This protease also cleaves cell-produced eIF4G, which suppresses host protein
translation (Glaser et al., 2003). Further rounds of cleavage by viral proteases
produce mature proteins, which form new viral particles with positive RNA
genomes, which then escape from the cell by lysis.
1.2.3 Rhinovirus infection
Most rhinoviruses are restricted to human infection due to their use of ICAM-1,
though zoonotic infection of mice is possible with minor group rhinoviruses or
genetic modification to allow expression of human ICAM-1 (Bartlett et al., 2008);
it was previously believed a block on rhinoviral replication existed in mice (Lomax
and Yin, 1989), but it appears that if this exists it is at least surmountable.
Transmission occurs easily between humans by direct contact or indirectly via
contaminated surfaces (Winther et al., 2007), likely by self-inoculation through
touching the nose and eyes with contaminated hands. The virus then infects
the epithelium of the upper airways because of trophism for growth at 33◦C
(Papadopoulos et al., 1999), but can also lead to LRTIs, especially in asthmatics
(Corne et al., 2002). Infection leads to nasal obstruction, mucus production,
sore throat and malaise (Rosenbaum et al., 1971). Symptoms closely correlate
with viral shedding, which lasts between 7-14 days in healthy adults and chil-
dren, but can last for more than 40 days in immunocompromised patients with
hypogammaglobulinaemia (Peltola et al., 2013).
1.2.4 Immune responses
Rhinovirus, as is common for respiratory viruses, replicates mainly within ep-
ithelial cells, though it is detected in the underlying fibroblasts in biopsies from
patients (Bedke et al., 2009; Papadopoulos et al., 2000) and is capable of infecting
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macrophages in vitro (Laza-Stanca et al., 2006). Within epithelial cells, rhinoviral
RNA (either single stranded or double stranded intermediaries) is recognised by
TLR3, TLR7/8, RIG-I and MDA-5. Detection leads to the cell producing a range
of pro-inflammatory and antiviral cytokines, including IL-6, IL-8, TNF-α, IP-10,
IFN-α and IFN-β (Kim and Gern, 2012, Kelly and Busse, 2008). Macrophages
also respond to rhinovirus with cytokines such as IL-8, TNF-α and type I, II
and III interferons (including IFN-γ not produced from the epithelium), though
whether cell invasion and replication are required for these responses is not clear
(Gern et al., 1996; Korpi-Steiner et al., 2006; Laza-Stanca et al., 2011, 2006).
Large numbers of neutrophils are seen in response to a rhinovirus infection, driven
by IL-8 and G-CSF release from the epithelium (Jarjour et al., 2000).
The adaptive immune response to rhinovirus has been studied in less detail,
however a key early finding was the generation of IgA in the serum of experi-
mentally infected subjects, which could be generated by vaccination strategies
and protected against subsequent challenge (Butler et al., 1970; Mitchison, 1965;
Perkins et al., 1969). However, it soon became apparent that due to the hetero-
geneity of rhinovirus serotypes, cross-protection was necessary but difficult to
obtain (Fox, 1976; Palmenberg, 1987).
Rhinovirus infection induces T cell chemokines such as IP-10 and RANTES (Pa-
padopoulos et al., 2001) as well as the Th1-polarising cytokine IFN-γ. Compared
to RSV infection, rhinovirus induces a T helper CD4+ dominant response in the
lungs of healthy patients with significantly less involvement of CD8+ cytotoxic
T cells (Heidema et al., 2008). In tonsillar T cells, proliferative responses to
two rhinovirus serotypes were shown to be entirely CD4+ T cell dependent, as
depletion of this subset completely abrogated the response; in contrast deple-
tion of CD8+ T cells had no effect (Wilamasundera et al., 1998). Cloning of
rhinovirus-specific CD4+ cells from the peripheral blood of healthy volunteers
showed that most individual T cells were capable of responding to at least two dif-
ferent serotypes of rhinovirus, with most secreting IFN-γ and some secreting IL-4
and IL-5, though other T cell cytokines were not tested (Gern et al., 1997b). This
cross-reactivity between subtypes is likely to be against the conserved internal
proteins of rhinovirus, which are not accessible for antibody binding.
T cell-derived cytokines have been shown to feed back and affect epithelial
responses to rhinovirus, with both IFN-γ (Konno et al., 2002) and IL-4 (Piela-
Smith et al., 1992) shown to increase ICAM-1 expression, the receptor for the
major rhinovirus group, leading to increased rhinovirus infection. IFN-γ also
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enhanced subsequent RANTES production in epithelial cell culture (Konno et al.,
2002). Conversely, IL-17 has been shown to reduce RANTES secretion from
epithelial cultures infected with rhinovirus, but synergistically increases both IL-8
and human β-defensin 2 (HBD2) responses to rhinovirus, without affecting viral
replication (Wiehler and Proud, 2007).
1.3 Rhinovirus-induced asthma exacerbations
1.3.1 Rhinovirus challenge studies
While observational studies of naturally occurring colds in asthmatics have shown
a clear correlation with asthma exacerbations (Corne et al., 2002; Johnston et al.,
1995; Papadopoulos et al., 2011), experimental challenge with rhinovirus of healthy
and asthmatic subjects (both in vivo and with ex vivo tissue infection models)
has allowed detailed investigation of underlying mechanisms of rhinovirus-induced
exacerbations.
1.3.2 Lower airways replication
Although asthmatics are not found to have more frequent rhinovirus infections
than healthy controls (Corne et al., 2002), several studies have found that rhi-
novirus is able to infect the lower airways of asthmatics using both PCR (Mosser
et al., 2005) as well as in situ hybridisation (Papadopoulos et al., 2000). In
addition, asthmatics display symptoms of lower airway disease in response to a
rhinovirus infection, whereas healthy controls do not (Corne et al., 2002; Gern
et al., 1997a; Message et al., 2008).
1.3.3 Epithelial responses
The epithelium is the main site of rhinovirus infection and replication, and is also
considered an important site controlling allergic responses in the lung (Lloyd and
Saglani, 2010).
While innate interferons are released upon rhinovirus infection, interferons β
and λ are blunted in some asthmatics and levels inversely correlate with increased
Page 34
1.3. RHINOVIRUS-INDUCED ASTHMA EXACERBATIONS
viral loads in epithelium ex vivo (Contoli et al., 2006; Edwards et al., 2013; Wark
et al., 2005).
In addition to inducing Th1 and neutrophil chemokines (such as IP-10 and
IL-8) as is common in virus infections (Wark et al., 2007), rhinovirus has also
been shown to induce the eosinophil chemokines RANTES and eotaxin (Furukawa
et al., 2004; Papadopoulos et al., 2001) and Th2 response mediators such as
TSLP (Kato et al., 2007), both of which have the ability to increase asthmatic
inflammation in the airways. The Th2 cytokines IL-4, IL-5 and IL-13 have also
been shown to increase the expression of the rhinovirus receptor ICAM-1 (Bianco
et al., 1998; Piela-Smith et al., 1992), suggesting a possible positive feedback loop
that could exacerbate Th2-rhinovirus responses. In addition, rhinovirus induces
the production of mucins from the epithelium (Hewson et al., 2010; Inoue et al.,
2006), which are a major component of airways obstruction and occlusion in
asthma exacerbations.
1.3.4 Cellular responses
Asthma is classically associated with an influx of granulocytic cells to the airways,
mainly eosinophils, with sustained, increased neutrophil numbers also a feature of
more severe asthmatic phenotypes. Changes to these cellular responses following
experimental rhinovirus infection have been measured in healthy and asthmatic
subjects, showing that asthmatics recruit significantly increased numbers of
eosinophils (Gru¨nberg et al., 2001; Kato et al., 2011) and neutrophils (Message
et al., 2008) in response to rhinovirus infection compared to healthy controls. Fol-
lowing experimental rhinovirus infection, eosinophils, neutrophils and rhinovirus
load all correlate with a fall in lung function measured by PEF or PC20 (Gru¨nberg
et al., 1997; Message et al., 2008) and in natural infection rhinovirus-induced
neutrophilia is associated with asthma exacerbations (Denlinger et al., 2011).
Eosinophils induced by rhinovirus in asthmatics remain elevated 6 to 10 weeks
after infection during convalescence (Fraenkel et al., 1995).
While T cells are suggested to be important for co-ordinating much of the
cellular cascade underlying the asthmatic response, little is currently known about
their role in rhinovirus-induced exacerbations. Few studies have investigated
T cells directly following infection of asthmatics, but it has been shown that
rhinovirus induces CD4+ and CD8+ T cells in the epithelium as seen by histology
(Fraenkel et al., 1995; Gru¨nberg et al., 2001). The induction of γδ T cells by
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a rhinovirus infection has recently been published by our laboratory (Glanville
et al., 2013), showing significant recruitment only in asthmatics, which correlates
with a fall in lung function as well as increases in both virus load and eosinophils
in the airways.
PBMCs from subjects pre-infection showed that both higher IFN-γ secretion in
response to rhinoviral stimulation (Parry et al., 2000) and higher total CD4+IFN-
γ+ T cell numbers determined by flow cytometry (Message et al., 2008) predicted
lower subsequent viral shedding following infection. Cytokine staining of airway
CD4+ T cells at baseline also showed that Th1 cells (CD4+IFN-γ+) inversely
correlated with the fall in PEF after subsequent rhinovirus infection, but that
IL-4, IL-5 and IL-13 staining in CD4+ T cells positively correlated with increases
in chest scores (Message et al., 2008). T cells have also been indirectly investigated
by measuring T cell cytokines, showing that PBMC from asthmatics produce
more IL-4 but less IFN-γ and IL-12 than healthy controls in response to rhinovirus
(Papadopoulos et al., 2002).
1.3.5 Treatment
The effects of existing asthma therapies, corticosteroids and β2 agonists, on
rhinovirus infection have been investigated in vitro, and have been shown to
synergistically suppress rhinovirus-induced inflammatory mediators (Skevaki et al.,
2009; Volonaki et al., 2006). However, infection of ex vivo bronchial epithelial
cells has been shown to indirectly reduce airway smooth muscle sensitivity toβ2
agonists (Van Ly et al., 2013), and salbutamol (a SABA) or salmeterol (a LABA)
used alone enhanced rhinovirus-induced inflammatory mediators from epithelial
cells. One study in experimentally-infected asthmatics showed corticosteroid
treatment improved subsequent AHR but had little effect on inflammatory cell
populations (Gru¨nberg et al., 2001), with corticosteroid use being shown to cause
rhinovirus persistence in healthy controls (Gustafson et al., 1996; Puhakka et al.,
1998). In addition, use of the leukotriene receptor antagonist Montelukast alone
was shown to have little effect on experimental rhinovirus-induced exacerbation
when used prophylactically (Kloepfer et al., 2011).
While viral infection is known as a major precipitant of asthma exacerbations,
current treatment continues to target symptoms and dampen lung inflammation,
with no virus-specific therapies licensed at present. Because of the number of
rhinovirus serotypes, non–serotype-specific treatments have been sought. As
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∼90% of serotypes bind ICAM-1, a soluble ICAM-1 was developed but was
deemed impractical (prophylaxis required six applications a day) and of minimal
clinical benefit in healthy subjects (Turner et al., 1999). Pleconaril, an inhibitor
of picornaviruses, has been shown to reduce the duration of rhinovirus infection
in healthy controls (Pevear et al., 2005), but has not gained FDA approval in the
USA due to lack of substantial clinical benefit (Hansbro et al., 2008); it has not
been tested in asthmatics. Targets within the virus replication cycle have also
been sought, however Rupintrivir, a drug targeting a rhinoviral protease, did not
show efficacy in human challenges (Hayden et al., 2003) and development was
halted (Patick et al., 2005).
It has been observed that prophylactic treatment with a macrolide antibiotic
(telithromycin) was able to reduce asthma symptoms (Johnston et al., 2006),
and subsequent in vivo work showed an anti-rhinoviral effect for the structurally
related compound azithromycin (Gielen et al., 2010). Investigations into this
mechanism are ongoing within our group.
Because of the deficient interferon response to rhinovirus seen in some asth-
matics, an attractive therapeutic strategy would be interferon supplementation.
Currently, only one trial has been undertaken in asthmatics, showing that IFN-α
improved lung function and reduced corticosteroid requirement (Simon et al.,
2003). However, no specific investigation of viral burden was made. In another
study, ex vivo IFN-β treatment of HBECs from asthmatics reduced viral load
after subsequent infection (Cakebread et al., 2011).
1.4 Mouse models
1.4.1 Rhinovirus primary infection model
To further investigate mechanisms of rhinovirus-induced exacerbations, animal
models were developed. Initially it was thought that there was an innate block
on rhinovirus replication in mouse cell lines (Yin and Lomax, 1983), possibly
involving the non-structural P2 protein (Harris and Racaniello, 2003; Lomax and
Yin, 1989) and a mouse infection model was subsequently developed requiring
an adapted rhinovirus strain and pre-treatment with actinomycin D, which was
thought to suppress the host immune response (Yin and Lomax, 1986). The
discovery of ICAM-1 as the receptor for the major group of rhinoviruses (Greve
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et al., 1989), which is divergent from its mouse orthologue, also suggested most
rhinoviruses would be unable to infect mice. However, the minor group were
shown capable of binding to murine cells (Hastings et al., 1993) and the receptor
was identified as the LDL receptor (Herdy et al., 2004), leading to a demonstration
of the permissive infection and replication of rhinovirus serotype 1A in the mouse
fibroblast M cell line (Reithmayer et al., 2002). Further work showed that mouse
epithelial cell lines were capable of efficient rhinovirus replication with either a
minor or major group virus, with the major group cell entry being facilitated
either by rhinovirus RNA transfection or expression of human ICAM-1 in the cell
line (Tuthill et al., 2003).
Mouse models of rhinovirus infection have been developed, representing many
of the characteristics of human infection including neutrophilia, proinflammatory
cytokines (IL-1β, KC, IL-6) and antiviral interferons (IFNs α, β, λ, γ) (Bartlett
et al., 2008). Negative (replicative) strand is detected by RNA probe (Bartlett
et al., 2008) as well as qPCR (Newcomb et al., 2008) in rhinovirus infected mice,
but not in controls treated with UV-inactivated rhinovirus. These models have
allowed detailed investigation of the pathways involved in these responses, showing
that CXCR2 is required for neutrophil recruitment in response to rhinovirus infec-
tion, subsequent TNF-α secretion and loss of lung function (Nagarkar et al., 2009);
that signalling via TLR3, MDA 5 and RIG-I is important for rhinovirus-induced
interferon (Slater et al., 2010) and, along with with NFκB, pro-inflammatory
cytokine responses (Bartlett et al., 2012; Wang et al., 2011a).
Potential novel treatment methods have also been assessed in this model, show-
ing inhibition of rhinovirus replication by a protease pseudosubstrate (Falah et al.,
2012) and treatment of mice post-infection with Quercetin reduced subsequent
viral load and cytokine responses (Ganesan et al., 2012).
1.4.2 Rhinovirus exacerbation of allergic airways disease
Successful infection of mice has also allowed the investigation of rhinovirus-
induced exacerbations in mouse models. Much of the current understanding
of allergic asthma has come from mice; they do not spontaneously develop
asthma, so sensitisation to an experimental allergen before challenge is required
to develop allergic airways disease (AAD). Many models use hen egg ovalbumin
as a model allergen with varying protocols, but most involve initial sensitisation
intraperitoneally with aluminium salts as an adjuvant before challenging the
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airways with ovalbumin alone (Kumar and Foster, 2002; Lloyd, 2007; Nials and
Uddin, 2008). Other models make use of known asthma allergens such as house
dust mite (Gregory and Lloyd, 2011) or cockroach extracts (Arizmendi et al.,
2011; Kim et al., 2012); however while these are more ‘real world’ allergens,
they exhibit batch variability and lack research tools such as mice transgenic for
allergen-specific TCR.
These mouse models represent many of the features of acute asthma, in-
cluding Th2 driven inflammation, allergen-specific IgE, mast cell degranulation,
eosinophilia, and AHR (Stevenson and Birrell, 2011). Further aspects, such as
airways remodelling and collagen deposition, can also be modelled with long
term, chronic allergen exposure. These models have led to mechanistic insights of
Th2-driven asthma pathogenesis, allowing observation of phenotypes after genetic
deletion or antibody blocking of key mediators, which were then subsequently
observed in humans. However, treatments suggested by these experiments have
only had moderate success in clinical trials of human asthmatics (Nials and Uddin,
2008). Partly this appears to reflect the heterogeneity of the human asthmatic
population, as analysis of asthmatic subgroups show that an anti-IL-13 antibody,
Lebrikizumab, improved lung function only in patients with high serum periostin
at baseline (Thomson et al., 2012), and an anti-IL-5 antibody, Mepolizumab, only
showed significant effects in asthma populations with high baseline eosinophilia.
As rhinovirus is a major cause of asthma exacerbations, mouse models of
AAD allow the investigation of the mechanisms involved. A model of rhinovirus
exacerbation of AAD has been developed, where rhinovirus infection during
ovalbumin-driven inflammation leads to increases in eosinophils, lymphocytes,
mucins and AHR over ovalbumin challenge alone (Bartlett et al., 2008). A
protective role for γδ T cells has since been seen following γδ T cell depletion in
this model (Glanville et al., 2013). Within these models, the role of IL-17 and
Th17 cells has yet to be explored.
1.5 IL-17 and Th17
1.5.1 Discovery
When T helper cells were first discovered, they were initially subdivided by
their differential help to B cells (Tada et al., 1978). After the identification
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of secreted cytokines (‘lymphokines’) and co-expression of CD3 and CD4, they
were subdivided into Th1 and Th2 by their ability to secrete IFN-γ and IL-4,
respectively (Mosmann and Coffman, 1989). Th1 were broadly considered to
support anti-viral cytotoxic T cells, while Th2 supported humoural responses to
extracellular bacteria and parasites (de Carli et al., 1994).
The gene for IL-17 was initially identified from a rodent cDNA library by
its restricted expression in T cell clones and was at first named cytotoxic T
lymphocyte antigen (CTLA)-8. This initial identification also found 57% sequence
homology with a protein sequence, ORF13, identified in the genome of the
virus herpesvirus Saimiri, a virus that was trophic for T cells (Rouvier et al.,
1993). A homologue of the gene was found in humans, and with the sequenced
human genome a new family of cytokines was discovered and named IL-17A to F
(Aggarwal and Gurney, 2002). Their role in neutrophilic responses was quickly
identified (Hoshino et al., 1999; Witowski et al., 2000).
At the same time, a central role for Th1 cells in pathogenesis of experimental
autoimmune encephalomyelitis (EAE; a mouse model of multiple sclerosis) was
suggested when polyclonal anti-IL-12 antibodies blocked development of the
disease (Leonard et al., 1995). However, anti-IFN-γ treatment or IFN-γ gene
deletion led to development of more severe disease (Krakowski and Owens, 1996).
The discovery of a novel cytokine, IL-23, thatwas a heterodimer of the IL-12p40
chain and the newly identified IL-23p19 (Oppmann et al., 2000), led to the
realisation that polyclonal anti-IL-12 antibodies would also neutralise IL-23 in
addition to IL-12. The comparison of Il23p19 knockout mice to Il23p35 (the IL-12
specific chain) knockouts showed that IL-23 was the cytokine driving development
of EAE (Cua et al., 2003). One of the main differences in Il23p19 knockout mice
was a dramatic reduction in IL-17–producing T cells. This observation led to the
defining of a novel T helper cell subset separate to Th1 and Th2, termed ‘Th17’
that is dependent on IL-23 for its differentiation (Bettelli et al., 2007).
1.5.2 IL-17 family
The IL-17 family consists of the six cytokines IL-17A to F (summarised in
table 1.1) with IL-17A, as the first discovered, known simply as IL-17 (as well as
the depreciated name CTLA-8) (Gaffen, 2009). The main function of signalling by
IL-17 family members is the induction of inflammation, especially the recruitment
of neutrophils.
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IL-17A and IL-17F share the greatest homology, forming homodimers as well
as an IL-17A/F heterodimer (Wright et al., 2007), and are produced by Th17
cells as well as other professional (mostly innate) immune cells (Cua and Tato,
2010). IL-17A, F and A/F all signal via a heteromeric complex formed of the
proteins IL-17RA and IL-17RC but bind with different affinities, which may
explain differences in responses (Wright et al., 2008). IL-17RA is reasonably
ubiquitous in its expression on most tissues (including haemopoetic cells), whereas
IL-17RC is mainly limited to epithelial tissues, including lung epithelium (Ge
and You, 2008). Upon signalling, IL-17A and F both induce proinflammatory
(IL-6), anti-microbial (HBD2) and neutrophil chemotactic (IL-8/KC) cytokines
(Gaffen, 2008).
IL-17C has recently been studied, after having been shown to play a major
role in mouse models of gut infection (Pfeifer et al., 2012) and colitis (Ramirez-
Carrozzi et al., 2011). While IL-17C has similar effects to IL-17A and F, it is
produced not by specialised immune cells but by the epithelium, and is recognised
by IL-17RE, which is also restricted to epithelial expression, possibly signalling
in combination with IL-17RA (Ramirez-Carrozzi et al., 2011).
IL-17E (also known as IL-25), while a member of the IL-17 family, has been
shown to initiate Th2 responses and eosinophilia (Fort et al., 2001; Tamachi
et al., 2006) as opposed to neutrophilia. As with IL-17C, it is produced by the
epithelium.
The final two family members, IL-17B and IL-17D, are the least well studied
and their roles are currently unclear, however there are suggestions that like other
family members, they are involved with induction of inflammation (Iwakura et al.,
2011).
1.5.3 Cellular source
The canonical source of IL-17 is the specific T helper cell, Th17. T helper cells
require recognition of antigen through their T cell receptor (TCR), presented
on MHC II by professional antigen presenting cells (APC), after which the
local environment cytokine milieu directs their development. Although IL-23
was identified as critical for differentiation of Th17 cells and for licensing their
cytokine secretion (Croxford et al., 2012), its receptor (IL-23R) is not expressed
on na¨ıve T cells.
Page 41
CHAPTER 1. INTRODUCTION
Family
Member
Source Receptor Function
IL-17A
(IL-17)
T, γδ, NKT and
LTi cells
IL-17RA+
IL-17RC
Neutrophil recruitment,
fungal/bacterial defence,
autoimmunity
IL-17B Neurons,
chondrocytes,
breast cancer
IL-17RB Inflammation? Autoimmunity?
IL-17C Lung and
intestinal
epithelium,
keratinocytes
IL-17RA+
IL-17RE
Neutrophil recruitment,
fungal/bacterial defence
IL-17D Skeletal muscle,
brain, adipose
tissue, heart,
lung and
pancreas
Unknown Inflammation?
IL-17E
(IL-25)
Brain, kidney,
lung epithelium,
prostate, testis,
spinal cord,
adrenal gland
and trachea
IL-17RA+
IL-17RB
Induction of Th2 responses
IL-17F T, γδ, NKT and
LTi cells
IL-17RA+
IL-17RC
Neutrophil recruitment,
fungal/bacterial defence,
autoimmunity
IL-17A/F T, γδ, NKT and
LTi cells
IL-17RA+
IL-17RC
Inflammation
Table 1.1: IL-17 family members (Adapted from: Gaffen, 2009; Iwakura et al.,
2011; Ramirez-Carrozzi et al., 2011; Starnes et al., 2002).
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1.5.4 Th17 development
The upstream requirements of Th17 differentiation leading to IL-23R expression
have been identified as TGF-β and IL-6 (Mangan et al., 2006). Under the effect
of TGF-β alone, T cells are driven to differentiate into regulatory T cells (T reg)
by the induction of FoxP3, but the presence of IL-6 diverts this pathway to
induce STAT3 activation, leading to RORγt and IL-23R expression (Bettelli
et al., 2006; Yang et al., 2007). IL-23 signalling through the IL-23R is required for
full differentiation, without which Th17 secrete few cytokines and are limited in
their ability to both control infection (Mangan et al., 2006) and mediate pathology
(Langrish et al., 2005). Some Th17 differentiation is still seen in IL-6 knockout
mice, and the cytokine IL-21, secreted by developing Th17 cells, is suggested to
be able to perform this function in IL-6 low environments (Nurieva et al., 2009),
providing a potential feedback mechanism to maintain differentiation. There are
likely to be other redundant mechanisms that can also induce Th17 polarisation,
as IL-1β and IL-23 alone have been shown to be sufficient in some models (Mills
et al., 2012). In addition, signalling through the intracellular aryl hydrocarbon
receptor (AhR) has been found to be important in Th17 development, synergising
with RORγt to drive Th17 differentiation and suppressing FoxP3 expression
(Quintana et al., 2008).
Although Th1 and Th2 cells can develop into central and effector memory
phenotypes after differentiation, the ability of Th17 to do this is still under
investigation, as the Th17 phenotype has been shown to be more plastic, capable
of switching to a Th1 phenotype during resolution (Hirota et al., 2011). However
some form of Th17 memory is suggested by the dependence on Th17 in cross-
reactive immunity to Klebsiella pneumoniae following vaccination in mice (Chen
et al., 2011), as well as persistence of increased numbers following resolution of
inflammation in several models (Muranski et al., 2011).
1.5.5 IL-17+γδ T cells
The other well-studied IL-17 secretor is the IL-17+γδ T cell. Unlike Th17, in
mice these cells leave the thymus fully differentiated and in humans differentiate
soon after leaving, in both cases capable of rapidly secreting IL-17 in response
to stimulation (Ness-Schwickerath and Morita, 2011). It has been found that
a dichotomy in γδ T cell development exists, with developing γδ T cells either
becoming IFN-γ secretors, expressing the surface markers NK1.1, CD27 and
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CD122 as well as T-bet, or IL-17 secretors expressing IL-23R, CCR6 and RORγt
(but not CD27), much like Th17 cells (Michel et al., 2012; Ness-Schwickerath
and Morita, 2011). The master signal for this process is suggested to be γδ TCR
ligation; without ligation, the default development is towards an IL-17+γδ T cell
but signalling through the TCR diverts this towards an IFN-γ+γδ T cell (Meyer
et al., 2010). Unlike αβ TCR, γδ TCR are semi-invariant, yet the ligands for
these are poorly understood, but include non-classical MHC-like molecules and
bacterial toxins (Born et al., 2013). Additional requirements for IL-17+γδ T cell
development, such as TGF-β (Do et al., 2010) and IL-7 (Michel et al., 2012),
have also been suggested.
IL-17+γδ cells are found widely distributed around the body, including the
gut, skin and lung (Hirota et al., 2012). Although γδ T cells have a limited
TCR repertoire, IL-17+γδ have been shown to rapidly secrete IL-17 in response
to IL-23 and IL-1β, independently of TCR signalling (Dubin et al., 2012; Ribot
et al., 2010). Notably, γδ cells have also been shown to express TLR1, TLR2
and dectin 1 and secrete IL-17 in response to ligation of these innate receptors
(Martin et al., 2009); however others have suggested this is indirect via IL-1β and
IL-23 produced from myeloid cells in response to innate receptor ligation (Ribot
et al., 2010).
Both Th17 and IL-17+γδ specifically express the chemokine receptor CCR6,
which has MIP-3α as its single known ligand (Martin et al., 2009; Singh et al.,
2008). This receptor is also expressed on immature DCs (Ito et al., 2011)
but not other T cell subsets, with CD4+CCR6+ cells being highly enriched
for RORγt expression (Murdoch and Lloyd, 2010, supplementary data). The
specificity of CCR6 for recruitment of IL-17–producing cells firmly links them
with inflammatory responses.
1.5.6 Other sources
Other IL-17–secreting cells have been identified, including iNKT cells (Doisne
et al., 2011) and the newly defined ILC3s (Spits et al., 2013), though the precise
mechanisms of their development are currently unclear. Lymphoid tissue inducer
(LTi) cells are also dependent on RORγt for their development (Cherrier and
Eberl, 2012), and lymph nodes do not develop in mice with Rorc gene deletion
(Kurebayashi et al., 2000). There have also been reports of IL-17 detection
in cytotoxic T cells (Yen et al., 2009), neutrophils (Wozniak et al., 2011) and
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macrophages (Kasahara et al., 2012); however these are yet to be confirmed, and
may only operate in very specific models.
1.5.7 IL-17 in immunity
The addition of Th17 to the T helper subsets filled a perceived gap in the
immune armoury, whereby neither Th1 nor Th2 were considered effective against
certain extracellular infections, especially fungi (Curtis and Way, 2009). The
main function of IL-17 is to increase neutrophil chemokine (IL-8/KC, LIX) and
granulopoietic (G-CSF, GM-CSF) responses from multiple cell types, especially
the epithelium (Kolls and Linde´n, 2004). IL-17 signalling increases mRNA
stability (Hartupee et al., 2007), which in turn increases levels of secreted IL-8
(KC and LIX in the mouse) and G-CSF leading to enhanced neutrophil responses
to pathogens. In support of this role, patients with Job’s syndrome have been
shown to have autosomal dominant mutations in the STAT3 gene, leading to
a significant loss of Th17 cells. These patients suffer recurrent infections by a
narrow set of pathogens, notably the fungus Candida albicans (Ma et al., 2008).
Additional defects in the IL-17 pathway have also been seen in other patients
with similar susceptibilities (Cypowyj et al., 2012). Effective vaccination against
Bordetella pertussus has also been shown to be dependent on Th17 responses
in mice, as while Th2 cells were dispensable, Th17 responses were required and
acted in synergy with Th1 cells (Higgins et al., 2006).
IL-17 has been seen in response to viral infections, including hepatitis B and C
(Wang et al., 2013), HIV/SIV (Hartigan-O’Connor et al., 2011), RSV (Mukherjee
et al., 2011) and influenza. The role of IL-17 in viral immunity is unclear, as
different studies show either positive or negative effects, for instance IL-17 in
influenza infection can be protective (Wang et al., 2011b) or pathogenic (Li et al.,
2012).
1.5.8 IL-17 in immune-mediated disease
IL-17 was initially identified as a crucial mediator in rheumatoid arthritis
(Chabaud et al., 1998), and since has been identified in several other autoim-
mune diseases including psoriasis (Elloso et al., 2012) inflammatory bowel disease
(Kanai et al., 2012) and EAE (Lee et al., 2011), and is a major mediator of the
inflammation seen in these diseases. In the gut, Th17 development is driven
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by the presence of the microbiota, specifically segmented filamentous bacteria
(SFB) which express the protein serum amyloid A (Ivanov et al., 2009). Mice
lacking SFB colonisation have diminished Th17 development and subsequent
attenuated development of EAE and autoimmune arthritis (Lee et al., 2011; Wu
et al., 2010a).
A role of IL-17 has begun to be suggested in atopic conditions, with a possible
role in the pathogenesis of atopic dermatitis (AD) suggested by its presence in
AD lesions (Koga et al., 2008) and IL-17 is increased in serum from patients with
allergic rhinitis (Ciprandi et al., 2008). However, the largest body of data exists
for a role of IL-17 in asthma.
1.5.9 IL-17 in asthma
Asthmatics were initially seen as a homogenous patient population, with Th2,
eosinophilia and IgE driven pathology leading to the asthmatic phenotype. Since
discovering that underlying pathology is heterogeneous, with different mechanisms
leading to similar asthmatic phenotypes, the role of other immune pathways has
been investigated.
The presence of neutrophils in the airways of asthmatics and their correlation
with asthma severity (Turato et al., 2007) led to the hypothesis that IL-17, which
induces neutrophil granulopoesis and recruitment, may play a role in these non-
classical asthma phenotypes. Initial studies in humans found increased IL-17
protein in asthmatic compared to healthy lungs (Molet et al., 2001); in one study
IL-17 levels negatively correlated with lung function assessed by PC20 (Barczyk
et al., 2003). Levels of IL-17 were also seen to be higher in moderate-to-severe
compared to mild asthmatics (Agache et al., 2010; Chakir et al., 2003) and
positively correlated with sputum neutrophils, IL-8 and myeloperoxidase (MPO)
(Bullens et al., 2006; Sun et al., 2005). Staining of biopsies gained from asthmatics
also shows increases in IL-17 positive cells in the submucosa of asthmatics versus
healthy individuals (Al-Ramli et al., 2009; Doe et al., 2010) though no co-staining
was undertaken to identify the source cells. Other studies have identified a
significant increase in Th17 cells in peripheral blood of asthmatics (Zhao et al.,
2010). Importantly, IL-17 is likely to work in concert with underlying Th2-driven
inflammation, as underlined by the recent discovery of IL-17 secreting Th2 cells
in humans and mice (Wang et al., 2010).
Mouse models of asthma support these observations in humans. In classical
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systemic sensitisation to ovalbumin with aluminium hydroxide model, IL-17 has
been detected upon challenge as well as having potential roles in sensitisation and
resolution (Hellings et al., 2003; Murdoch and Lloyd, 2010; Schnyder-Candrian
et al., 2006). Th17 also dominate chronic ovalbumin models and mediate airway
remodelling (Zhao et al., 2012). Transfer of ovalbumin-specific Th17 into recipient
mice was sufficient to induce neutrophilia and AHR following ovalbumin challenge
of the airways. This AHR was steroid insensitive, unlike similar responses induced
by ovalbumin-specific Th2 transfer (McKinley et al., 2008). Sensitisation to
ovalbumin with LPS as adjuvant through the airways recruits Th17 to the
lung, and subsequent ovalbumin challenge induces AHR which is dependent on
neutrophils and IL-17 (Wilson et al., 2009).
These data have been considered strong enough to explore the IL-17 pathway
as a target in human asthma (Halwani et al., 2013; Park and Lee, 2010) and
several trials are currently ongoing (studies NCT01478360 and NCT01199289;
from http://clinicaltrials.gov).
1.6 IL-17 in rhinovirus-induced asthma
exacerbations
As discussed, few published studies have assessed T cell involvement in rhinovirus-
induced asthma exacerbations of human subjects, and the only observation so far
of IL-17 is concentrations in the supernatant of PHA-stimulated PBMCs ex vivo
from asthmatics versus healthy controls, which showed no significant differences
(Message et al., 2008). However no assessment was made on samples from the
lung or airways, and two mouse models of viral exacerbation, using RSV in
ovalbumin or cockroach-allergen models, have shown significant induction of IL-17
responses in the lung by virus with allergen over allergen alone (Ishioka et al.,
2013; Mukherjee et al., 2011). The effect of IL-17 in increasing rhinovirus-induced
IL-8 and HBD2 in an airway epithelial cell line (Wiehler and Proud, 2007) also
suggests a role of IL-17 in viral exacerbations.
Further rhinovirus infection studies of asthmatics and healthy controls have
recently been carried out in our group (Jackson et al., manuscript submitted).
In this study, mild and moderate atopic asthmatics, as defined by the GINA
guidelines, were infected with rhinovirus serotype 16 along with non-atopic healthy
controls. Daily following infection, nasal lavage was taken by washing the nasal
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cavity repeatedly with 5ml of sterile saline, and upper and lower respiratory
symptom scores were recorded (as defined by Jackson et al. 1958).
IL-17 protein concentrations assessed in nasal lavage by electrochemilumines-
cence assay (Meso Scale Discovery; MSD, Rockville, USA) showed induction of
IL-17 in response to rhinovirus infection in most individuals, with significant
increases in asthmatic groups (figures 1.3a and 1.3b). Peak IL-17 concentrations
showed positive correlations with both peak upper (figure 1.3c) and lower (fig-
ure 1.3d) respiratory symptom scores. The induction of IL-17 by rhinovirus and
correlation with symptom scores suggests IL-17 may play a role in rhinovirus-
induced asthma exacerbations.
Page 48
1.6. IL-17 IN RHINOVIRUS-INDUCED ASTHMA EXACERBATIONS
a
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100
Days Post Infection
Na
sa
l L
av
ag
e 
IL
-
17
 
(p
g/
m
l)
b
Ba
se
lin
e
Pe
ak
Ba
se
lin
e
Pe
ak
Ba
se
lin
e
Pe
ak
0.1
1
10
100
1000
Healthy Mild Moderate
* **
Asthma
N
as
al
 
La
v
ag
e 
IL
-
17
 
(p
g/
m
l)
c
0 5 10 15 20
0.1
1
10
100
1000
0.2559 0.0012r2= , P=
Peak Upper Respiratory Symptom Score
Pe
ak
 
Na
sa
l L
av
ag
e 
IL
-
17
 
(p
g/
m
l)
d
0.3708
0 5 10 15 20
0.1
1
10
100
1000
< 0.0001r2= , P=
Peak Lower Respiratory Symptom Score
Pe
ak
 
Na
sa
l L
av
ag
e 
IL
-
17
 
(p
g/
m
l)
Healthy Mild Asthma Moderate Asthma
Figure 1.3: IL-17 responses are seen in nasal lavage after rhinovirus infection of healthy and
asthmatic subjects. Human atopic asthmatics of mild and moderate asthma severity (based on
GINA guidelines) and healthy controls were infected with rhinovirus serotype 16. Nasal lavage
was undertaken daily for 10 days post infection and lavage fluid stored at -80◦C. Symptom
scores were assessed daily by subjects using the Jackson scale, consisting of 12 symptoms graded
0-3, split into upper and lower respiratory symptoms. IL-17 protein concentration was measured
in nasal lavage fluid by electrochemiluminescence assay (a), and paired baseline and peak IL-17
concentrations were plotted for each subject, grouped according to asthma severity (b). Peak
IL-17 concentrations were plotted against peak upper (c) and lower (d) respiratory symptom
scores. Mean concentrations are shown ± SEM. Significance between IL-17 concentrations was
calculated by Kruskal-Wallis test and significant correlations calculated by Fisher test. Data
courtesy of Jackson, unpublished observations.
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2 Materials and Methods
2.1 Materials
2.1.1 Reagents
Buffer/Medium Composition
10% / 4% / 2%
DMEM medium
10% / 4% / 2% (v/v) heat inactivated foetal calf serum (FCS;
PAA Laboratories, Yeovil, UK) in high glucose (4.5g/l) Dul-
becco’s Modified Eagle Medium (DMEM; PAA) supplemented
with 20mM HEPES (Invitrogen, Paisley, UK) and 0.075% (v/v)
sodium bicarbonate (Invitrogen).
10% RPMI medium 10% (v/v) heat inactivated FCS (PAA) in Roswell Park Memo-
rial Institute medium 1640 (RPMI; PAA) supplemented with
with 20mM HEPES (Invitrogen), 0.075% (v/v) sodium bi-
carbonate (Invitrogen), 100U/ml penicillin (Invitrogen) and
100µg/ml streptomycin (Invitrogen).
Bronchoalveolar
lavage (BAL) medium
0.38% (w/v) lidocane (Sigma-Aldrich, Shaftesbury, UK),
5.5mM ethylenediaminetetraacetic acid (EDTA; Invitrogen) in
phosphate buffered saline (PBS; PAA).
Ammonium-Chloride-
Potassium (ACK)
lysis buffer
Deionised water with 155mM ammonium chloride (Sigma-
Aldrich), 10mM potassium hydrogen carbonate (Sigma-
Aldrich) and 0.1mM EDTA (Invitrogen). Adjusted to pH7.2-
7.4 and 0.22µm filter sterilised.
Luria-Bertani (LB)
broth
1.0% (w/v) tryptone (Sigma-Aldrich), 0.5% (w/v) yeast extract
(Sigma-Aldrich), 1.0% NaCl (w/v; VWR) in deionised water,
adjusted to pH 7.0 and autoclaved. 50µg/ml of ampicillin
(Sigma-Aldrich) added once cooled, before use.
Luria-Bertani (LB)
agar
As for Luria-Bertani broth, with 15 mg/ml agar (BD Bio-
sciences, Oxford, UK) added before autoclaving. 50µg/ml of
ampicillin added once cooled, before use.
Table 2.1: Buffers and media composition.
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Marker Manufacturer Clone Fluoro-
chrome
Final Con-
centration
(µg/ml)
Fc Block
(CD16/CD32)
BD Biosciences 2.4G2 N/A 5
Live Dead Invitrogen N/A Near Infrared 1:1000 dilution
T Cell Panel (1)
CD3 BD Biosciences 500A2 Pacific Blue 0.5
CD4 BD Biosciences RM4-5 APC 1.33
CD8 BD Biosciences 53-6.7 PE-Cy7 0.5
γδ TCR BD Biosciences GL3 FITC 1.25
IL-17A BD Biosciences TC11-18H10 PE 0.5
IFN-γ BD Biosciences XMG1.2 AF700 0.5
IL-4 BD Biosciences 11B11 PerCP-Cy5.5 1
T Cell Panel (2)
CD3 BD Biosciences 500A2 AF700 1
CD4 BD Biosciences RM4-5 V450 1
CD8 BD Biosciences 53-6.7 V500 1
γδ TCR BD Biosciences GL3 FITC 1.25
NK1.1
(C57BL6 mice)
BD Biosciences PK136 PerCP-Cy5.5 0.25
NKp46
(BALB/c mice)
BD Biosciences 29A1.4 PerCP-Cy5.5 1
IL-17A BD Biosciences TC11-18H10 PE 0.5
IFN-γ BD Biosciences XMG1.2 PE-Cy7 0.5
IL-4 BD Biosciences 11B11 APC 0.5
RORγt Intranuclear Stain
CD3 BD Biosciences 500A2 Pacific Blue 1
CD4 BD Biosciences RM4-5 APC 1
CD8 BD Biosciences 53-6.7 V500 1
γδ TCR BD Biosciences GL3 FITC 1.25
Gr-1 (Ly6G/C) BD Biosciences RB6-8C5 AF700 0.2
RORγt eBioscience B2D PE 1
Conventional Dendritic Cells
CD3 BD Biosciences 17A2 FITC 1.25
CD19 BD Biosciences 1D3 FITC 1.25
F4/80 eBioscience BM8 eFluor 450 2
MHC-II
(I-Ad/I-Ed)
BD Biosciences 2G9 PE 0.05
CD11c BD Biosciences HL3 PerCP-Cy5.5 2
Fluorescent
Ovalbumin
Invitrogen N/A AF647 50µg/mouse
Table 2.2: Antibody details and concentrations. All antibodies are monoclonals unless
otherwise stated.
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Gene Concen-
tration
(nM)
Sequence 5’-3’
Forward 50 GTGAAGAGCCACTTGTGCT
Reverse 300 GCTACAGGGTTAAGGTTAGCC
Rhino-
virus
Probe 175 TGAGTCCTCCGGCCCCTGAATG
Forward 300 TCAGACTACCTCAACCGTTCCA
Il17a Reverse 300 AGCTTCCCAGATCACAGAGGG
Probe 175 TCACCCTGGACTCTCCACCGCA
Forward 300 AGCCATGGTCAAGTCTTTGCTACTGT
Il17f Reverse 300 CAACTCTCACAGTGTTATCCTCCAGGG
Probe 175 GCAGGGGTTCCTGCCTTGCAGAAGGCTGGG
Forward 300 GGTGCAAGGGCTTCTTCC
Rorc Reverse 300 TCGGTTGCGGCTGGTT
Probe 175 TGGCCTACTCCTGCACGCGTCA
Forward 300 AGAGGAGCGGAGAGAGACTCTGT
Muc5ac Reverse 300 CTCCATCTCTCTCTCAGGGTAGTTCT
Probe 175 CGAGAGGAGATCACACAGTTGCAATGCA
Forward 300 GAGCAGTGGCTATGTGAAAATCAG
Muc5b Reverse 300 CAGGGCGCTGTCTTCTTCAT
Probe 175 ATCCGCCTAGTCCTCACCTTCCTGTGG
Forward 300 GGAGGCTTTCTGGCGCCGAT
Il17ra Reverse 300 GGTGGTCGGCCGAGTAGACG
Probe 175 CCCCCACCCCTGAGGCCCAGGAAGGT
Forward 300 TTGCGCCCTCTGTGTCCGTG
Il17rc Reverse 300 GGCCTGGAGAGAGGCGTTCC
Probe 175 TGGCCGTGCATGGGCACTGGGCAGA
Forward 300 CCATCATGAACAGGTGGAT
Ifnb Reverse 300 GAGAGGGCTGTGGTGGAGAA
Probe 175 CTCCACGCTGCGTTCCTGCTGTG
Forward 900 AAAGGATTGCCACATTGCTC
Ifnl2/3 Reverse 900 TCAAGCAGCCTCTTCTCGAT
Probe 175 TCCCCAAAAGAGCTGCAGGC
Forward 900 TCAAGTGGCATAGATGTGGAAGAA
Ifng Reverse 900 TGGCTCTGCAGGATTTTCATG
Probe 175 TCACCATCCTTTTGCCAGTT
Forward 300 CGCCGCTAGAGGTGAAATTCT
18S Reverse 300 CATTCTTGGCAAATGCTTTCG
Probe 175 ACCGGCGCAAGACGGACCAGA
Table 2.3: qPCR primer and probe sequences. All probes had 5’ FAM and 3’ TAMRA
tags. Primers were supplied by Invitrogen, probes were supplied by Eurofins MWG
Operon (Bersberg, Germany). Il17f, Rorc, Il17ra and Il17rc primers and probes were
designed for this project; others were previously designed and used within our lab.
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2.2 Methods
2.2.1 Tissue culture and virological techniques
Virus propagation
The minor group (LDL-R binding) human Enterovirus rhinovirus A, serotype 1B
(RV1B; American Type Culture Collection, Teddington, UK), was grown in HeLa
cells (European Collection of Cell Cultures, Health Protection Agency, Porton
Down, UK). 25 large flasks (175cm2) of HeLa cells were grown to confluence
in 10% DMEM medium, and then infected with an innoculum of RV1B in 2%
DMEM medium. Cells were harvested the next day once observed to easily detach
by striking the flask, then washed several times in PBS and concentrated in 36ml
of PBS and stored at -80◦C.
To purify virus, frozen cell pellets were freeze-thawed and cell debris was
removed by centrifugation (4,500rpm, 20 minutes). 4ml of 5M NaCl (VWR) and
2.8g polyethylene glycol (6000 MW; Sigma-Aldrich) was added to the clarified
supernatant, and virus was left to precipitate on ice for 1 hour. Virus was then
pelleted by centrifugation (4,500rpm, 60 minutes), dissolved in 15ml PBS and
insoluble matter removed by centrifugation (4,500rpm, 15 minutes). Supernatant
was filter sterilised with 0.2µm syringe filters and concentrated using a 100,000MW
filter centrifuge tube (Millipore, Watford, UK) to a final volume of approximately
2.5ml and frozen in aliquots at -80◦C.
Assessment of viral titre
As new virus batches were used for each study, these were assessed for infectiv-
ity firstly by in vitro culture and secondly, if sufficiently infective, by in vivo
administration.
Determination of viral titre in vitro
The concentration of live virus in each batch was assessed by 50% tissue culture
infectious dose (TCID50). A 10-fold dilution series of virus stock was made and
individual dilutions were seeded along with 1.05× 104 Ohio HeLa cells in a total
volume of 200µl 4% DMEM medium per well. Multiple replicate wells of each
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dilution were made. Using the method by Reed and Muench (1938), TCID50 was
estimated from the total observed cytopathic effect in the replicates of each viral
dilution.
Assessment of viral infection in vivo
Virus batches with sufficiently high viral titres (>1× 107 TCID50/ml) were
assessed for in vivo infection in mice, as determined by neutrophil and lymphocyte
responses in bronchoalveolar lavage (BAL) at days one and four. Typically, 50µl of
neat virus induced 50-80% neutrophils in BALB/c mice and 40-60% neutrophils in
C57BL/6 mice at day one, which cleared by day four. Lymphocytes were typically
absent at day one, but by day four constituted approximately 10% of BAL cells
in both mouse strains. For primary infection experiments, virus stock that gave
>40% neutrophilia at day one was used neat. For exacerbation experiments with
intraperitoneal sensitisation (below), the amount of virus required to give 30-50%
neutrophilia in the BAL at day one was estimated by infecting mice with 1:2 and
1:4 dilutions of virus preparation.
For inactivated virus controls, rhinovirus was irradiated with UV light for 30
min using a UV crosslinker (CX-2000; UVP, Cambridge, UK).
2.2.2 Animals
Female C57BL/6 and BALB/c mice were purchased from Charles River (Margate,
UK) at six weeks old and were housed in specific-pathogen free conditions within
the animal facilities at Imperial College London. Mice were treated under UK
Home Office regulations and licences.
2.2.3 Rhinovirus infection
Mice were lightly anaesthetised in an exposure box with inhaled isoflurane and
oxygen at 2 litres/minute (Merial, Harlow, UK) and 50µl of neat rhinovirus
was given intranasally (i.n.). Control mice were given 50µl of UV-inactivated
rhinovirus.
For experiments involving addition of either 0.5µg recombinant IL-17A (rIL-17;
ImmunoTools, Friesoythe, Germany) or 50µg fluorescently-labelled ovalbumin
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(AF-OVA; Invitrogen); these additional proteins were added in a volume of 5µl
PBS to the 50µl of rhinovirus immediately prior to i.n. administration. Controls
had 5µl of PBS only added.
2.2.4 Rhinovirus-induced AAD exacerbations
Systemic sensitisation to ovalbumin with aluminium hydroxide
The model of allergic airways disease (AAD) with intraperitoneal (i.p.) sensitisa-
tion was performed as in Bartlett et al. (2008). On day one mice were injected i.p.
with 50µg ovalbumin (Merck Chemicals, Beeston, UK) with 2mg of aluminium
hydroxide (Al(OH)3; Sigma-Aldrich) as adjuvant in a total volume of 200µl PBS,
which was shaken for at least one hour before use (to allow complexes to form)
and agitated again immediately before injection (to ensure even suspension).
Mice were then challenged i.n. with 50µg of ovalbumin in 50µl PBS after light
anaesthesia with isoflurane on days 10, 11 and 12. Rhinovirus exacerbation of
AAD was achieved by adding virus (at a dose resulting in 30-50% neutrophilia
at day one from in vivo batch tests) to the final challenge ovalbumin dose (day
12), all in a total of 50µl PBS. All control mice were sensitised as above but
had either UV-inactivated rhinovirus added to the final ovalbumin challenge, or
ovalbumin challenges were replaced with PBS challenges, with active rhinovirus
or UV-inactivated rhinovirus added to the final challenge, as detailed in table 2.4.
Where mentioned, UV-inactivated rhinovirus was replaced with PBS as a control.
Group Sensitisation
Day 1
Challenges
Days 10-12
Virus
Day 12
PBS-UV Alum/Ovalbumin PBS UV-inactivated
rhinovirus
RV Alum/Ovalbumin PBS Rhinovirus
OVA-UV Alum/Ovalbumin Ovalbumin UV-inactivated
rhinovirus
OVA-RV Alum/Ovalbumin Ovalbumin Rhinovirus
Table 2.4: Groups for AAD with systemic sensitisation. Where indicated in the
text, UV-inactivated rhinovirus was replaced with PBS.
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Figure 2.1: Protocol for aluminium hydroxide and ovalbumin intraperitoneal
sensitisation.
Intranasal sensitisation to ovalbumin with LPS
A Th17-driven model of AAD was modified from Wilson et al. (2009). Mice were
sensitised to ovalbumin on days 1 and 7 by i.n. instillation of 100 µg ovalbumin
with 0.1µg lipopolysaccaride (LPS; from Escherichia coli 0111, Sigma-Aldrich)
as adjuvant in a total of 50µl PBS whilst lightly anaesthetised with inhaled
isoflurane. In some experiments, where indicated, controls were treated with LPS
alone in 50µl PBS.
Challenges were optimised during the project, however they were given either
as a single exposure to nebulised 1% ovalbumin over one hour on day 14, or i.n.
instillation of 50µg ovalbumin in 50µl PBS on the days indicated in the text and
associated protocol figure. For rhinovirus exacerbation of AAD, 45µl of neat
virus was added to the final challenge dose in a total volume of 50µl. Control
mice had ovalbumin challenges replaced with PBS alone, or rhinovirus replaced
with either UV-irradiated rhinovirus or PBS, as indicated. Experimental group
nomenclature is detailed in table 2.5.
Lung function
The lung function of mice was measured one day after final challenge by whole
body plethysmography (WBP) as an assessment of total airway obstruction,
whereby pressure changes in the main chamber in relation to a reference chamber
were measured (Hamelmann et al., 1997). Unrestrained, fully conscious mice were
allowed to acclimatise in the main chamber of a plethysmograph (Electro-Medical
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Group Sensitisation
Days 1 and 7
Challenge
Days (12-)14
Virus
Day 14
UV Only PBS PBS UV-inactivated
rhinovirus
Unsensitised
Controls
RV Only PBS PBS Rhinovirus
LPS LPS Ovalbumin -
Sensitisation
Controls LPS-OVA LPS/
Ovalbumin
Ovalbumin -
PBS LPS/
Ovalbumin
PBS PBS
PBS-RV LPS/
Ovalbumin
PBS Rhinovirus
OVA LPS/
Ovalbumin
Ovalbumin PBS
Exacerbation
Groups
OVA-RV LPS/
Ovalbumin
Ovalbumin Rhinovirus
Table 2.5: Groups for AAD with intranasal sensitisation.
Measurement Systems (EMMS), Alton, UK) for 45 minutes, after which control
responses at both baseline and to challenge with distilled H2O were measured.
The mice were then challenged with a series of increasing doses of nebulised
methacholine (Sigma-Aldrich) in distilled H2O for one minute, with responses
recorded over the following four minutes. Mice were allowed to recover between
doses for a further four minutes and were visually monitored for signs of distress
throughout. Data was analysed using eDacq software (version 1.8; EMMS) and
reported as area under the curve (AUC) of the unitless measurement enhanced
pause (Penh; figure 2.2b) over the four minute recording period.
2.2.5 Tissue and sample collection
Mice were culled at the indicated time points by an i.p. injection of 0.2ml
pentobarbital (pentobarbitone sodium 20% w/v solution; Animalcare Limited,
York, UK) and samples were taken as follows:
Page 58
2.2. METHODS
a
b
Penh =
Te − Tr
Tr
× PEP
PIP
Figure 2.2: (a) Measurements used to calculate Penh from whole body plethys-
mography. Te, expiratory time; PIP, peak inspiratory pressure; PEP, peak
expiratory pressure; Tr, relaxation time, time for the pressure decay to 36% of
total box pressure during expiration. (b) Calculation of Penh. Modified from
Hamelmann et al. (1997)
Bronchoalveolar lavage (BAL)
Mice were cannulated via the trachea with narrow tubing attached to a needle and
1ml of BAL medium was washed in and out of the lungs three times (from a total
of 1.5ml). Resultant BAL fluid (BALF) was kept on ice until processing, whereby
cells were pelleted by centrifugation (10,000rpm, 2 minutes), the supernatant
snap frozen with liquid nitrogen and stored at -80◦C. For BAL cells, erythrocytes
were lysed by brief resuspension of the cell pellet in ACK buffer, which was
neutralised with a 2x volume of PBS. The remaining leukocytes were then
pelleted by centrifugation (10,000rpm, 2 minutes) and resuspended in 1ml 10%
RPMI medium.
Lung lobe for flow cytometric analysis
The left lung lobe was removed, rinsed in PBS and placed in 10% RPMI medium
on ice. Leukocytes were purified by macerating the lung in a gentleMACS C
tube (Miltenyi Biotec) with 1mg/ml collagenase type XI (Sigma-Aldrich) and
80U/ml DNAse type I (Sigma-Aldrich) in 10% RPMI medium. After 45 minutes
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incubation at 37◦C, 5% CO2 the lung was dissociated into a single cell suspension
in the gentleMACS C tube and cells pelleted by centrifugation (1,500rpm, 10
minutes). Erythrocytes were then lysed by resuspension of the cell pellet in
ACK buffer for 5 minutes, which was neutralised with a 2x volume of PBS. The
remaining leukocytes were washed in PBS, passed through a 100µm filter and
resuspended in 10% RPMI medium.
To recover dendritic cells (DC) for flow staining from the lung lobe, leukocytes
were purified by macerating the lung using scissors (determined to be less DC
cytopathic than a gentleMACS C tube) and incubated with collagenase type IV
(400µg/ml, Sigma-Aldrich) in 10% RPMI medium. After 45 minutes incubation
at 37◦C, 5% CO2, the lung was further dissociated into a single cell suspension
by passing through a 21-gauge needle three times using a 20ml syringe (BD
Biosciences). Processing was then continued as above.
Lymph node for flow cytometric analysis
Lung draining mediastinal lymph nodes were removed with forceps, and placed in
10% RPMI medium on ice. Cells were released from the lymph node capsule by
gentle agitation between two sterilized slides into 10% RPMI medium. Cells were
pelleted by centrifugation (1,500rpm, 5 minutes) and erythrocytes were lysed by
brief resuspension of the cell pellet in ACK buffer, which was neutralised with 2x
volume of PBS. The remaining leukocytes were then pelleted by centrifugation
(1,500rpm, 5 minutes) and resuspended in 5ml 10% RPMI medium.
Lung lobe for mRNA analysis
The apical right lung lobe was removed, rinsed in PBS, snap frozen in RNAlater
(Qiagen, Crawley, UK) using liquid nitrogen and stored at -80◦C.
Cells for mRNA analysis
Purified 1× 105 BAL cells or 1× 106 lung leukocytes were lysed by shearing in
RLT lysis buffer (Qiagen) using a pipette, snap frozen in liquid nitrogen and
stored at -80◦C.
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Lung Lobe for protein
Remaining lung (right lower lung lobes) was removed, rinsed in PBS, snap frozen
using liquid nitrogen and stored at -80◦C.
2.2.6 Assays
Cell counts
A sample of cell suspension was diluted 1:2 with 1% trypan blue (Sigma-Aldrich)
and total viable cell counts were enumerated using disposable haemocytometers
(Multicount 10; Immune systems, Torquay, UK) and a light microscope.
Differential cell counts
100µl of cells from 1ml total BAL cell suspension was spun down (500rpm, 5
minutes) onto a slide in a cytocentrifuge (Shandon Cytospin 3; Thermo Scientific,
Basingstoke, UK) and allowed to air dry. The slides were then stained using Quick-
Diff kit (Reagena, Toivala, Finland) and, using a light microscope, approximately
300 cells per slide were recorded as either macrophages, eosinophils, neutrophils
or lymphocytes based on cell morphology and granule staining.
Enzyme-linked immunosobant assay (ELISA)
Protein levels were assessed in BALF and lung homogenate. BALF was defrosted
and diluted as required. Lung homogenate was prepared by bead-milling the lung
tissue with a TissueLyser LT (Qiagen) in protease inhibitor cocktail (cOmplete
Mini EDTA-free, Roche) dissolved in PBS for 4 minutes. Debris was removed by
centrifugation (10,000rpm, 10 minutes) and the supernatant diluted as required.
DuoSet ELISA kits (R&D, Abingdon, UK) were used to assay protein levels
following the instructions provided. Plates were washed three times between
steps with 0.05% (v/v) Tween 20 (Sigma-Aldrich) in PBS (PBS-Tween). Briefly,
primary antibody was incubated on a 96-well plate (Nunc MaxiSorp, Thermo
Scientific) overnight, and non-specific binding blocked with 1% (w/v) bovine
serum albumin (BSA; Sigma-Aldrich) in PBS (reagent diluent). Samples and
standard curves (diluted in reagent diluent as appropriate) were added and
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incubated for two hours. Biotin-conjugated secondary antibody in PBS was
added and incubated for two hours. Horseradish peroxidase (HRP) conjugated
to strepatavadin (Invitrogen) was added at 0.125µg/ml and incubated for 20
minutes. Tetramethylbenzidine (TMB ; Invitrogen) was added and development
of colour monitored, which was stopped with 1M H 2SO4 (Sigma-Aldrich) when
the standard curve was well developed. Absorbance was then measured on a
plate reader (Spectra Max plus 384; MDS Analytical Technologies, Wokingham,
UK) at 450nm with corrections made for plate and background absorbance at
540nm and concentrations calculated from the standard curve.
Muc5AC protein was measured after adhesion to an ELISA plate by allowing
BALF samples to evaporate from the plate in a 37◦C incubator overnight. The
plate was blocked as above, and then biotinylated anti-Muc5AC antibody (clone
45M1; Neomarkers, Fremont, USA) was added at 400pg/ml in PBS-Tween with
0.2% BSA and incubated for 2 hours. The ELISA was then developed as above
following secondary antibody incubation.
The limit of detection (LOD) for an individual plate was calculated as 3
standard deviations (SD) above the mean OD of the blank wells. Any wells below
the LOD were considered to have a zero concentration.
Myeloperoxidase (MPO) assay
To indirectly assess neutrophil activation, the peroxidase or chlorination activity
of released MPO was measured in the BALF using the EnzChek MPO activity
assay kit (Invitrogen). Briefly, 50µl of reagent (table 2.6) was added to either 50µl
of BALF or appropriately diluted recombinant mouse MPO standard in the well
of a 96-well black opaque plate (Corning, Amsterdam, Holland). MPO activity
converted reagent to a fluorescent product. Fluorescent emission was measured
for each assay as in table 2.6, after appropriate development of the standard
curve, using a fluorescent plate reader (FLUOstar Omega, BMG LABTECH
GmbH, Ortenberg, Germany) and expressed either as fluorescent units or MPO
concentration calculated from the standard curve.
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Assay Reagent Excitation Emission
Peroxidation Amplex UltraRed 544nm 590nm
Chlorination 3’-(p-aminophenyl) fluorescein (APF) 485nm 520nm
Table 2.6: Myeloperoxidase activity reagents.
2.2.7 Quantitative real time PCR
cDNA preparation
RNA was extracted from frozen samples and converted to cDNA using RNeasy
and Omniscript kits, respectively, as per manufacturers instructions (both Qiagen).
Briefly, lung lobe previously stored in RNAlater was removed and lysed in RLT
buffer by bead-milling using a TissueLyser LT (Qiagen), after which debris was
removed by centrifugation (10,000rpm, 3 minutes). RNA was precipitated from
the resultant supernatant with ethanol. Cell samples, previously lysed and frozen
in RLT, were defrosted and RNA was directly precipitated with ethanol. RNA
was bound to an RNeasy spin column (Qiagen), washed and contaminating DNA
was digested with DNAse I (Qiagen). Finally, RNA was eluted with 42µl (for
lung lobe) or 30µl (for cell samples) of RNAse-free water. RNA concentration
was measured using a spectrophotometer (NanoDrop 1000; Thermo Scientific).
For conversion to cDNA, 2µg RNA (for lung lobe) or 14µl eluent (for cell samples,
due to low RNA concentration) of RNA was added to a reaction mix containing
an excess of reverse transciptase, deoxynucleotide triphosphates (dNTP; both
from Omniscript kit, Qiagen) and random hexamers (Promega, Southampton,
UK) which was then incubated at 37◦C in a water bath for 11
2
hours.
Design of qPCR primers and probes
qPCR primers and probes were designed in-house, either previously by other
lab members or, for project-specific primers and probes, using Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with the mRNA se-
quence retrieved from the nucleotide database (http://www.ncbi.nlm.nih.gov/
nuccore/), both being provided by the National Center for Biotechnology Infor-
mation within the National Institutes of Health, USA. Primer-BLAST parameters
(such as product length, melting temperatures, etc) were optimised for Taqman
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qPCR and required that the amplified sequence span an intron-exon boundary,
to exclude cloning of any contaminating genomic DNA. Forward and reverse
primers were purchased from Invitrogen and probes, conjugated to carboxyfluores-
cein (FAM) and tetramethylrhodamin (TAMRA), were purchased from Eurofins
(Ebersberg, Germany).
Generation of qPCR standards
To generate standards, qPCR (as below, with an additional 5 minute elongation
step) was run on samples with expected high expression of the target sequence.
The resulting qPCR product was then cloned using a TOPO TA cloning kit
(Invitrogen) as per manufacturers instructions.
Briefly, PCR product was incubated with TOPO vector plasmid for 5 minutes
which was subsequently incubated with One Shot Escherichia coli (E. coli) for
30 minutes on ice. The E. coli were then transformed by heat shock at 42◦C
for 30 seconds in a water bath, recovered in SOC medium for one hour and
then plated onto LB agar plates (including ampicillin). Ampicillin resistant
colonies (i.e. those with resistance conferred by plasmid inclusion), were picked
and grown in 5ml ampicillin-containing LB broth overnight. Plasmid was then
purified using a QIAprep mini prep kit as per manufacturers instructions (Qiagen).
Briefly, bacterial cells were pelleted by centrifugation (10,000rpm, 10 minutes)
and resuspended in buffer P1. Cells were then lysed in buffer P2 and genomic
DNA precipitated with buffer N3. Cell debris and genomic DNA was removed
with centrifugation (13,000prm, 10 minutes) and the supernatant was added to a
QIAprep spin column. The column was washed and plasmid DNA eluted in 50µl
of H2O.
Purified plasmids were then screened for target sequence insertion into the
plasmid by qPCR with the primers and probes originally used to generate the
target sequence. High-expressing plasmids were re-transformed into E.coli as
above, with the overnight culture in 5ml LB broth used to prime a further
overnight culture in 100ml LB broth. Plasmid was then purified with a QIAprep
maxi prep (Qiagen) as per manufacturers instructions (similar to the above
QIAprep mini prep). The concentration of maxi prep-purified plasmid was then
measured using a spectrophotometer (NanoDrop 1000; Thermo Scientific), diluted
to 1× 1010 plasmid copies per µl and frozen in aliquots at -20◦C.
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qPCR assay
1µl of cDNA sample or appropriately diluted plasmid standard was added to a
reaction mix of 6.25µl QuantiTect Probe PCR Master Mix (Qiagen), forward
and reverse primers and FAM-TAMRA probe at suitable concentrations and
appropriate to the target gene (see table 3) in a total volume of 12.5µl in a well
of a qPCR plate (MicroAmp fast 96-well reaction plate; Applied Biosystems,
Paisley, UK). The qPCR reaction was then run on a 7500 Real-Time PCR System
(Applied Biosystems) for 45 cycles, consisting of double-strand melting at 95◦C for
15 seconds followed by annealing and extending at 60◦C for 60 seconds. The cycle
at which fluorescence of free FAM in the sample passed a threshold value (Ct),
appropriate to the data as set by the user, was determined. When a standard
curve was available, absolute quantity (per cell number or per RNA quantity, as
appropriate for the processing of the sample) was calculated. When no standard
curve was available (as it was not possible to clone some qPCR products) the
relative quantity was calculated first by normalisation to an endogenous control
(either to 18S rRNA copies by the 2-∆∆Ct method or to total RNA concentration
by the 2-∆’Ct method) and subsequent normalisation to the mean of the control
group (calibrator sample), giving fold change of gene expression over control
(Livak and Schmittgen, 2001).
To determine the method detection limit (MDL) for individual qPCR assays,
all available standard curves were combined and plotted as the log of plasmid
copies versus the Ct value and a linear regression line calculated. Assuming the
absolute minimum quantity possible to detect in 1µl of sample to be one copy,
the lower 95% confidence interval of the linear regression where it intersected the
y-axis (i.e. 100 ≡ 1 copy) was taken to be the Ct value for the MDL. Any wells
below the MDL were considered to have a zero concentration.
2.2.8 Flow cytometry
Flow cytometry staining
Purified leukocytes were washed in flow buffer (1% (w/v) BSA in PBS) and
dispensed into a 96 v-well plate. For intracellular staining, 3× 106 cells were
plated and for surface/intranuclear staining, 1× 106 lung, 2× 106 lymph node or
1× 105 BAL cells were plated. All staining was incubated in the dark. Cells were
pelleted and resuspended in Fc block (anti-CD16 and CD32, BD Biosciences)
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at 5µg/ml in flow buffer, to which was added surface stain antibodies at a final
concentration as indicated in table 2.2 and incubated for 30 minutes on ice. Cells
were then washed in PBS and stained with live/dead cell stain (Invitrogen) at
a 1:1000 dilution in PBS (Invitrogen) for 15 minutes, washed in PBS and fixed
with 2% (v/v) formaldehyde (Sigma-Aldrich) in PBS for 20 minutes. Finally,
cells were washed and then resuspended in flow buffer.
For intracellular cytokine staining, cells were first stimulated with PMA
(50ng/ml; Sigma-Aldrich), ionomycin (500ng/ml; Sigma-Aldrich) and GolgiStop
(1:1000 dilution; BD Biosciences) in 10% RPMI medium with a final cell concen-
tration of 1× 106/ml at 37◦C, 5% CO2 for 4 hours before surface staining. After
surface staining and fixing as above, cells were washed and then resuspended in
0.5% (w/v) saponin (Sigma-Aldrich) in flow buffer for permeabilisation. Anti-
bodies for cytokines were added at a final concentration as indicated in table 2.2
in 0.5% saponin and incubated for 30 minutes. Cells were then washed and
resuspended in flow buffer.
For intranuclear staining with anti-RORγt antibody, surface-stained cells were
fixed and permeabilised with Foxp3 fixation/permeabilisation buffer (eBioscience)
for 30 minutes, washed, anti-RORγt antibody added in permeabilisation buffer
(eBioscience) at a final concentration of 1µg/ml and incubated for 30 minutes.
Cells were then washed in permeabilisation buffer and resuspended in flow buffer.
Stained cells were acquired on an LSR II flow cytometer (BD Biosciences) and
analysed using FlowJo software (version 7.6; Tree Star, Ashland, USA)
Gating strategy
The gating strategy for intracellular cytokine staining is shown in figure 2.3. In
all experiments, only live, singlet cells are shown. A lymphocyte gate is used to
exclude macrophages (which are highly autofluorescent) from subsequent analysis,
except where gross cell staining investigations were carried out as mentioned
in the text. NK cells are shown by NK1.1 staining in C57BL/6 or NKp46 in
BALB/c mice. T cells are then gated on CD3 and subdivided into CD4+, CD8+
or γδ TCR+ (within CD4-CD8- cells). Cytokine staining was investigated within
these lymphocyte subsets and reported as total numbers within the left lung lobe.
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2.2.9 Statistical analysis
Data was represented graphically using Prism (version 4, GraphPad Software, San
Diego, USA), plotting group means and displaying error bars as standard error of
the mean (SEM). Significant differences were calculated by Mann-Whitney (for
comparing two groups) or Kruskal-Wallace with Dunns post-test (for more than
two groups) between groups as indicated. For time courses, two-way ANOVA was
performed with Bonferroni post-test. As Kruskal-Wallace with Dunns post-test
is more stringent than two-way ANOVA, fewer comparisons are significant with
this test. However, comparisons considered biologically relevant are discussed
as trends and fold change or percentage difference with standard deviation is
given. Significance is marked as ∗ ∗ ∗ = 0.005 ≥ P, ∗∗ = 0.01 ≥ P > 0.005 or
∗ = 0.05 ≥ P > 0.01.
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3 Primary Infection in Mice
3.1 Introduction and Rationale
Rhinoviruses, as well as being the most frequent cause of the common cold, are
associated with exacerbations of the respiratory diseases asthma and COPD
(Mallia and Johnston, 2006). Despite being discovered in the 1950s, there is
currently no effective vaccine for preventing, or drugs for treatment of, rhinovirus-
induced exacerbations of these diseases (Ganesan et al., 2012).
Primary infection with rhinovirus in a mouse model induces an influx of
neutrophils and lymphocytes into the airways of the lung, including T helper,
T cytotoxic, γδ T and NK cells (Bartlett et al., 2008; Glanville et al., 2013).
Both innate and adaptive lymphocyte responses are important for clearing virus
infections from the lung (Bruder et al., 2006), and it has been previously shown
in our animal model that rhinovirus induces IFN-γ secretion from T helper cells
in response to rhinovirus (Glanville et al., 2013).
The novel T helper subset Th17 is generated in response to fungal infections
(Zelante et al., 2009), but has been associated with autoimmune diseases as well
as severe, neutrophilic asthma (Nakagome et al., 2012; Vargas-Rojas et al., 2011).
There is also evidence that it can be induced by viral infections of the lung such as
influenza and RSV (Almansa et al., 2011; Mukherjee et al., 2011). Whilst human
experimental infection studies in asthmatics and healthy controls, carried out
within our group, have shown small but significant induction of IL-17 following
rhinovirus infection (Jackson, unpublished), little is known about Th17 and IL-17
secreting cells during rhinovirus infection. To further investigate induction of
IL-17 by rhinovirus and identify potential sources we shall utilise a mouse model
of primary rhinovirus infection, measuring IL-17 by ELISA, qPCR and flow
cytometry over the infection time course in our mouse model, allowing more
detailed investigation than in human studies.
To date, our published rhinovirus mouse studies have used the mouse strain
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BALB/c for primary infection models. However, efficient rhinovirus infection
has also been shown in C57BL/6 mice (Wang et al., 2011a). For investigation
of IL-17 responses this strain has several advantages; it lacks the Th2 bias of
BALB/c mice that can skew immune responses to challenges such a viruses, and
Th17-related knockouts (Il17a-/-, Il17f-/-, Rorc-/-) are only currently available on
the C57BL/6 background. Thus investigation of IL-17 responses will be carried
out in C57BL/6 mice.
3.2 Aims
We aim to characterise the IL-17 and Th17 responses in the lungs and airways
of C57BL/6 mice during a primary rhinovirus infection, using the minor group
serotype RV1B. This shall be addressed via:
i Intracellular staining for cytokines to detect the recruitment and/or develop-
ment of Th17 (CD4+IL-17+) or other IL-17A–producing cells, or intranuclear
staining for RORγt to detect Th17 (CD4+RORγt+) or other RORγt+ cells, in
response to a primary rhinovirus infection by flow cytometry and in relation
to the cytokines IFN-γ and IL-4.
ii ELISA to detect the Th17-inducing proteins IL-6, IL-1β and IL-23 and the
Th17 secreted proteins IL-17A and IL-17F.
iii qPCR to detect the Th17-associated mRNA transcripts Il17a, Il17f and Rorc.
iv Characterising the time course of any detected IL-17 response.
3.3 Hypotheses
Rhinovirus infection induces an increase in Th17 cells in the lung in addition
to the previously observed Th1 responses, and this increase is associated with
increases in secreted Th17 proteins and Th17 genes, and preceded by increases in
IL-6, IL-1β and IL-23.
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3.4 Results
3.4.1 Confirmation of in vivo rhinovirus infection
Upon successful infection of mice with rhinovirus it has been shown that neu-
trophils are rapidly recruited to the lung airway, with lymphocytes appearing
from day two. Rhinoviral RNA is also detectable in the lung tissue following
infection (Bartlett et al., 2008). To confirm successful infection of mice, the
presence of neutrophils as well as lymphocytes, macrophages and eosinophils in
the BAL was assessed by differential cell counts (figure 3.1), and the presence of
rhinoviral RNA in lung homogenate was assessed by qPCR (figure 3.2).
Infection of C57BL/6 mice induced a rapid increase in total BAL cells by 24
hours, peaking at 48 hours but remaining high out to seven days post infection
(figure 3.1a). This increase was initially driven by neutrophils, which peak at 24
hours and were thereafter rapidly cleared, disappearing from the BAL by day four
(figure 3.1b). Lymphocytes were recruited to the lung later, peaking at day two
but continuing to remain significantly high out to day 7 (figure 3.1c), when along
with a small but significant increase in macrophage numbers (figure 3.1d) they
continued to cause a higher BAL cellularity. Eosinophils were not detected during
the course of a primary rhinovirus infection. Rhinoviral RNA was detectable at
significantly high levels in lung tissue 8 hours after rhinovirus infection, after
which copy number fell (figure 3.2).
Recruitment of neutrophils to the lung airway was preceded by a significant
induction of proinflammatory (IL-6) and neutrophil chemotactic cytokines (KC,
MIP-2α; figure 3.3) at 8 hours which fell by 24 hours. The neutrophil chemokine
LIX was also increased significantly at 8 hours, however unlike IL-6, KC and
MIP-2α, the secretion of LIX peaked with neutrophil recruitment at 24 hours
and remained significantly higher out to 48 hours than in mice treated with
UV-inactivated rhinovirus.
3.4.2 Detection of secreted IL-17 and IL-17F
As IL-17 is a potent inducer of KC (CXCKL1) and LIX (CXCL5), their presence
after infection in mice may indicate early secretion of IL-17. To assess IL-17
induction by rhinovirus in our mouse model, levels of both IL-17 and the related
cytokine IL-17F were measured in BALF (at 4, 8, 12, 24, 48, 96 and 168 hours post
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Figure 3.1: BAL leukocyte responses to a primary rhinovirus infection. C57BL/6 mice were
infected i.n. with rhinovirus serotype RV1B (RV), controls receiving UV-inactivated RV1B
(UV-RV), at time zero. Total leukocytes infiltrating the lung airways were counted using a
haemocytometer (a) and indentified as neutrophils (b), lymphocytes (c) or macrophages (d)
from cytospins stained with QuickDiff. Eosinophils were not seen in a primary rhinovirus
infection. Total numbers are shown as the mean ± SEM. Data is combined from 6 independent
experiments and n = 8-22 mice per time point. p.i.; post infection.
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Figure 3.2: Rhinovirus is detectable in the lung tissue following primary rhi-
novirus infection. C57BL/6 mice were infected i.n. with either rhinovirus serotype
RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero. RNA was purified
from the apical right lung lobe, converted to cDNA and copies of rhinovirus
determined by qPCR. Mean RNA copies per µg of total RNA are shown ± SEM,
n = 4 mice per time point, experiment representative of 6 repeats.
infection) of mice dosed with either live or UV-inactivated rhinovirus. Neither
protein was detectable above the limit of detection at any time point (data not
shown). Although abundant proteins, such as chemokines, are easily detectable
in BALF, it may be difficult to detect proteins secreted at low levels and rapidly
utilised, such as T cell-derived cytokines. In humans, cytokines are only weakly
detectable in BALF, however, significant levels can be detected using synthetic
absorptive matrix (SAM) to sample the mucosal lining of the lung and nose, which
provides a more concentrated sample and recent clinical trials in our department
have have made use of this. Although attempts are being made to develop this
technique in the mouse, it is technically difficult; however we are able to easily
sample leukocytes from both the lung tissue and airway than from a human.
3.4.3 Assessment of IL-17+/RORγt+ leukocytes
The presence of IL-17 and its cellular source, even in small numbers, can be
detected using flow cytometry on leukocyte samples from the lung. Lymphocytes
were seen to be recruited into the airways in the differential counts of BAL cells
(figure 3.1c). Surface staining of these BAL cells showed significant increases in
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Figure 3.3: Cytokines are induced in response to a primary rhinovirus infection. C57BL/6
mice were infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero. Protein concentrations in the BALF were measured using ELISA for
IL-6 (a), KC (b), LIX (c) and MIP-2α (d). Mean concentrations are shown ± SEM, n = 4
mice per time point, experiment representative of 6 repeats.
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total CD3+ T cells as well as CD4+, CD8+ and γδ+ subtypes (figure 3.4). CD4+
and γδ+ T cell populations are the two main cell types known to secrete IL-17,
but CD8+ cells have also been shown to be capable of IL-17 secretion (Hamada
et al., 2009). However intracellular staining for cytokines requires prior polyclonal
stimulation with PMA and ionomycin and cytokine secretion inhibition with
monesin, which kills a large number of cells. BAL cells are a limited in number
(5× 105 at the peak after infection) and a modest recovery rate after stimulation
means that too few BAL cells can be assayed for investigation of cytokine staining.
Many more cells can be recovered from the lung tissue, with the left lobe alone
giving up to 107 leukocytes. Figure 3.5 shows the same T cell surface staining for
lung leukocytes as in figure 3.4. Although there was a basal level of T cells in the
lung with UV-irradiated rhinovirus controls due to continual T cell trafficking
in and out of the highly vascular organ, as well as tissue-resident T cells, the
same trends for increases in T cell types as in the BAL were seen in the lung,
with significantly more CD3+CD4+ T cells at day 7 with a rhinovirus infection
than with UV inactivated rhinovirus. The lung tissue is an important site for T
cell action in response to virus and cells within the airways would have trafficked
through the lung tissue.
Figure 3.6 shows the results of staining lung cells for cytokine production. Cells
were stained for IFN-γ and IL-4 as well as IL-17 after polyclonal stimulation.
Previous investigations by our lab have shown an induction of CD4+IFN-γ+ (Th1)
cells following rhinovirus infection, thus this can serve as a positive control for
T cell responses to rhinovirus. As can be seen in figure 3.6b, there was a clear
induction of Th1 cells following rhinovirus infection, with significant levels by
day 4, persisting to day 7. However, no similar induction of CD4+IL-17+ (Th17)
nor CD4+IL-4+ (Th2) was seen over the same period; although a significant
difference in Th17 was seen at 96 hours, this was not reproducible and unlikely to
be physiologically relevant. Very low levels of IL-17 staining were seen within the
γδ+ or the CD8+ T cell subsets of all mice and this staining was not increased
during a rhinovirus infection (data not shown).
Cells capable of IL-17 production have been shown to express the transcription
factor RORγt, both in CD4+ and γδ+ T cell populations (Kanai et al., 2012).
RORγt+ T cells have also been shown to be capable of secretion of other Th17-
related cytokines such as IL-17F, without co-secretion of IL-17 (Yang et al., 2008).
To ascertain whether any RORγt+ cells are present after a rhinovirus infection as a
separate population from the above investigated IL-17+ cells, intranuclear staining
for RORγt was performed. As this process does not require prior stimulation
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Figure 3.4: T cells are recruited into the airways after primary rhinovirus infection. C57BL/6
mice were infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero. Leukocytes from the airways were stained for the surface markers CD3
(a), CD4 (b), CD8 (c) and γδ T cell receptor (d). Mean cell numbers are shown ± SEM, n = 4
mice per time point, experiment representative of 3 repeats.
Page 76
3.4. RESULTS
a
8 1 2 4 7
0.0
1.0
2.0
3.0
4.0
5.0
Days p.i.
H
o
u
rs
 
p.
i.
To
ta
l L
o
be
 
CD
3+
 
Ce
lls
 
x
10
6
b
8 1 2 4 7
0.0
0.5
1.0
1.5
2.0
2.5
Days p.i.
H
o
u
rs
 
p.
i.
*
To
ta
l L
o
be
 
CD
3+
CD
4+
 
Ce
lls
 
x
10
6
c
8 1 2 4 7
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Days p.i.
H
o
u
rs
 
p.
i.To
ta
l L
o
be
 
CD
3+
CD
8+
 
Ce
lls
 
x
10
6
d
8 1 2 4 7
0.0
2.5
5.0
7.5
10.0
Days p.i.
Ho
u
rs
 
p.
i.To
ta
l L
o
be
 
CD
3+
γγ γγ δδ δδ
+
 
Ce
lls
 
X1
04
UV-RV RV
Figure 3.5: T cells are increased in the lung tissue after primary rhinovirus infection. C57BL/6
mice were infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero. Leukocytes from the lung tissue were stained for the surface markers
CD3 (a), CD4 (b), CD8 (c) and γδ T cell receptor (d). Mean cell numbers are shown ± SEM,
n = 4 mice per time point, experiment representative of 6 repeats.
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Figure 3.6: Only IFN-γ–secreting T cells are recruited after a rhinovirus infection. C57BL/6
mice were infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero. Leukocytes from the lung tissue were stained for the surface markers CD3
and CD4, and intracellularly for the cytokines IL-17 (a), IFN-γ (b) and IL-4 (c) .Representative
flow plots (d). No significant increases in IL-17 were seen in other T cell subsets. Mean cell
numbers are shown ± SEM, n = 4 mice per time point, representative of three repeats.
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(and subsequent loss of viable cells) it was also possible to assess staining in
sufficient numbers of BAL cells.
The results of RORγt staining within the CD4, CD8 and γδ T cell subsets are
shown in figure 3.7. Within the lung tissue, a proportion of both CD4+ and γδ T
cells stained for RORγt, with no staining within the CD8+ population. However,
there was no significant difference in RORγt+ cells between live and UV-irradiated
rhinovirus treated mice in any T cell subset. Interestingly, although there was no
difference in RORγt+γδ+ cells between groups, RORγt+ cells represented a large
proportion of the total γδ T cell population within the lung (mean 53.8%, SD
15.3%). This was not the case with IL-17 staining within the γδ T cell subset,
suggesting a majority of these RORγt+γδ+ cells are not capable of producing
IL-17 in response to polyclonal stimulation.
In the airways, again no RORγt+ cells were detected within the CD8+ T cell
subset. A small infiltration of CD4+RORγt+ cells was seen (figure 3.7b), though
both overall numbers and percentage of total CD4+ remain low (mean 5.8%, SD
3.5% at day four), and this observation was not significant at any time point up
to day four post infection.
RORγt+γδ+ cell numbers also increased within the BAL, and these reached
significance by day four. The increases seen were in line with increases in total γδ
T cells of which a large proportion was RORγt+ (mean of 65.0%, SD of 20.6%).
This proportion was similar to that seen in the lung tissue above (and was not
significantly different), suggesting that there is no preferential recruitment of
RORγt+γδ+ cells into the BAL from the lung tissue.
In addition to the clear evidence for T cells, several other cell types have also
been reported to secrete IL-17, notably macrophages, neutrophils, NK and NKT
cells (Michel et al., 2007; Passos et al., 2010; Wozniak et al., 2011). IL-17 and
RORγt staining was not seen within neutrophil (Gr-1high) nor macrophage (high
FSC/SSC) populations (data not shown), though macrophages could be more
specifically explored with staining for F4/80. Both NK and NKT cells express
the marker NK1.1 in C57BL/6 mice, and NK1.1+ NK cells were recruited to
the lung and BAL during a rhinovirus infection of C57BL/6 mice (Jayaraman,
2012). NKT cells may be distinguished by co-expression of CD3 and NK1.1,
however this is not the case for all NKT populations (Michel et al., 2007) and no
distinct NK1.1+CD3+ double positive populations were seen during the course
of a rhinovirus infection (data not shown). However, to rule out any possible
contribution of NK/NKT-derived IL-17 during a rhinovirus infection, NK1.1
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Figure 3.7: RORγt is expressed in a large proportion of γδ T cells in the lung tissue, which
are recruited into the airways. C57BL/6 mice were infected i.n. with either rhinovirus serotype
RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero. Leukocytes from the lung tissue
(left) or airways (right) were stained for the surface markers CD4 (a, b), CD8 (c, d) andγδ T
cell receptor (e, f) and intracellularly for the transcription factor RORγt. Mean cell numbers
are shown ± SEM, n = 4 mice per time point.
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and IL-17 staining were investigated in the lung tissue, and NK1.1 and RORγt
staining investigated in both the lung tissue and airways.
NK responses to rhinovirus infection are shown in figure 3.8. Rapid and
significant recruitment of NK1.1+ cells to the BAL was seen by 12 hours, and
similar trends were mirrored in the lung, though these did not reach significance. In
the BAL, few NK1.1+ cells stained for RORγt and this did not differ significantly
with infection. In the lung tissue, a large proportion of NK1.1+ cells stained
positive for IFN-γ following infection (mean 63.5%, SD 3.6% at 12 hours) and
this sub-population reached significance at 12 hours (figure 3.8d). However, no
physiologically relevant RORγt or IL-17 staining was seen at any point up to
four days following infection.
3.4.4 Th17-associated gene expression
To confirm the above results, as well as detect any partial induction of a Th17
phenotype up to, but not beyond, gene expression, mRNA levels of Th17 associated
genes were measured within lung tissue and BAL leukocytes. mRNA levels for
the cytokine genes Il17a and Il17f were measured in purified leukocytes from the
lung and BAL cells (figure 3.9). In lung leukocytes very low numbers of mRNA
copies for Il17a and Il17f were detected above the method detection limit (MDL)
in rhinovirus infected mice but these were not significantly different from UV-RV
treated mice (figures 3.9a and 3.9b). No copies of either gene were detectable
in BAL cells (not shown). As a positive control, Ifng gene expression was also
measured in the above samples and showed significant induction at 8 hours in
both lung leukocytes and BAL cells (figures 3.9c and 3.9d), with a second peak
of significant production in BAL cells at day 7, which may represent NK cell and
T helper cell production respectively. The levels of Ifng were several orders of
magnitude above the minimal levels of Il17a and Il17f detected.
To complete gene expression investigations, the level of Rorc expression was
also measured by qPCR. No significant induction of Rorc was seen at any time
point with a rhinovirus infection (data not shown).
3.4.5 Investigating the Th17 differentiation pathway
Our observations have shown that there is no detectable induction of IL-17
nor related proteins or genes following a rhinovirus infection in mice, which
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Figure 3.8: NK1.1+ cells only respond with IFN-γ to a primary rhinovirus infection. C57BL/6
mice were infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero. Leukocytes from the airways (a, b) or lung tissue (c, d, e, f) were
stained for the surface markers CD3 and NK1.1 and intracellularly for the cytokines IL-17,
IFN-γ and IL-4 or the transcription factor RORγt. Mean cell numbers are shown ± SEM, n =
4 mice per time point.
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Figure 3.9: The Th17-related genes Il17a and Il17f are not significantly increased following
a rhinovirus infection. C57BL/6 mice were infected i.n. with either rhinovirus serotype RV1B
(RV) or UV-inactivated RV1B (UV-RV) at time zero. RNA was purified from from lung tissue
leukocytes (a, b, c) or BAL cells (d), converted to cDNA and gene copies determined by qPCR.
Mean RNA copies per 105 cells are shown ± SEM, n = 4 mice per time point.
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conflicts with recent clinical observations. Differences may be due to the variation
in sampling and assays; however infection in the mouse is seen to be ‘milder’
compared to experimental infection in humans, likely due to the virus being more
adapted to human infection. Virus persistence in mice is also shorter than in
a human, possibly due to limits on replication, although replication is clearly
required for inflammatory responses in the model. With this in mind, IL-17
responses may be a feature of ‘stronger’ infections as seen in humans and so we
set out to investigate other aspects of the Th17 pathway to see where deficiencies
may exist.
Historically, the signals required to induce full Th17 differentiation have been
difficult to tease apart, to some extent caused by use of different models and
human versus animal variations (reviewed in Korn et al. 2009). However a
basic consensus on the requirements now exists in the literature, with an initial
requirement for a combination of TGFβ, IL-6, IL-1β and IL-21 inducing STAT3
transcription, leading to IL-23 receptor expression. IL-23 receptor (IL-23R) is not
expressed on na¨ıve T cells, so this process makes the ‘proto-Th17’ cell sensitive
to IL-23 signalling, which leads to RORγt transcription and full differentiation
including further upregulation of IL-23R and production of Th17 cytokines (Harris
et al., 2007; Hirahara et al., 2010). The requirement for differentiation of other
IL-17 producing cell types is less well studied; however some studies have shown
a similar requirement of IL-23 signalling to induce IL-17 secretion from γδ T cells
(Sutton et al., 2009).
The lung is known for having a basal expression of TGFβ (Bartram and Speer,
2004) which is also induced in response to damage and dampens inflammatory
responses. Significant IL-6 production in response to a rhinovirus infection has
been shown in figure 3.3a. IL-21 was not measured, however high levels of IL-6
are thought to render the requirement for exogenous IL-21 redundant, possibly
by inducing autocrine production of IL-21 (Nurieva et al., 2007).
To further investigate Th17 inducing cytokines, the levels of IL-1β and IL-
23 were measured in the BALF of mice following rhinovirus infection. IL-1β
responses are shown in figure 3.10, with a significant peak at 12 hours. However,
IL-23 was not detectable in the BALF at any time point after infection (data
not shown). This absence of IL-23 in the lung, along with a lack of a significant
increase in RORγt staining in CD4+ T cells, suggests that differentiation of Th17
following rhinovirus infection in mouse may stall at the stage of IL-23/RORγt
stabilisation of Th17 commitment and these cells fail to survive or progress to
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Figure 3.10: Th17 polarising IL-1β, but not the Th17 stabilising IL-23, is
produced after a primary rhinovirus infection. C57BL/6 mice were infected i.n.
with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at
time zero. Concentrations of IL-1β and IL-23 in the BALF were measured using
ELISA; IL-23 was not detected. Mean concentrations are shown ± SEM, n = 4
mice per time point.
IL-17 production. Lack of IL-23 may also explain the lack of IL-17 responses
from γδ T cells, even though a large proportion express RORγt and thus are
likely to express IL-23R.
3.4.6 Th17 recruitment and sensitivity
Another possible reason for the discrepancies between human observations and
the mouse model is that infection in humans may recruit existing memory Th17,
which have been shown to be present in the peripheral blood of healthy human
subjects and to higher levels in asthmatics (Bajoriuniene et al., 2012), but are only
detected at low numbers in the spleens of specific pathogen-free mice (Lexberg
et al., 2008). Th17 cells can be distinguished from other T helper lineages by
their high expression of the chemokine receptor CCR6 (which is also expressed
on dendritic cells). CCR6 is unique in the fact that it is the only chemokine
receptor to have a single known ligand, MIP-3α (CCL20). Thus, as shown in
Page 85
CHAPTER 3. PRIMARY INFECTION IN MICE
a
4 8 12 1 2 4
0
250
500
750
1000
Days p.i.Hours p.i.
*** ***
*
B
AL
 
 
CC
L2
0     
// //
M
IP
3 αα αα
(p
g/
m
l)
b
4 8 12 1 2 4
0
20
40
60
80
100
120
Days p.i.Hours p.i.
***
B
AL
 
CC
L5
 
/ R
AN
TE
S
(p
g/
m
l)
UV-RV RV
Figure 3.11: T cell chemokines induced following a primary rhinovirus infection
target both Th17 and Th1 cells. C57BL/6 mice were infected i.n. with either
rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero.
Protein concentrations in the BALF were measured using ELISA for either MIP-
3α (a) or RANTES (b). Mean concentrations are shown ± SEM, n = 4 mice per
time point, representative of 2 repeats.
figure 3.11, we measured the levels of MIP-3α in the BAL, and also those of
the T cell chemokine RANTES (CCL5) as a comparison. Both chemokines were
induced by rhinovirus infection and peaked at 12 hours post infection. MIP-3 α
was expressed at much higher levels than RANTES, and was significant from 8
to 24 hours. RANTES is partly responsible for the recruitment of Th1 cells to
the lung, but the high levels of MIP-3α suggest that if large numbers of Th17
were present in the infected mouse they would also be recruited to the lung in
response to rhinovirus.
The ability of target cells (mainly epithelial cells in the lung) to respond to
IL-17 via the IL-17 receptor is also important for Th17 action. For both IL-17A
and IL-17F the receptor is a heterodimer of the proteins IL-17RA and IL-17RC.
To examine if a rhinovirus infection alters the expression of either receptor subunit,
the fold change in expression of their mRNA was measured in lung tissue following
a rhinovirus infection figure 3.12. Although a small drop in expression is seen at
8 hours, mRNA expression for both receptor chains is increased at 24 hours post
infection, which is significant for Il17ra.
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Figure 3.12: IL-17 receptor gene expression increases one day after a primary
rhinovirus infection. C57BL/6 mice were infected i.n. with either rhinovirus
serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero. RNA was
purified from the apical right lung lobe, converted to cDNA and fold change of
the receptor genes Il17ra (a) and Il17rc (b) was determined by qPCR. Mean
fold changes are shown ± SEM, n = 4 mice per time point, representative of 2
repeats.
3.4.7 Immunomodulation of the rhinovirus response
Work in our lab is attempting to modulate the immune response to a broad
range of rhinovirus serotypes in the hopes of preventing ensuing exacerbations
in asthmatics, using a proprietary Th1 adjuvant. While a primary rhinovirus
infection did not induce IL-17 responses, the opportunity was taken to investigate
whether prior vaccination could prime the immune system to produce IL-17 in
response to rhinovirus. Samples from a vaccination study in BALB/c mice were
made available. Mice were treated with either PBS, adjuvant alone, or adjuvant
plus proteins from one of two related rhinovirus serotypes (RV1B or RV16) on
days 1 and 22, following which all groups were infected with live RV1B on day
56. Lung cells were harvested at 6 days following infection and stained for flow
analysis of cytokine expression.
As shown in figure 3.13, BALB/c mice pre-treated with PBS or adjuvant alone
had no induction of Th17 cells following infection, similar to responses seen in
na¨ıve C57BL/6 mice (figure 3.6). However mice treated with adjuvant and viral
protein showed a large induction of Th17 in the lung in response to infection with
rhinovirus (to levels higher than seen with Th1 in a primary infection), whether
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Figure 3.13: Th17 responses to a primary infection are induced by prior immunomodulation.
BALB/c mice were treated systemically with adjuvant either alone or supplemented with
protein from either rhinovirus serotype 1B or the closely related serotype 16 on days 1 and 22.
All mice were then infected with rhinovirus serotype 1B on day 56 and lungs were collected on
day 62. Purified lung leukocytes were stained for the surface markers CD3, CD4, CD8 and
intracellularly for the cytokines IL-17 (a) and IFN-γ (b). Representative flow plots of CD4 and
IL-17 staining for PBS and RV16 vaccinated mice are shown (c). Mean cell numbers are shown
± SEM, n = 4 mice per group.
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the protein was from the same (RV1B) or a related (RV16) rhinovirus serotype.
As a comparison, Th1 responses were also measured in this model (figure 3.13b)
and were also increased above those seen in a primary infection, as well as being
above the Th17-induced responses. These observations show that while a primary
rhinovirus infection does not induce IL-17, prior exposure to rhinovirus under
the right conditions (in this case with adjuvant) can prime the immune system
to respond with IL-17 to a subsequent rhinovirus infection. Additionally, we have
confirmed our ability to detect Th17 when present.
3.4.8 Myeloid-derived suppressor cell induction
While exploring the activation of neutrophils by CD11b expression, a population
of cells distinct from neutrophils (Gr-1high) that were also CD11b+ but only
intermediate for Gr-1 expression was seen to be induced by a rhinovirus infection
in mice (figure 3.14). A strikingly similar population called myeloid-derived
suppressor cells (MDSC), induced in the lung by LPS, has previously been
reported (Arora et al., 2010). LPS contamination of our virus is excluded by the
lack of both neutrophil and MDSC recruitment in UV-irradiated virus controls,
suggesting MDSC recruitment in our model requires rhinovirus replication.
As these cells may be mistaken for neutrophils when performing differential
counts due to similar morphology, their induction over the course of a rhinovirus
infection was studied by flow cytometry. Figure 3.15 shows significant increases
of MDSC in both the lung tissue and airways, with both peaking at day two, an
observation that also agrees with the previously reported kinetics of LPS-induced
MDSC (Arora et al., 2010). MDSC are significantly increased in the lung at day
one, but do not appear in the BAL until day two, after which they begin to clear
from both compartments, though they remain significantly raised in BAL out to
day 7.
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a b
c d
Figure 3.14: A population of cells resembling myeloid-derived suppressor (MDSC) cells are
induced after a primary rhinovirus infection. LPS induces a population of CD11b+Gr-1int cells
(a, b) that are shown to be a suppressive population known as MDSC (adapted from Arora
et al. 2010). C57BL/6 mice were infected i.n. with either rhinovirus serotype RV1B (RV) or
UV-inactivated RV1B (UV-RV) at time zero (c, d). Lungs were collected at day 2 and purified
leukocytes were stained for the surface markers Gr-1 and CD11b.
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Figure 3.15: CD11b+Gr-1int MDSC-like cells are increased in lung tissue and recruited to the
lung airways after a primary rhinovirus infection. C57BL/6 mice were infected i.n. with either
rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero. Leukocytes
from the lung tissue (a) or cells from the airway (b) were stained for the surface markers Gr-1
and CD11b. Mean cell numbers are shown ± SEM, n = 4 mice per time point.
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3.5 Summary and Discussion
The literature describes the induction of IL-17 in response to several virus infec-
tions in both humans and mice, including those within the lung (Almansa et al.,
2011; Mukherjee et al., 2011). In concurrence with this, our observations from a
study of experimental rhinovirus infection of both asthmatics and healthy controls
also showed IL-17 production in a subset of patients (Jackson, unpublished).
In our mouse model of primary rhinovirus infection in C57BL/6 mice, we ob-
served persistence of rhinoviral RNA in the lung tissue and induction of chemokines
subsequently leading to recruitment of both neutrophils and lymphocytes in the
airways, followed by significant increases in Th1 cells in the lung tissue. However,
we have been unable to detect IL-17 production. IL-17 was not seen by ELISA,
flow cytometry or qPCR, nor was the Th17/IL-17 master transcription factor
RORγt seen by flow cytometry (except in a fixed proportion of γδ T cells) or
qPCR. These investigations covered a detailed time course from four hours to 7
days and samples from both the lung tissue and the airways, thus we are confident
in this negative finding.
As suggested, this lack of an IL-17 response may be due to a weaker infection in
a mouse failing to induce the later stages of Th17 development, driven by RORγt
and requiring IL-23, neither of which were induced in infected mice. The initial
stages of Th17 differentiation require TGFβ, IL-6, IL-1β and IL-21 and these
are either high in the lung at baseline (TGFβ), detectable following a rhinovirus
infection (IL-6 and IL-1β) or likely to be induced in this environment (IL-21;
discussed above). However these cytokines were only measured in the BALF taken
from the airways of the lung, whereas the main site of T cell differentiation is the
regional lymph nodes, though it can also occur directly within the lung tissue
(Neyt et al., 2012). We also do not know the cellular source of these cytokines,
which may affect the potential for them to polarise T cells. Secretion from a
dendritic cell (DC) would likely mean high levels of these cytokines around the
micro-environment of polarising T cells receiving full signalling including TCR
ligation to MHC-II, as well as the likelihood of these DCs trafficking through
the regional lymphatics and coming into contact with large numbers of na¨ıve T
cells. If these cytokines are only produced from locally resident non-APC cells,
e.g. epithelial cells, then alone they may have little effect on T cell polarisation.
Further investigation of the draining lymph node cytokine environment and lung
tissue by immunohistochemistry or flow cytometry would provide further details.
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However, if the initial requirements for Th17 polarisation are met, then some
T cells should show signs of beginning this process, notably the expression of
IL-23R and phosphorylated STAT3. Thus, measuring the presence of these two
mediators in CD4+ T cells by flow cytometry within the lung and/or draining
lymph node would reveal whether rhinovirus infection in a mouse is capable of
inducing Th17 cells in the presence of IL-23. In a model of infection with prior
vaccination, we were however able to see induction of a significant number of
Th17.
Another possibility for the source of IL-17 in human studies may be the
recruitment and activation of a pool of existing Th17 cells which only exist at a
low level in laboratory mice, but have been shown to be increased in the peripheral
blood of asthmatics. The peak of IL-17 detection was between days three and
four following rhinovirus infection in human subjects (figure 1.3a), which may
be too rapid to be due to de novo induction of Th17. The levels of MIP-3α, the
sole known ligand for the chemokine receptor CCL6 which is highly expressed
on the Th17 subset of T cells as well as dendritic cells, was seen to be closely
correlated with levels of IL-17 in our experimentally infected human subjects
(Jackson, unpublished). We also see induction of high levels of MIP-3α within our
mouse model, suggesting that if a pool of existing memory Th17 were available
they could be recruited to the lung.
γδ T cells are also capable of secreting IL-17, and may be an alternative source
of IL-17 following a rhinovirus infection in our human studies. A subset of γδ T
cells are thought to leave the thymus differentiated to an IL-17 phenotype, and
are distinguished by their expression of CCR6, IL-23R and RORγt, much like
Th17 cells (Shibata, 2012). γδ T cells are seen in the lung and have been shown
to reside adjacent to the airway wall (Wands et al., 2005) where they are thought
to mediate early innate responses, which would also agree with the early peak of
IL-17 in our human subjects.
In our observations, γδ T cells are increased in the lung tissue of rhinovirus-
infected mice, and are also recruited into the airway. Previous studies in mice
have shown that a large proportion of these γδ T cells display the TCR chain
Vγ4, a subpopulation that is thought to be immunosuppressive in mouse models
of asthma (Glanville et al., 2013) as well as being enriched for IL-17 producing
γδ T cells (Roark et al., 2012). Although Vγ4+γδ T cells were recruited along
with total γδ T cells, there was no preferential recruitment as their proportion
to total γδ T cells did not change. In a similar manner, in this study a high
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proportion (approximately half) of γδ T cells expressed RORγt by flow cytometry
at baseline, but this proportion did not change within the increased γδ T numbers
in rhinovirus-infected mice, again suggesting no preferential recruitment. There
is potentially a large amount of overlap between the Vγ4+ and RORγt+γδ T
cell populations within the lung, but concurrent staining would be required to
confirm this.
Although a large proportion of γδ T cells in the lung stain positive for RORγt,
few γδ T cells stain positive for IL-17 following polyclonal stimulation, suggesting
that although RORγt+γδ T cells may be capable of IL-17 production, in our
model of rhinovirus infection they are not stimulated to do so. It may be that
signals required to differentiate these cells into IL-17 producers are not present;
as in Th17 differentiation discussed above, IL-23 may be required, and studies
have shown a subset of γδ T cells express the IL-23R and that γδ T cells can
produce IL-17 in response to IL-23 (Sutton et al., 2009). However this process is
less well studied than in Th17.
This lack of IL-17 production in our mouse model in response to rhinovirus
infection may be due to several factors. Discussed above is the idea that IL-23
is a key mediator of the IL-17 response from both αβ and γδ T cells, but is
not seen in a primary infection in the mouse. DCs are the main cell capable of
secreting IL-23, and the most relevant for T cell polarisation. It has been shown
that ligation of TLR7/8 with the synthetic compound R848 that mimics ssRNA
can induce DCs to secrete IL-23 (Schwarz et al., 2013), however from our current
observations a primary rhinovirus (a ssRNA virus) failed to do so in our model.
This may be a reflection of the different tropism of rhinovirus for mouse and
human tissues. The rhinovirus used in our mouse models, serotype 1B (RV1B),
is from a clinical isolate and is grown in a human cell line (HeLa). Although we
can show replication in our mouse model both directly and through lack of a
response with UV-inactivated rhinovirus, mice are not a natural host and thus
rhinovirus infection may not induce the full response as in humans.
RV1B is also a minor group rhinovirus, which bind and enter their target cell
via the LDL receptor, which is conserved between humans and mice. In human
studies we use the major group serotype 16 (RV16), which enters the target cell
via ICAM-1, which is not conserved and thus major group rhinoviruses will not
infect wild type mice. Although we are not aware of major differences in clinical
outcome between the major and minor groups, this may have an effect. We have
a transgenic mouse line which expresses human ICAM-1 and is efficiently infected
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by major group viruses, including RV16, so it would be possible to investigate
IL-17 induction by the major group RV16 in these mice.
The other potential reason discussed for lack of an IL-17 response may be
the lack of prior respiratory infectious challenge in mice versus the challenge
experienced status of humans. Although we screen our human subjects for prior
exposure to rhinovirus RV16 by circulating antibody titre, it is highly likely that
they have not only been exposed to other respiratory viruses but that many of
these will be related rhinovirus serotypes, which are thought to cause most of the
approximately 2-4 colds individuals suffer per year (Arroll, 2011; Fendrick et al.,
2003). This repeated exposure may generate a pool of cells able to respond to our
experimental RV16 infections with IL-17 secretion which is missing in laboratory
mice. Repeated respiratory infection may also cause innate imprinting of the
lung, skewing the default response to subsequent virus infections (Noble, 2009).
It is known that human asthmatics have higher circulating Th17 (Bajoriuniene
et al., 2012) and in a mouse model of asthma it has been shown that Th17 are
induced by sensitisation and are important for subsequent responses to challenge,
as IL-17R deficiency markedly reduces measurements of allergic airways disease
(Schnyder-Candrian et al., 2006). Conversely, IL-17 responses from γδ T cells
have been shown to drive resolution of inflammation in this model (Murdoch
and Lloyd, 2010). In our lab, we have developed a rhinovirus exacerbation of
this model, where an infection at the time of challenge with allergen exacerbates
the subsequent allergic responses. It has been shown that many markers of the
Th2 compartment, the main driver of this model, are exacerbated by rhinovirus
infection but to date we have not investigated whether the increasingly important
Th17 component is similarly exacerbated.
Finally we discovered, by serendipity, the induction of a population of cells
resembling recently described MDSC. These are thought to be a population of
cells capable of suppressing T cell responses to antigen and have been implicated
in the protective effect of LPS exposure prior to allergen challenge in a mouse
model of asthma (Arora et al., 2010). Although not directly related to IL-17
responses, this is an interesting population which we have previously missed, and
may have mistaken for neutrophils as they appear to have a similar morphology,
though more detailed phenotyping would be needed to confirm this observation.
Further investigation, including more detailed flow cytometry characterisation
of recruited cell types, may reveal further subtleties of the role of rhinovirus in
asthma exacerbation and add to our current understanding.
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4 Exacerbation of AAD Induced
by Systemic Sensitisation
4.1 Introduction and Rationale
In human experimental infection studies, we observed IL-17 secretion in response
to a rhinovirus infection; however we were unable to detect similar responses in a
mouse model of primary rhinovirus infection. As discussed in chapter 3, there
may be several reasons for this, including a lack of prior challenges that create an
environment able to respond with IL-17, or the relative weakness of the infection
in mice.
Human asthmatic subjects had higher IL-17 responses to rhinovirus than
healthy controls (figure 1.3), and have also been shown to have higher levels of
circulating Th17 cells in peripheral blood (Bajoriuniene et al., 2012). Although
asthma is classically thought of as a Th2-mediated disease involving IL-5 and
IL-13, raised IgE, mast cells and eosinophilia, IL-17 is detected in the lungs of
asthmatics by mRNA and histology (Bullens et al., 2006; Doe et al., 2010). As
well as its role in neutrophil recruitment, IL-17 is also able to activate endothelial
and smooth muscle cells and to contribute to smooth muscle contraction (Griffin
et al., 2012; Kudo et al., 2012).
Similarly, the ‘classic’ mouse AAD model of asthma, involving systemic sensiti-
sation to ovalbumin with aluminium salts as adjuvant and subsequent ovalbumin
challenge, is dependent on STAT6-induced Th2 cytokines, raised IgE, mucus and
eosinophilia (Chapoval et al., 2011). However, more recent studies have shown
production of IL-17 (Hellings et al., 2003; Park et al., 2010; Schnyder-Candrian
et al., 2006), the necessity of IL-17 signalling for sensitisation (Schnyder-Candrian
et al., 2006), and a role for IL-17 in resolution of inflammation (Murdoch and
Lloyd, 2010). In a more chronic ovalbumin model, Th17 cells appear to dominate
the cellular immune response and mediate airway remodelling (Zhao et al., 2012).
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In our lab we have developed a model of rhinovirus-exacerbated allergic airways
inflammation, whereby, following systemic sensitisation, a rhinovirus infection
at the time of final exposure leads to increased Th2-mediated airway pathology.
This is characterised by cellular inflammation and secretion of eosinophil and
Th2 chemokines, along with mucus hyper-secretion and reduced lung function,
modelling many aspects of the responses observed in human asthma (Bartlett
et al., 2008).
However, we have not previously investigated Th17 responses in this model to
assess if they are similarly increased. Greater neutrophil responses to rhinovirus
are seen in sensitised mice concomitantly challenged with ovalbumin compared
to those given rhinovirus alone, a process that may be mediated by IL-17 in the
lung. Although rhinovirus alone failed to induce IL-17 in na¨ıve mice, infection
may have the ability to amplify an already initiated response as seen in the
ovalbumin model, potentially by increasing recruitment and/or the activation
of Th17/IL-17+γδ T cells. Our investigations in this model to date show that
rhinovirus can exacerbate Th2 responses, which are similarly not induced in a
primary rhinovirus infection.
As discussed previously, we will continue our investigations of AAD exacerbation
in C57BL/6 mice due to the availability of knockout mice and a less Th2-biased
immune response than in BALB/c mice. Although less Th2-prone, C57BL/6
mice have been used extensively for the ovalbumin AAD model, maintaining a
similar Th2/eosinophil response; several papers have demonstrated comparable
pathology of the model in both strains (Gueders et al., 2009; Takeda et al., 2001).
Initially, we shall characterise our rhinovirus exacerbation model in C57BL/6
mice and then proceed to assess IL-17 responses.
4.2 Aims
We aim to characterise the IL-17 and Th17 responses in the lungs and airways of
C57BL/6 mice during a rhinovirus-exacerbated model of AAD, using the minor
group rhinovirus serotype RV1B. This shall be addressed via:
i Measuring BAL inflammatory cells, inflammatory mediators and lung function
and comparing these to responses in BALB/c.
ii ELISA to detect the Th17-inducing proteins IL-6 and IL-23.
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iii ELISA to detect the Th17 secreted proteins IL-17A and IL-17F, and measure
any rhinovirus-induced increases.
iv Flow cytometry to detect IL-17+ cells in the lung tissue, and measure any
rhinovirus-induced increases, comparing them to increases in Th2 (CD4+IL-4+)
cells.
v Characterising any changes over time in the model.
4.3 Hypotheses
Rhinovirus enhances IL-17 responses in our exacerbated AAD model alongside the
characterised Th2 increases, and this increase is preceded by increases in either
the Th17-recruiting chemokine MIP-3α and/or increases in the Th17-polarising
cytokine IL-23.
4.4 Results
4.4.1 Confirming exacerbation of AAD by rhinovirus in
C57BL/6 mice
It has been shown, within our group, that infection of BALB/c mice with
rhinovirus at the time of final ovalbumin challenge leads to increases in neutrophils
and eosinophils in the airways, alongside inflammatory and Th2 cytokines in
BALF, as well as exacerbating changes in lung function (Bartlett et al., 2008).
To confirm a similar phenotype when the model is transferred to C57BL/6
mice, we assessed the inflammatory cell infiltrate in the airways by differential
count (figure 4.1) and measured the cytokines IL-6, KC, eotaxin 1 and TARC
in the BALF (figure 4.2) on days 1, 4 and 7 after final challenge, and assessed
lung function by whole body plethysmography (WBP) on day 1 post-infection
(figure 4.3).
Following ovalbumin challenge of sensitised C57BL/6 mice, the airways were
infiltrated by eosinophils and lymphocytes, as well as neutrophils which are not
seen in BALB/c mice but are noted in the literature (Gueders et al., 2009; Kearley
et al., 2009). Surprisingly, a rhinovirus infection reduced many inflammatory
components of ovalbumin-challenged mice, with significantly fewer eosinophils
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(figure 4.1b) at day 4. Neutrophils in exacerbated mice were higher than both
rhinovirus alone and ovalbumin alone at day one (figure 4.1c), but this was
only significant compared to ovalbumin alone, and by day 4 this trend had
reversed, with fewer neutrophils in exacerbated mice compared to ovalbumin
alone. Both lymphocytes (figure 4.1d) and macrophages (figure 4.1e) were
significantly increased in ovalbumin-challenged mice at day four, but a rhinovirus
infection did not affect these responses.
The cytokine responses (figure 4.2) in the BALF exhibited a mixed expression
profile, and did not correlate with the cellular responses above. While eosinophils
were significantly reduced by a rhinovirus infection in ovalbumin-challenged mice,
the eosinophil chemokine eotaxin 1 was significantly increased (figure 4.2a), to over
three times the concentration, at day one. Conversely, although neutrophils were
highest in exacerbated mice, the neutrophil chemokine KC was only significantly
induced in unchallenged, rhinovirus infected mice and remained significantly
increased in this group out to day 7 (figure 4.2b) even though neutrophils had
disappeared from this group by day four. Neutrophils were present in both
ovalbumin challenged groups and persisted to day four, yet there was no significant
detection of KC in either these groups.
The T cell chemokine TARC, recognised by the chemokine receptor CCR4 which
is expressed on Th2 cells (as well as DCs) was induced by ovalbumin challenge, but
this induction was significantly reduced at day one with a concomitant rhinovirus
infection (figure 4.2c). However TARC persisted in both ovalbumin-challenged
groups and was not significantly different at days 4 or 7. The pro-inflammatory
cytokine IL-6 was significantly induced at day one by ovalbumin challenge, and a
rhinovirus infection further significantly increased induction (figure 4.2d).
As a final measure of AAD, we assessed lung function in C57BL/6 mice on
day one by WBP with methacholine challenge (figure 4.3). Sensitisation and
challenge with ovalbumin in BALB/c mice induces airway hyper-responsiveness
and we have previously shown this is enhanced by a rhinovirus infection. In
C57BL/6 mice, ovalbumin challenge following sensitisation did not induce hyper-
responsiveness. However, a rhinovirus infection at the time of challenge increased
enhanced pause (Penh) at baseline over mice only challenged with ovalbumin
or infected with rhinovirus (which were no different to PBS-challenged mice).
However infected and challenged mice were no more responsive to subsequent
methacholine challenge than control groups, suggesting that the effect on lung
function did not involve changes of sensitivity to cholenergics.
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Figure 4.1: BAL leukocyte responses in a C57BL/6 model of AAD are not exacerbated
following a rhinovirus infection. C57BL/6 mice were sensitised systemically to ovalbumin with
aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) and
infected i.n. with rhinovirus serotype RV1B (RV) at time zero (day of final challenge). Controls
had either ovalbumin or rhinovirus (or both) replaced with PBS. Total leukocytes infiltrating the
airways were counted using a haemocytometer (a) and indentified as eosinophils (b), neutrophils
(c), lymphocytes (d) or macrophages (e) from slides prepared with a cytocentrifuge and stained
with QuickDiff. Total numbers are shown as the mean ± SEM. Significant differences from
PBS (∗), RV (e) or OVA (f) are shown. n = 4 mice per time point; data is representative
of 3 repeats.
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Figure 4.2: Chemokines are induced inversely to their respective cell types by a rhinovirus
infection in a C57BL/6 model of AAD. C57BL/6 mice were sensitised systemically to ovalbumin
with aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) and
infected i.n. with rhinovirus serotype RV1B (RV) at time zero (day of final challenge). Controls
had either ovalbumin or rhinovirus (or both) replaced with PBS. Protein concentrations in the
BALF were measured using ELISA for eotaxin 1 (a), KC, (b), TARC, (c) and IL-6 (d). Mean
concentrations are shown ± SEM. Significant differences from PBS (∗), RV (e) or OVA (f)
are shown. n = 4 mice per time point; experiment representative of 3 repeats.
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Figure 4.3: AHR in a C57BL/6 model of AAD is not exacerbated following a
rhinovirus infection. C57BL/6 mice were sensitised systemically to ovalbumin with
aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin
(OVA) and infected i.n. with rhinovirus serotype RV1B (RV) at time zero (day of
final challenge). Controls had either ovalbumin or rhinovirus (or both) replaced
with PBS. Mice were allowed to acclimatise in a chamber of a plesmograph,
after which they were challenged with rising doses of methacholine and responses
measured as the AUC of enhanced pause (Penh). Mean values are shown ± SEM.
Significant differences from PBS (∗), RV (e) or OVA (f) are shown. n = 4
mice per group.
4.4.2 IL-17 responses in exacerbation of AAD in
C57BL/6 mice
Experiments in C57BL/6 mice showed only a partial phenotype compared to the
established model in BALB/c. However, we continued to investigate our interest
in the IL-17 response in this C57BL/6 model.
We have previously measured Th2 cytokines in lung homogenate from this
model, therefore we also measured IL-17A and IL-17F in lung homogenate. As
shown in figure 4.4, both IL-17A and IL-17F were significantly increased in
ovalbumin-challenged mice at day 4. A rhinovirus infection at the time of allergen
challenge significantly reduced these responses, with no significant detection
of IL-17F over controls. At day one, both IL-17A and IL-17F were increased,
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Figure 4.4: Levels of the cytokines IL-17A and IL-17F are reduced by a rhi-
novirus infection in a C57BL/6 model of AAD. C57BL/6 mice were sensitised
systemically to ovalbumin with aluminium hydroxide, challenged on three consec-
utive days i.n. with ovalbumin (OVA) and infected i.n. with rhinovirus serotype
RV1B (RV) at time zero (day of final challenge). Controls had either ovalbu-
min or rhinovirus (or both) replaced with PBS. Protein concentrations in lung
homogenate were measured using ELISA for IL-17A (a) or IL-17F (b). Mean
concentrations are shown ± SEM. Significant differences from PBS (∗), RV (e)
or OVA (f) are shown. n = 4 mice per time point; experiment representative of
2 repeats.
but the only group to reach significance above unchallenged was IL-17A in
rhinovirus infected, ovalbumin challenged mice. By day 7, there were no significant
differences, but IL-17F had a trend for increases in both ovalbumin-challenged
groups.
We also measured the Th17 inducing cytokine IL-23 and the chemokine MIP-3α
(CCL20) in the BALF (figure 4.5). IL-23 was not detectable in any group (data
not shown). MIP-3α was significantly induced by both rhinovirus and ovalbumin
at day one, however there was no synergistic effect as the combination induced
similar levels to rhinovirus or ovalbumin alone. MIP-3α was still detectable at
day 7, though at lower levels with the highest and only significant response being
in infected and ovalbumin challenged mice, suggesting an effect of persistence
with the combination.
To complete the characterisation of the model in C57BL/6 mice, we stained lung
tissue cells for flow cytometry. Day four samples were not available. Cells were
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Figure 4.5: MIP-3α is induced by rhinovirus and ovalbumin but they do not
act synergistically. C57BL/6 mice were sensitised systemically to ovalbumin with
aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin
(OVA) and infected i.n. with rhinovirus serotype RV1B (RV) at time zero (day of
final challenge). Controls had either ovalbumin or rhinovirus (or both) replaced
with PBS. MIP-3α concentrations in BALF were measured using ELISA. Mean
concentrations are shown ± SEM. Significant differences from PBS (∗) are shown.
n = 7 mice per time point; combined results of 2 repeats.
stained for the T cell surface markers CD3, CD4, CD8 and γδ TCR (figure 4.6).
Ovalbumin challenge significantly increased the number of γδ cells at day one
(figure 4.6d), but a rhinovirus infection did not affect this, and these γδ cells
disappeared by day 7. For the other T cell subsets (CD4+, CD8+), there was
a trend for increase with ovalbumin challenge at day 7, however this was only
significant above unchallenged mice for CD3+CD4+ cells with both ovalbumin
challenge and a rhinovirus infection.
To further investigate T cells, intracellular staining for the cytokines IL-17,
IL-4 and IFN-γ was carried out (figure 4.7). Within the increased γδ T cell
population at day one, only IL-17 staining was observed. This population of
IL-17+γδ T cells was increased with ovalbumin treatment but was not further
affected by rhinovirus (figure 4.7d), similar to total γδ T cells, of which IL-17+γδ
T cells make up approximately a third (mean 35.4%, SD 9.8%). Th17 cells
(CD4+IL-17+; figure 4.7a) were significantly increased over untreated controls at
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Figure 4.6: Lung tissue T cells in a C57BL/6 model of AAD are not exacerbated following a
rhinovirus infection. C57BL/6 mice were sensitised systemically to ovalbumin with aluminium
hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) and infected i.n.
with rhinovirus serotype RV1B (RV) at time zero (day of final challenge). Controls had either
ovalbumin or rhinovirus (or both) replaced with PBS. Leukocytes from the lung tissue were
stained for the surface markers CD3 (a), CD4 (b), CD8 (c) and γδ T cell receptor (d). Mean
cell numbers are shown ± SEM. Significant differences from PBS (∗) or RV (e) are shown. n
= 11 mice per time point; combined results of 3 repeats.
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day one with ovalbumin treatment alone, and by day 7 were significantly increased
with ovalbumin treatment, but this was not increased by a rhinovirus infection.
Th2 cells (CD4+IL-4+; figure 4.7b), a key read out of exacerbation in this model,
were induced by ovalbumin challenge at day 7, but as with Th17 rhinovirus did
not affect this response. Th1 (CD4+IFN-γ+; figure 4.7c) cells were significantly
increased over untreated controls by ovalbumin treatment at day one, but this
was abrogated by rhinovirus infection. By day 7, this was reversed, with only
ovalbumin challenged, rhinovirus infected mice having significantly more Th1
than unchallenged controls, but this was not significant over ovalbumin challenge
alone.
4.4.3 Adapting the C57BL/6 model of AAD
Initial investigations of our rhinovirus-induced AAD exacerbation model in
C57BL/6 mice showed only a partial phenotype, with some markers being instead
reduced by rhinovirus. A feature of our BALB/c model is mild eosinophilic
inflammation with ovalbumin challenge, which allows for rhinovirus to exacerbate
the response. In C57BL/6 mice with ovalbumin challenge alone, granulocyte
inflammation (which also includes neutrophils, unlike in BALB/c mice) in the
airways was much greater both in terms of number and percentage of total BAL
cells; at day one after final challenge (figure 4.1), 6.1× 105 and 75% eosinophils
respectively, compared to 1× 105 and 24% in a representative BALB/c experi-
ment (figure 4.9). The additional presence of neutrophils ( 0.5× 105 and 7%) in
the airways of C57BL/6 mice challenged with ovalbumin added to this baseline
inflammation.
As this markedly increased inflammation was a clear phenotypic difference
between our established model in BALB/c mice and C57BL/6 mice, we attempted
to reduce the response to ovalbumin sensitisation and challenge by titration of
the respective ovalbumin doses. Reducing inflammation to similar levels as seen
in BALB/c mice, as well as potentially eliminating the neutrophil response, may
allow rhinovirus exacerbation to be demonstrated.
Firstly, we titrated ovalbumin challenge doses from 60µg to 0.1µg following
sensitisation to 50µg ovalbumin. Mice were challenged with the same dose on
three consecutive days following sensitisation. BAL samples were taken at day
one after the final challenge, defined from group experience as an optimal time-
point to assess response magnitude, and airway cells enumerated by cytospin;
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Figure 4.7: Lung tissue T cell cytokines in a C57BL/6 model of AAD are not exacerbated
following a rhinovirus infection. C57BL/6 mice were sensitised systemically to ovalbumin with
aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) and
infected i.n. with rhinovirus serotype RV1B (RV) at time zero (day of final challenge). Controls
had either ovalbumin or rhinovirus (or both) replaced with PBS. Leukocytes from the lung
tissue were stained for the surface markers CD3, CD4 and γδ T cell receptor and intracellularly
for the cytokines IL-17 (a, d), IL-4 (b) and IFN-γ (c). No significant differences in cytokine
staining were seen in other T cell subsets. Mean cell numbers are shown ± SEM. Significant
differences from PBS (∗) or RV (e) are shown. n = 11 mice per time point; combined results
of 3 repeats.
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total inflammation and granulocyte percentages are shown in figure 4.8a and
figure 4.8b respectively. Surprisingly, granulocyte inflammation in C57BL/6 mice
was relatively insensitive to ovalbumin challenge dose, with eosinophils remaining
around 70% and neutrophils around 5-15% at challenge doses of 60µg to 2µg.
Below this, the responses of individual mice became variable and collectively led
to a decrease in inflammation, but even a low challenge dose of 0.1µg induced
both eosinophils and neutrophils in some mice.
Subsequently, challenge with 40µg ovalbumin was assessed following sensitisa-
tion to 50, 25, 10 or 5µg of ovalbumin (figures 4.8c and 4.8d). As with varying
the challenge dose, varying the sensitisation dose had little effect on the inflam-
matory response. Both total cells and granulocytes (eosinophils and neutrophils)
remained similar at all sensitisation doses and were not significantly different.
Taken together, these results suggest that our protocol for ovalbumin-induced
AAD produces unacceptably high levels of granulocyte inflammation following
challenge of C57BL/6 mice, which does not allow for rhinovirus-induced exac-
erbation. It may still be possible to further adapt our protocol to achieve a
working model, which would be especially useful as a control for experiments
using knockout mice only available in C57BL/6; however, to investigate whether
this is a fruitful course of action and in the interests of time, IL-17 responses
were first investigated in our working BALB/c model to assess whether they are
significantly exacerbated compared to classical Th2 responses.
4.4.4 IL-17 responses in exacerbation of AAD in BALB/c
mice
As a comparison to the incomplete exacerbation seen in C57BL/6 mice, and
to assess whether exacerbation of IL-17 is seen alongside Th2 responses in an
established model, IL-17 was measured by flow cytometry and ELISA in rhinovirus-
exacerbated AAD of BALB/c mice. Mice were sensitised with 2mg aluminium
hydroxide to 50µg of ovalbumin and then challenged with 50µg of ovalbumin on
three consecutive days. Previous studies in this model (Glanville, 2010) have
shown that both the number of eosinophils and lymphocytes in the airways, as
well as total CD3+CD4+ T cells in both the airway and lung tissue, peak at day
7. The greatest differences between CD69 expression (a marker of activation) on
both γδ and CD4 T cells in ovalbumin alone versus rhinovirus-exacerbated mice
are at day 1 and 7 respectively, and these likely represent the most important
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Figure 4.8: Granulocytic inflammation in C57BL/6 mice does not vary with sensitisation
or challenge dose. C57BL/6 mice were sensitised systemically to ovalbumin with aluminium
hydroxide and subsequently challenged on three consecutive days i.n. with ovalbumin (OVA).
The sensitisation dose was maintained at 50µg and the challenge dose was varied as specified (a,
b), or the sensitisation dose was varied as specified and the challenge dose was maintained at
40µg (c, d). Total leukocytes infiltrating the lung lumen were counted using a haemocytometer
and indentified as eosinophils or neutrophils from cytospins stained with QuickDiff. Mean cell
numbers / percentages are shown ± SEM, n = 4 mice per group.
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responding T cells. Thus, for initial investigations of the IL-17 response in this
model, mice were assessed at days 1 and 7 post final challenge and infection.
To confirm exacerbation by rhinovirus, airway cells were enumerated and cy-
tokines measured in the BALF of BALB/c mice. As expected, a rhinovirus
infection exacerbated both neutrophils on day one compared to rhinovirus infec-
tion alone (figure 4.9b) and eosinophils on day 7 compared to ovalbumin alone
(figure 4.9a). Eosinophils on day one were present at similar levels in both groups
recieving ovalbumin challenge, but neutrophils persisted to day 7 in rhinovirus
infected, ovalbumin challenged mice whereas they were cleared by this time in
rhinovirus infected PBS-challenged mice. Both lymphocytes (figure 4.9c) and
macrophages (figure 4.9d) showed trends for exacerbated numbers at day 7, but
this was not significant. As a proportion of total cells, eosinophils were 24.1% at
day one and only rose to 38.7% at day 7 following ovalbumin challenges.
The cytokines IL-6, TARC and eotaxin 1 were also assessed by ELISA in
the BALF (figure 4.10). All cytokines showed a trend towards exacerbation by
rhinovirus, with IL-6 (figure 4.10a) and eotaxin 1 (figure 4.10c) significantly so at
day one.
Rhinovirus challenge of C57BL/6 mice did not exacerbate ovalbumin-induced
Th17 or Th2 cells. To assess T cell subsets in the lung tissue of BALB/c mice,
both surface (figure 4.11) and intracellular staining (figure 4.12) were carried
out. By day 7, total CD3+ T cells after ovalbumin challenge were significantly
increased by a rhinovirus infection (figure 4.11a) and within this population,
both CD4+ and CD8+ T cells were also significantly exacerbated (figures 4.11b
and 4.11c). On day one, we observed a trend for exacerbation of total CD3 T
cells, but only CD8+ T cells reached significance.
Investigation of specific T cell subsets by cytokine staining (figure 4.12) showed
that a large proportion of T helper cells in exacerbated mice at day 7 were
Th2 cells (CD4+IL-4+; 1.59× 105; figure 4.12b) and these were significantly
increased (greater than 2.5 fold) over ovalbumin only challenged mice. The other
T helper subsets measured (Th1, Th17) were present at lower levels (1.04× 105
and 0.73× 105 respectively) and were not significantly increased over ovalbumin
alone; Th17 numbers were only induced by ovalbumin challenge and were not
exacerbated by rhinovirus (figure 4.12a). IL-17+γδ T cells, the other well-studied
IL-17–producing subset that were seen in C57BL/6 mice, showed a trend for
exacerbation at both day 1 and 7 but again this was not significant (figure 4.12d).
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Figure 4.9: BAL leukocyte responses in a BALB/c model of AAD are exacerbated following
a rhinovirus infection. BALB/c mice were sensitised systemically to ovalbumin with aluminium
hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) or PBS and
infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at
time zero (day of final challenge). Total leukocytes infiltrating the lung lumen were indentified
as eosinophils (a), neutrophils (b), lymphocytes (c) or macrophages (d) from slides prepared
with a cytocentrifuge and stained with QuickDiff. Total numbers are shown as the mean ±
SEM. Significant differences from UV-RV (∗), RV (e) or UV-RV+OVA (f) are shown. n =
5 mice per time point.
Page 112
4.4. RESULTS
a
1 7
0
100
200
300
400
500
600
700


***

***
Days Post Infection
BA
L 
IL
-
6 
(p
g/
m
l)
b
1 7
0
500
1000
1500
2000
2500

***

***
*
Days Post Infection
BA
L 
CC
L1
7 
/ T
AR
C 
(p
g/
m
l)
c
1 7
0
10
20
30
40
50
60
70
80
90

*
Days Post Infection
B
AL
 
CC
L1
1 
/ E
o
ta
x
in
 
1 
(p
g/
m
l)
UV-RV RV UV-RV+OVA RV+OVA
Figure 4.10: Chemokines are exacerbated by a rhinovirus infection in a BALB/c model of
AAD. BALB/c mice were sensitised systemically to ovalbumin with aluminium hydroxide,
challenged on three consecutive days i.n. with ovalbumin (OVA) or PBS and infected i.n. with
either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV) at time zero (day of
final challenge). Protein concentrations in the BALF were measured using ELISA for IL-6 (a),
TARC (b) and eotaxin 1 (c). Mean concentrations are shown ± SEM. Significant differences
from UV-RV (∗), RV (e) or UV-RV+OVA (f) are shown. n = 5 mice per time point.
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Figure 4.11: Lung tissue T cell responses in a BALB/c model of AAD are exacerbated
following a rhinovirus infection. BALB/c mice were sensitised systemically to ovalbumin with
aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) or PBS
and infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B (UV-RV)
at time zero (day of final challenge). Leukocytes from the lung tissue were stained for the
surface markers CD3 (a), CD4 (b), CD8 (c) and γδ T cell receptor (d). Mean cell numbers are
shown ± SEM. Significant differences from UV-RV (∗), RV (e) or UV-RV+OVA (f) are
shown. n = 5 mice per time point.
Page 114
4.4. RESULTS
a
1 7
0.0
0.5
1.0
1.5
2.0

***
**

To
ta
l L
o
be
 
CD
4+
IL
17
+
 
Ce
lls
 
x
10
5
Days Post Infection
b
1 7
0.0
0.5
1.0
1.5
2.0


***
**

To
ta
l L
o
be
 
CD
4+
IL
4+
 
Ce
lls
 
x1
05
Days Post Infection
c
1 7
0.0
0.5
1.0
1.5
2.0

***
**
To
ta
l L
o
be
 
CD
4+
IF
N
γγ γγ+
 
Ce
lls
 
x
10
5
Days Post Infection
d
1 7
0.0
1.0
2.0
3.0
4.0
***
*
To
ta
l L
o
be
γγ γγ δδ δδ
+
IL
17
+
 
Ce
lls
 
x
10
5
Days Post Infection
UV-RV RV UV-RV+OVA RV+OVA
Figure 4.12: Lung tissue Th2 cells, but not Th17, are exacerbated in a BALB/c model of
AAD following a rhinovirus infection. BALB/c mice were sensitised systemically to ovalbumin
with aluminium hydroxide, challenged on three consecutive days i.n. with ovalbumin (OVA) or
PBS and infected i.n. with either rhinovirus serotype RV1B (RV) or UV-inactivated RV1B
(UV-RV) at time zero (day of final challenge). Leukocytes from the lung tissue were stained
for the surface markers CD3, CD4 and γδ T cell receptor and intracellularly for the cytokines
IL-17 (a, d), IL-4 (b) and IFN-γ (c). No significant increases in IL-17 were seen in other T cell
subsets. Mean cell numbers are shown ± SEM. Significant differences from UV-RV (∗), RV
(e) or UV-RV+OVA (f) are shown. n = 5 mice per time point.
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4.5 Summary and Discussion
Within our lab, we previously developed and published a mouse model of AAD
that is exacerbated by rhinovirus infection, modelling several characteristics
of the response to rhinovirus seen in human asthmatics, including worsening
lung function as measured by WBP. This model was developed in the BALB/c
mouse strain due to its bias towards Th2 responses, and thus suitability for
modelling atopic asthmatics. However, our initial observations of primary rhi-
novirus infection were carried out in C57BL/6 mice due to availability of relevant
knockout mice and a more balanced T cell response, thus we sought to continue
this work in the C57BL/6 strain when examining a model of exacerbated AAD.
The base ovalbumin model of AAD has been studied in C57BL/6 mice and
demonstrates a comparable phenotype of Th2-driven eosinophilic inflammation
and ovalbumin-specific IgE generation (Gueders et al., 2009).
Initially we sought to confirm that rhinovirus was able to exacerbate this
model in C57BL/6 in a similar manner to BALB/c mice. However we found that
although mice exhibited allergic inflammation following ovalbumin challenge, a
concomitant rhinovirus infection gave a mixed response, with only some mediators
exacerbated and others reduced. Chemokines and their target cells also appeared
to be inversely correlated (KC vs neutrophils, eotaxin 1 vs eosinophils), though
a more comprehensive investigation of related chemokines (LIX, eotaxin 2) and
earlier time points may help explain these discrepancies. Concerning lung func-
tion, although a rhinovirus infection in addition to ovalbumin challenge induced
higher Penh values than any other group, these mice were not more sensitive to
methacholine challenge with no further induction with increases in bronchocon-
strictant, and additionally there was no apparent airway hyperresponsiveness in
ovalbumin only challenged mice. This may be in part due to the more resistant
nature of C57BL/6 mice to changes in lung function, and significant differences
may be revealed by challenge at higher doses as in our system the C57BL/6 mice
appeared to tolerate doses of methacholine up to 50mg/ml without any distress.
Overall, rhinovirus appears to reduce allergic responses in C57BL/6 mice. Due
to the high levels of granulocytes in C57BL/6 mice compared to BALB/c, also
noted in the literature (Gueders et al., 2009; Kearley et al., 2009), we theorised
that this excessive inflammation in the airways compartment did not allow for
further expansion by rhinovirus, which instead produced a dampening effect.
In BALB/c mice, when inflammation and/or rhinovirus infection has been too
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strong, we see similar reduction of responses (unpublished observations). To
attempt to reproduce the model in C57BL/6 mice, we titrated both the ovalbumin
sensitisation and challenge doses; however, changing either dose had little effect
on the level of inflammation.
Although the effector responses (chemokines, inflammatory cells) were not
exacerbated C57BL/6 mice, we investigated T cell responses to fully characterise
the model. While an ovalbumin challenge induced significant numbers of Th2 and
Th17 cells at day 7 and IL-17+γδ T cells at day one, rhinovirus had no additional
effect. The proteins IL-17A and IL-17F were seen to be significantly reduced by
rhinovirus at day 4.
The lack of a response representative of human disease in C57BL/6 led us to
investigate IL-17 responses in BALB/c mice, to assess whether IL-17 exacerbation
occurred in a working AAD model. While effector responses and Th2 cells
were significantly exacerbated, Th17 induction by ovalbumin challenge was not
significantly enhanced by a concomitant rhinovirus infection.
Taken together, the above data suggest rhinovirus is unable to exacerbate the
IL-17 response to ovalbumin challenge in our current model of AAD. In BALB/c
mice, a rhinovirus infection preferentially expanded ovalbumin challenge-induced
Th2 cells at day 7, without having a significant effect on challenge-induced Th17.
In C57BL/6 mice, ovalbumin challenge also induced significant amounts of Th2
and Th17 cells by day 7, but a rhinovirus infection did not have any effect upon
this response. The IL-17+γδ T cell response in C57BL/6 mice was induced by
ovalbumin challenge (at day one) but was not exacerbated by rhinovirus. In
BALB/c mice this appears more complex, with induction by rhinovirus alone
at day one (which does not occur in unsensitised mice) to similar levels as with
ovalbumin challenge, and a suggestion of an increase with both challenge and
infection.
The lack of a clear phenotype in C57BL/6 mice makes further analysis in
this strain difficult. Although ovalbumin challenge produces a strong allergic
phenotype, rhinovirus did not appear to exacerbate the allergic phenotype and
there is a clear paucity of C57BL/6 rhinovirus-induced AAD work, potentially
for this reason. As discussed, strong inflammation may prevent exacerbation.
Additionally, lack of a Th2 bias in C57BL/6 mice may have led to rhinovirus
skewing the lung environment back towards a balanced Th1/Th2 response which
may dampen ongoing responses to ovalbumin, though there was no clear change
in Th1 cells within the lung tissue. Comparisons in the literature between strains
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suggest that while the overall response is for eosinophilic inflammation, there
may be differences in the underlying driving mechanisms (Leong and Huston,
2001). These differences may in part account for the lack of rhinovirus-induced
exacerbation in this strain, though detailed investigation would be needed to
confirm this.
Although an exacerbated phenotype was displayed in BALB/c mice, this
exacerbation appeared to be preferentially driven by Th2-type responses as this
was the only significantly exacerbated T cell subset at day 7. Correspondingly, we
have previously characterised increases in eosinophils, IL-4, IL-13, IL-25, Eotaxin 1
and 2, mucins and airway hyperresponsiveness in this model (Bartlett et al., 2008;
Beale, 2013). Interestingly, we do not see exacerbation of the related cytokine
IL-5 (responsible for eosinophil production and survival), which is suggested to
be the main mediator of ovalbumin-induced AAD and eosinophilia in C57BL/6
mice, as opposed to IL-4 and IL-13 in BALB/c mice (Leong and Huston, 2001).
This mechanism of preferential Th2 exacerbation by rhinovirus may also be an
immune evasion mechanism, avoiding anti-viral Th1/cytotoxic T cell responses.
Indeed, although a primary infection generates Th1 responses, we do not see
increases in CD8+IFN-γ+ cells. It has also been shown that the rhinovirus
proteinase 2A can selectively generate Th2 responses both in vitro and in vivo
(Singh et al., 2010), and this may be one mechanism by which rhinovirus expands
Th2 responses in this model; why this does not occur in a primary infection may
be due to the weakness of the infection in mice or, as for Th17, the lack of a
significant memory population in unchallenged mice.
Recent observations have suggested heterogeneity in asthma phenotypes. Not
all asthmatics are allergic and the observed inflammatory cell milieu in the lung
varies from eosinophilic to neutrophilic to paucigranulocytic (Simpson et al., 2006),
all of which are likely to have different underlying mechanisms. In relation to IL-17
responses, although asthmatics as a whole compared to healthy controls have
increased IL-17 in the lung, within the asthmatic population IL-17 levels correlate
with disease severity. The established systemic sensitisation and challenge model
possibly represents the mild, atopic, eosinophilic phenotype which although a
majority of the asthmatic population, does not encompass those with the severest
disease and the bulk of the clinical burden. The interaction of IL-17 and rhinovirus
(not necessarily IL-17 induction by rhinovirus) may be an important initiator
of exacerbation in these severe asthmatics. High IL-17/Th17 -driven models of
asthma exist; chronic exposure of sensitised mice to ovalbumin drives a switch to
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a Th17-dominated disease (Zhao et al., 2012). A shorter Th17-dependent model
has also been published using an intranasal sensitisation to ovalbumin with either
LPS or TNFα as adjuvant (Wilson et al., 2009; Zhao et al., 2012). Investigation
within these models may assist our understanding of rhinovirus interaction with
IL-17.
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5 IL-17 Modulation of a
Rhinovirus Infection
5.1 Introduction and Rationale
Human experimental infection studies carried out within our group have demon-
strated that IL-17 secretion occurs in the lung following rhinovirus infection of
both healthy and asthmatic subjects. However, this observation was not con-
sistent with our mouse primary infection model. Additionally, in our current
systemic sensitisation AAD model, rhinovirus infection preferentially exacerbates
allergen-driven Th2 responses. While Th17 cell numbers are not increased, the
presence of IL-17 in the mouse lung may still be able to mediate exacerbated
responses to rhinovirus, but this may be difficult to assess in our Th2-dominant
AAD model.
We have previously shown that a subset of asthmatics have a deficient interferon
response to rhinovirus, leading to more severe infections and worse lung function.
IL-17 may have a complementary role, as it is known to increase stabilisation
of a range of mRNAs (especially proinflammatory and neutrophil chemotactic
cytokines) and activate the endothelium, leading to increased protein translation
and cell transmigration respectively (Griffin et al., 2012; Hartupee et al., 2007).
Additionally, it has been shown in culture that IL-17 can increase human epithelial
responses to RSV or rhinovirus by synergistically increasing production of IL-8,
IL-6 and human beta defensin 2 (HBD2) (Ryzhakov et al., 2011; Wiehler and
Proud, 2007). These data suggest that IL-17 present in our model of AAD may
potentially drive the exacerbated production of the neutrophil chemokine KC (a
mouse homologue of IL-8) and subsequent neutrophilia.
As IL-17 has wide ranging effects, investigation in an appropriate in vivo
model may show further effects that cannot be modelled in cell culture, such as
changes to lung function. An AAD model with a dominant IL-17 component
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would provide a better tool than our current model, as more pronounced IL-17
responses would be less obscured by Th2-driven responses. Several experimental
mouse models exist, notably chronic ovalbumin exposure after intraperitoneal
sensitisation (Zhao et al., 2012) or intranasal sensitisation and challenge (Wilson
et al., 2009). While these models still demonstrate aspects of allergic airways
disease such as Th2 cells, granulocyte inflammation and changes in lung function,
they also have high IL-17, Th17, neutrophils and, in the case of chronic exposure,
collagen deposition and lung remodelling.
Initially however, it would be useful to establish any interactions of IL-17 with
rhinovirus in vivo and compare these to existing in vitro data. To this end, we
will assess the effect of supplementing a rhinovirus infection with recombinant
IL-17 (rIL-17). The fact that rhinovirus does not induce IL-17 responses in mouse
may be an advantage in these investigations, as it will allow investigation of rIL-17
effects on lung viral infections without a positive feedback from virus-induced
IL-17, such as seen with RSV. (Bera et al., 2011; Mukherjee et al., 2011).
Productive infection of C57BL/6 mice was demonstrated in chapter 3, and
so to allow comparisons to this dataset we will also conduct rIL-17 experiments
in C57BL/6 mice. The effect of rIL-17 on ovalbumin uptake in the lung has
previously been successfully investigated using an intranasal dose of 0.5µg (Zhao
et al., 2012). Thus rhinovirus infection will be supplemented with 0.5µg of rIL-17
at the time of dosing with virus.
5.2 Aims
We aim to assess how IL-17 in the lung alters the course of a primary rhinovirus
infection in C57BL/6 mice, using rhinovirus serotype 1B. This will be achieved
by:
i Assessing BAL inflammatory cells and mediators following primary rhinovirus
infection supplemented with rIL-17 and compare to a primary infection alone.
ii Measuring rhinovirus copy number and antiviral gene expression to assess
whether rIL-17 affects antiviral responses to a primary rhinovirus infection.
iii Using flow cytometry to assess whether rIL-17 affects T cell responses to a
primary rhinovirus infection.
iv Using whole body plethysmography to assess whether rIL-17 can induce airway
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changes in response to rhinovirus infection.
v Characterising any changes in the above over a time course.
5.3 Hypotheses
Administration of rIL-17 at the time of rhinovirus infection increases airway
inflammation and disease pathology without increasing antiviral activity.
i rIL-17 increases proinflammatory and neutrophil chemotactic chemokines in
response to rhinovirus, with a subsequent increase in neutrophil recruitment
into the lung.
ii Neutrophil increases lead to increased pathology.
iii Increased inflammation and tissue permeability increases rhinovirus load in
the lung.
5.4 Results
5.4.1 Airway responses to rhinovirus with supplemental
rIL-17
Upon infection of C57BL/6 mice with rhinovirus we have shown that proinflam-
matory and chemotactic cytokines are induced, with neutrophils and lymphocytes
subsequently being recruited into the airways. To assess the effect of rIL-17 on
primary infection, BAL cell counts (figure 5.1) and BALF cytokines (figure 5.2)
were measured.
UV-irradiated rhinovirus or rIL-17 alone did not induce significant cell recruit-
ment. Rhinovirus infection recruited cells to the airways and this was significantly
increased by addition of rIL-17 (figure 5.1a). While rhinovirus alone recruited
significant numbers of neutrophils within 12 hours after infection (figure 5.1b),
the addition of rIL-17 both brought this recruitment forward to 8 hours and
concurrently significantly increased the total number of neutrophils present in
the airways between 8 and 24 hours. Neutrophil numbers with additional rIL-17
peaked at 12 hours, with levels over 2.2-fold greater than the delayed peak of
neutrophils recruited by rhinovirus alone at 24 hours. By 48 hours neutrophils
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present with additional rIL-17 had fallen to similar levels as with rhinovirus alone,
and were cleared from both infected groups by four days.
Conversely, the effect of rIL-17 on lymphocyte recruitment in response to rhi-
novirus infection is minimal (figure 5.1c). Rhinovirus infection recruits significant
lymphocyte numbers into the airways by day two and this persists to day four.
Infected mice treated with additional rIL-17 also recruited significant numbers
of lymphocytes, though this appeared more a consistent process with earlier
recruitment by 24 hours steadily increasing to similar levels by day four.
The number of macrophages within the airways was not significantly different
with any treatment (figure 5.1d), although significant increases in macrophage
numbers were previously seen by day 7 after rhinovirus infection alone (beyond
the time frame of this experiment).
Cytokines in the BALF were also investigated (figure 5.2). Previously we have
shown that rhinovirus infection alone induces the proinflammatory cytokines IL-6
and IL-1β and the neutrophil chemokines KC and LIX (chapter 3). Surprisingly,
supplementing rhinovirus infection with rIL-17 did not affect the proinflammatory
IL-6/IL-1β response (figures 5.2a and 5.2b); however in concurrence with earlier
and enhanced neutrophil recruitment there was significant earlier production
of both KC and LIX at four hours, preceding induction with rhinovirus alone
(figures 5.2c and 5.2d).
Early induction of KC at four hours by additional rIL-17 represented levels
higher than induced at any time with rhinovirus alone (which peaks at 8 hours),
and suggests an even greater peak may be seen earlier than four hours after
infection. rIL-17 appears to induce a biphasic LIX response to rhinovirus, inducing
an early peak at four hours in addition to increasing the response at 24 hours. In
comparison, rhinovirus alone induced a single peak of LIX at 24 hours which was
significantly lower than levels with additional rIL-17.
The mucin genes Muc5ac and Muc5b were measured in the lung tissue by qPCR,
and fold change of expression is shown in figure 5.3. Infection with rhinovirus
increased expression of both mucins, with Muc5ac peaking at 48 hours and Muc5b
earlier at 24 hours. No significant differences were seen when rIL-17 is added to a
rhinovirus infection, with Muc5ac showing an identical response, however there
is a suggestion of persistence of Muc5b expression at 4 days.
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Figure 5.1: rIL-17 selectively expedites and increases neutrophil recruitment to the airways.
C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with 0.5µg
of rIL-17, with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at
time zero. Total leukocytes infiltrating the lung airways were counted using a haemocytometer
(a) and indentified as neutrophils (b), lymphocytes (c) or macrophages (d) from cytospins
stained with QuickDiff. Eosinophils were not seen. Total numbers are shown as the mean ±
SEM; significant differences between rhinovirus supplemented with rIL-17 and UV-RV (∗),
rIL-17 (e) or rhinovirus alone (f) are shown. Data is representative of three repeats, n = 4
mice per time point.
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Figure 5.2: rIL-17 induces earlier and greater neutrophil chemokine responses to rhinovirus.
C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with
0.5µg of rIL-17, with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus
alone at time zero. Protein concentrations in the BALF were measured using ELISA for IL-6
(a), IL-1β (b), KC (c) and LIX (d). Mean concentrations are shown as the mean ± SEM;
significant differences between rhinovirus supplemented with rIL-17 and UV-RV (∗), rIL-17
(e) or rhinovirus alone (f) are shown. Data is representative of three repeats, n = 4 mice
per time point.
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Figure 5.3: rIL-17 does not alter mucin gene transcription in the lung after
rhinovirus infection. C57BL/6 mice were infected i.n. with rhinovirus serotype
RV1B (RV) supplemented with 0.5µg of rIL-17, with controls receiving UV-
inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero. RNA was
purified from the apical right lung lobe, converted to cDNA and fold change in
gene expression for either Muc5ac (a) or Muc5b (b) was determined by qPCR.
Mean fold changes are shown± SEM; significant differences between rIL-17 and
UV-RV (∗) or rIL-17 (e) are shown. n = 4 mice per time point.
5.4.2 Neutrophil activation with supplemental rIL-17
Having observed increased neutrophilia following rIL-17 dosing with infection, we
sought to further phenotype the response by assessing neutrophil degranulation in
the airways. This would determine whether the supplemental rIL-17 could, along
with increasing neutrophil recruitment, also induce differential activation. We
measured the activity of the neutrophil enzyme myeloperoxidase (MPO) released
into the airways (figure 5.4). MPO is contained in the primary (azurophilic)
granules, which are formed early in neutrophil maturation but have the least
propensity to degranulate, therefore MPO release denotes terminal neutrophil
activation (Amulic et al., 2012). The peroxidation activity of MPO leads to
formation of reactive species, which while intended to destroy invading pathogens,
will also cause pathology within the lung. MPO responses inappropriate to the
pathogen burden will lead to unnecessary pathology.
MPO peroxidation activity is expressed in figure 5.4 as arbitrary units of
fluorescence. No activity was seen in mice treated with UV-irradiated rhinovirus
or rIL-17 alone. In mice infected with rhinovirus alone, significant MPO activity
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Figure 5.4: rIL-17 enhanced neutrophil responses are associated with increases
in MPO release. C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B
(RV) supplemented with 0.5µg of rIL-17, with controls receiving UV-inactivated
RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero. Myeloperoxidase (MPO)
activity in the BALF was assessed by measuring the amount of Amplex UltraRed
substrate converted to its fluorescent product after 10 minutes. Mean fluorescence
(arbitrary units) shown as the mean ± SEM; significant differences between
rhinovirus supplemented with rIL-17 and UV-RV (∗), rIL-17 (e) or rhinovirus
alone (f) are shown. n = 4 mice per time point; data was not available for
UV-RV or rIL-17 alone at 72 and 96 hours.
was seen by 24 hours within the airways, where it peaked in association with
the peak of neutrophil numbers. Although the addition of rIL-17 induced earlier
recruitment of neutrophils, it did not induce earlier MPO activity, with the
kinetics being similar to with rhinovirus alone. However, additional rIL-17 still
led to increased MPO activity at 24 hours, with 2.2-fold greater activity than
with rhinovirus alone. After 24 hours MPO activity fell in both groups with
similar kinetics to neutrophil numbers, being similar at two days and falling to
baseline by day four.
To determine relative activity, we calculated fluorescence per neutrophil at
each time point MPO activity was present (not shown). There were no significant
differences in this value between rhinovirus alone and with rIL-17 addition,
suggesting the additional neutrophils recruited by the presence of rIL-17 have
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similar functional characteristics.
5.4.3 T cell responses with supplemental rIL-17
Rhinovirus infection in mice induces an influx of T helper, T cytotoxic, γδ T
and NK cells into the lung tissue and airways. IL-17 increases the stability of
multiple mRNAs, including those for neutrophil chemokines (Hartupee et al.,
2007), and this corresponds with our observed increases in KC and LIX seen
with rIL-17 supplementation of a rhinovirus infection. Although with rIL-17
supplementation we saw specific increases in neutrophils and not lymphocytes
in the airways by differential counts (figure 5.1), changes may occur in the
lymphocyte subsets recruited, in the localised lung tissue, or there may be
changes in further chemokines which would be important in an AAD model.
Thus, to investigate whether IL-17–induced changes also affected lymphocyte
recruitment, we examined the T cell chemokines MIP-3α, chemotactic for Th17/IL-
17+γδ T cells (and DCs), and RANTES, chemotactic for Th1, Th2 and NK cells
(figure 5.5). We also investigated T cell recruitment by flow cytometry in the
airways (figure 5.6) and lung tissue (figure 5.7).
We have shown that rhinovirus induces secretion of MIP-3α into the airways.
Interestingly, the addition of rIL-17 induced considerably earlier and enhanced
MIP-3α secretion in response to rhinovirus infection (figure 5.5a). Whilst rhi-
novirus alone induced significant levels of MIP-3α by 8 hours, the addition of
rIL-17 induced significant, higher levels within 4 hours following infection. MIP-
3α remained significantly higher in rhinovirus infected mice treated with rIL-17
until 24 hours, where it fell to levels similar to those with rhinovirus alone. In
contrast, while RANTES is also induced by rhinovirus infection, it is not increased
by the addition of rIL-17 (figure 5.5b), although there is a trend for persistence
with rIL-17 treatment after 12 hours.
To investigate the recruitment of lymphocytes, airway leukocytes were stained
for the surface markers CD3, CD4, CD8, γδ TCR and NK1.1 and analysed by
flow cytometry (figure 5.6). Neither UV-irradiated virus nor rIL-17 alone induced
lymphocyte recruitment. A rhinovirus infection recruited significant numbers of
CD3+ lymphocytes into the airways by 48 hours; addition of rIL-17 appeared
to reduce this, with significantly fewer CD3 + T cells in the airways at 48 hours
(figure 5.6a). Within the CD3+ T cell subsets, CD8+ T cells are also significantly
reduced at 48 hours, with CD4+ T cells showing a trend for reduction. There
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Figure 5.5: rIL-17 induces earlier and greater production of the Th17 and DC
chemokine MIP-3α. C57BL/6 mice were infected i.n. with rhinovirus serotype
RV1B (RV) supplemented with 0.5µg of rIL-17, with controls receiving UV-
inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero. Protein
concentrations in the BALF were measured using ELISA for MIP-3α (a) and
RANTES (b). Mean concentrations are shown ± SEM; significant differences
between rhinovirus supplemented with rIL-17 and UV-RV (∗), rIL-17 (e) or
rhinovirus alone (f) are shown. n = 4 mice per time point.
was no significant difference in γδ T cells, but there was a trend for rIL-17 to
increase their numbers. NK cells had a different kinetic after rhinovirus infection,
with significant numbers in the airways by 12 hours, after which they began to
fall. rIL-17 did not significantly affect this recruitment.
The same analysis of T cell subsets was carried out within the lung tissue,
shown in figure 5.7. As the lung tissue contains a large background population
of lymphocytes, differences were more difficult to discern. Overall, there were
no significant differences between a rhinovirus infection with or without rIL-17
within the CD3+ T cell subsets; only a trend existed for increases in all subsets
at four hours and four days. However, there was a significant increase in NK cells
at 4 hours with the addition of rIL-17.
To investigate any possible change in the cytokine polarisation of T cells, we
also analysed lung tissue leukocytes for the cytokines IL-17, IFN-γ and IL-4
(figure 5.8). No significant cytokine staining was seen in the CD8+ subsets, and
no staining for IL-4 was seen in any subset (not shown). Rhinovirus infection
has been shown to induce Th1 (CD4+IFN-γ+) but not Th17 (CD4+IL-17+) T
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Figure 5.6: rIL-17 only transiently changes some lymphocyte subsets in the airways. C57BL/6
mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with 0.5µg of rIL-17,
with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time
zero. Leukocytes from the airways were stained for the surface markers CD3 (a), CD4 (b),
CD8 (c) and γδ T cell receptor (d) or NK1.1 (e). Mean cell numbers are shown ± SEM;
significant differences between rhinovirus supplemented with rIL-17 and UV-RV (∗), rIL-17
(e) or rhinovirus alone (f) are shown. n = 4 mice per time point.
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Figure 5.7: rIL-17 only transiently increases some lymphocyte subsets in the lung tissue.
C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with
0.5µg of rIL-17, with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus
alone at time zero. Leukocytes from the lung tissue were stained for the surface markers CD3
(a), CD4 (b), CD8 (c) and γδ T cell receptor (d) or NK1.1 (e). Mean cell numbers are shown
± SEM; significant differences between rhinovirus supplemented with rIL-17 and UV-RV (∗),
rIL-17 (e) or rhinovirus alone (f) are shown. n = 4 mice per time point.
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cells, and additional rIL-17 did not significantly change this profile (figures 5.8a
and 5.8b). IL-17+γδ T cells were not induced by a rhinovirus infection alone;
however addition of rIL-17 appeared to induce significant numbers at four hours
only (figure 5.8c). NK cells only stained positive for IFN-γ; rhinovirus infection
induced NK+IFN-γ+ cells in the lung tissue, peaking at 12 hours (figure 5.8d).
Additional rIL-17 induced significantly more NK+IFN-γ+ cells in the airways at
8 hours, but followed the same kinetics at all other time points.
Finally, we investigated the expression of RORγt in lymphocytes (figure 5.9).
No significant differences were seen in the lung tissue following rIL-17 supplemen-
tation (data not shown). In the airways, we saw a small proportion of CD4 + T
cells staining positive for RORγt, but this was comparable to that seen with rhi-
novirus alone and neither infected group was significant over controls (figure 5.9a).
Similarly, RORγt+γδ T cell responses to rhinovirus (as seen in chapter 3) were
not affected by additional rIL-17 (figure 5.9b).
5.4.4 Recruitment of cDCs and uptake of allergen
Previous work in our lab has shown recruitment of DCs to the lung follow-
ing rhinovirus infection, notably a significant increase in inflammatory DC
(CD11c+MHC-II+) at 24 hours, which persists to day 7 (unpublished obser-
vations). rIL-17 has been reported to increase the uptake of experimental allergen
by lung tissue CD11c+ cells (Zhao et al., 2012) . The significant increase in MIP-
3α after supplementing a rhinovirus infection with rIL-17 may also preferentially
recruit DCs, which express the MIP-3α receptor, CCR6, that is important in their
recruitment to mucosal and inflammatory sites (Kallal et al., 2010). In addition,
the activation of the endothelium by IL-17 upregulates adhesion molecules that
selectively allow greater transmigration by neutrophils over lymphocytes (Griffin
et al., 2012); however we do not know how rIL-17 may affect DC transmigration
into the lung.
To investigate DC recruitment, and assess whether rIL-17 treatment results
in increased uptake of experimental allergen by DCs, mice were given 50µg of
Alexa Fluor 647-tagged fluorescent ovalbumin (AF-OVA) intranasally in addition
to treatment with rhinovirus with or without rIL-17. All controls were also
given AF-OVA, except an additional fluorescence control group which was given
non-fluorescent ovalbumin alone (24 hours only). Cells from both lung tissue and
draining (mediastinal) lymph nodes were harvested at 6 and 24 hours and stained
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Figure 5.8: rIL-17 only transiently increases some T cell subsets in the lung tissue. C57BL/6
mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with 0.5µg of rIL-17,
with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero.
Leukocytes from the lung tissue were stained for the surface markers CD3, CD4, CD8 andγδ
T cell receptor and intracellularly for the cytokines IL-17 (a, c), IFN-γ (b, d) and IL-4 (not
shown). No significant increases were seen in IL-4 in any T cell subset nor in IL-17 or IFN-γ in
any other T cell subsets. Mean cell numbers are shown ± SEM; significant differences between
rhinovirus supplemented with rIL-17 and UV-RV (∗), rIL-17 (e) or rhinovirus alone (f) are
shown. n = 4 mice per time point.
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Figure 5.9: rIL-17 does not affect RORγt-expressing cell recruitment to the
airways in response to rhinovirus. C57BL/6 mice were infected i.n. with rhi-
novirus serotype RV1B (RV) supplemented with 0.5µg of rIL-17, with controls
receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero.
Leukocytes from the lung tissue were stained for the surface markers CD3, CD4
(a) and γδ T cell receptor (b) and intracellularly for the transcription factor
RORγt. Mean cell numbers are shown ± SEM; significant differences between
rhinovirus supplemented with rIL-17 and UV-RV (∗) or rIL-17 (e) are shown.
n = 4 mice per time point.
for MHC-II and CD11c as markers of conventional DCs (cDC), after exclusion of
lymphocytes and macrophages by CD3 and CD19 or F4/80 staining, respectively
(figure 5.10).
Results are shown in figure 5.11. Six hours after infection, there was little
change in the total number of cDCs within either the lung or lymph node between
any groups. AF-OVA+ cDCs, which had taken up antigen, did not differ between
groups but were present within the lung tissue in large numbers (mean 38.7%,
SD 6.8%). Few AF-OVA+ cDCs were present within the lymph nodes at this
time (mean 5.7%, SD 2.6%).
By 24 hours there had been significant recruitment of cDC cells into the lung
tissue in mice infected with rhinovirus compared to control mice and a significant
concomitant increase in AF-OVA+ cDCs. Additionally, the proportion of total
cDCs that were AF-OVA+ was significantly increased in rhinovirus-infected mice
(mean 49.8%, SD 3.6%) over controls (mean 34.9%, SD 3.1%). However, additional
rIL-17 did not affect either total or AF-OVA+ cDCs, nor did it induce changes
Page 135
CHAPTER 5. IL-17 MODULATION OF A RHINOVIRUS INFECTION
a b
c d
Figure 5.10: Gating strategy for flow cytometry of cDCs; representative lung sample.
C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV) supplemented with
0.5µg of rIL-17, with controls receiving UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus
alone at time zero. All mice also received 50µg of fluorescent ovalbumin (AF-OVA), except a
fluorescent control group at 24 hours which received non-fluorescent ovalbumin alone (OVA).
Leukocytes were stained for the surface markers CD3, CD19, F4/80, CD11c and MHC-II. T
cells and B cells were excluded by their expression of CD3 or CD19 respectively (a), then
macrophages were excluded by expression of F4/80 (b). cDCs were gated by CD11c+MHC-II+
expression (c). AF-OVA+ cDCs (red) were gated by fluorescence above the ovalbumin alone
control (blue) (d).
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Figure 5.11: rIL-17 does not affect cDC recruitment to the lung, but may impede migration
to the lymph node. C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV)
supplemented with 0.5µg of rIL-17, with controls receiving UV-inactivated RV1B (UV-RV),
rIL-17 or rhinovirus alone at time zero. All mice also received 50 µg of fluorescent ovalbumin
(AF-OVA), except a fluorescent control group at 24 hours which received non-fluorescent
ovalbumin alone (OVA). Leukocytes were harvested from the lung tissue (a, b) and draining
(mediastinal) lymph nodes (c, d) at 6 and 24 hours after infection, and were stained for the
surface markers CD3, CD19, F4/80, CD11c and MHC-II. T cells, B cell and macrophages
were excluded by their expression of CD3, CD19 or F4/80 respectively, before gating cDCs by
CD11c+MHC-II+ expression. AF-OVA+ cDCs were gated by fluorescence above the ovalbumin
alone control. Mean cell numbers are shown ± SEM; significant differences from non-fluorescent
ovalbumin (`), UV-RV (∗) or rIL-17 alone (e) are shown. n = 4 mice per group.
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alone.
In the draining lymph node there was significant accumulation of cDCs by
24 hours in mice treated with either live or UV-inactivated rhinovirus. These
cDC increases are likely to be from the lung as a large proportion of them are
AF-OVA+ (Mean 31.8%, SD 9.3%). Although not significant, there was a trend
for rIL-17 to reduce both the total and AF-OVA+ cDC recruited by a rhinovirus
infection. rIL-17 alone did not induce significant increases in cDC in the lymph
node nor trafficking of AF-OVA+ cDCs.
5.4.5 Antiviral activity with supplemental rIL-17
As rIL-17 increased neutrophil recruitment as well as several cytokine responses
to rhinovirus in our model, it may also increase other responses which may be
antiviral. To assess antiviral activity, we measured the mRNA levels of two
antiviral genes, Ifnb and Ifnl (figure 5.12), which are type I and III interferons
respectively and are produced by many cell types in response to infection. Inter-
ferons induce an antiviral state in neighbouring cells, reducing the ability of virus
to subsequently infect and propagate. Ifnb and Ifnl have both been shown to be
produced in response to rhinovirus in humans and mice (Bartlett et al., 2008;
Khaitov et al., 2009), and although there was a suggestion of a blunted response
in Ifnb at 8 hours with rIL-17, there were no significant changes in the magnitude
or the kinetics of either gene in response to rhinovirus when rIL-17 was added.
Finally, we measured viral load (figure 5.13) in the lung tissue. Rhinovirus
infection led to significant levels of rhinoviral RNA in the lung tissue which
was cleared to insignificant levels by day two. The addition of rIL-17, although
increasing neutrophil responses to rhinovirus, affected neither initial levels (at
four hours) nor clearance of rhinoviral RNA, with both infected groups following
similar kinetics.
5.4.6 Lung function
Increases in airway hyperresponsiveness (AHR) are seen by whole body plethys-
mography (WBP) following rhinovirus infection, and neutrophils have been shown
to be partially responsible for increases in AHR in models of both rhinovirus
infection and allergy, using neutrophil-depleting antibodies (Nagarkar et al., 2009;
Wilson et al., 2009). Thus, to investigate whether the observed increase in
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Figure 5.12: rIL-17 does not alter antiviral gene transcription in the lung
after rhinovirus infection. C57BL/6 mice were infected i.n. with rhinovirus
serotype RV1B (RV) supplemented with 0.5µg of rIL-17, with controls receiving
UV-inactivated RV1B (UV-RV), rIL-17 or rhinovirus alone at time zero. RNA
was purified from the apical right lung lobe, converted to cDNA and fold change
in gene expression for Ifnb (a) and Ifnl2/3 (b) was determined by qPCR. Mean
fold changes are shown ± SEM; significant differences between rIL-17 and UV-RV
(∗) or rIL-17 (e) are shown. n = 4 mice per time point.
rhinovirus-induced neutrophilia following rIL-17 supplementation could lead to
increases in AHR, we measured responses to methacholine 24 hours after treat-
ment by WBP (figure 5.14). As we had not seen large changes in C57BL/6 mice
up to 50mg/ml of methacholine previously (figure 4.3), we increased challenges
to 200mg/ml, which was safely tolerated by the mice.
As can be seen in figure 5.14, mice infected with a rhinovirus had a trend for
increased AHR above 50mg/ml; however this was not significant. rIL-17 alone
had no effect on lung function, but with rIL-17 supplementation of a rhinovirus
infection, there was a trend for an increase in lung obstruction both at baseline
and with lower doses of methacholine compared to rhinovirus alone. This suggests
there may be changes to baseline lung function, which may be better elucidated
using more invasive methods of assessing lung function that bypass the upper
airway obstruction.
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Figure 5.13: rIL-17 does not affect clearance of rhinovirus from the lung
tissue. C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV)
supplemented with 0.5µg of rIL-17, with controls receiving UV-inactivated RV1B
(UV-RV), rIL-17 or rhinovirus alone at time zero. RNA was purified from the
apical right lung lobe, converted to cDNA and copies of rhinovirus determined
by qPCR. Mean RNA copies per µg of total RNA are shown ± SEM; significant
differences between rhinovirus supplemented with rIL-17 and UV-RV (∗), or
rIL-17 (e) are shown. n = 4 mice per time point.
5.4.7 Persistence of rIL-17 following a rhinovirus
infection
To confirm equivalent rIL-17 bioavailability in the lungs of all mice following
treatment, as well as to assess possible induction in the airways, IL-17 was
measured in the BALF by ELISA over a time course (figure 5.15). Neither
UV-irradiated nor infective rhinovirus induced IL-17 in the BALF, as previously
observed (chapter 3). IL-17 was detectable early after dosing at comparable levels
both in mice administered with rIL-17 alone or in conjunction with rhinovirus;
however by 12 hours there were significantly greater levels of IL-17 remaining in
mice concomitantly infected with rhinovirus, and this persisted to 24 hours when
IL-17 has been cleared from the airways of mice treated with rIL-17 alone. IL-17
is cleared in both groups by 48 hours.
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Figure 5.14: rIL-17 does not increase lung obstruction in response to rhinovirus.
C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV) supple-
mented with 0.5µg of rIL-17, with controls receiving PBS, rIL-17 or rhinovirus
alone at time zero. One day after challenge, mice were allowed to acclimatise
in a chamber of a plesmograph, after which they were challenged with rising
doses of methacholine and responses measured as the AUC of enhanced pause
(Penh). Mean values are shown ± SEM; significant differences between rhinovirus
supplemented with rIL-17 and rIL-17 alone (e) are shown. n = 4 mice per group.
For both rIL-17 treated groups, there was an increase in the amount of IL-17
detected at 8 hours compared to 4 hours, suggesting either de novo production of
IL-17 or an increase in the availability of administered rIL-17. As the total amount
of protein detected was much lower than that administered (approximately 2ng
versus 500ng), flow cytometry did not detect significant populations of IL-17
producing cells and IL-17 is not known to directly induce its own production, it
is likely that this increase was due to more rIL-17 being available, perhaps taking
time to diffuse into the lung from the nasal cavity.
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Figure 5.15: rIL-17 persists in the lungs of mice concomitantly infected with
rhinovirus. C57BL/6 mice were infected i.n. with rhinovirus serotype RV1B (RV)
supplemented with 0.5µg of rIL-17, with controls receiving UV-inactivated RV1B
(UV-RV), rIL-17 or rhinovirus alone at time zero. IL-17 protein concentrations in
the BALF were measured using ELISA. Mean concentrations are shown ± SEM;
significant differences between rhinovirus supplemented with rIL-17 and UV-RV
(∗), rIL-17 (e) or rhinovirus alone (f) are shown. n = 4 mice per time point,
representative of 3 experiments.
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5.5 Summary and Discussion
IL-17 has been shown to increase neutrophil chemotactic and pro-inflammatory
responses in both cell culture and animal models (Mukherjee et al., 2012; Wiehler
and Proud, 2007). We have also shown the induction of IL-17 by rhinovirus
in human subjects (Jackson, unpublished); unfortunately we were unable to
reproduce this observation in our mouse model of rhinovirus infection. However,
this gave us a potentially valuable model to study the effects of IL-17 on an
infection in vivo without the confounding factor of IL-17 induction by rhinovirus,
allowing comparison to in vitro virus experiments and the study of in vivo
consequences of a high IL-17 environment, such as found in the lungs of severe
asthmatics.
The addition of rIL-17 to a rhinovirus infection of C57BL/6 mice significantly
increased the numbers of neutrophils to the airways (figure 5.1b). This was
preceded by earlier and greater induction of the neutrophil chemokines KC
and LIX and was associated with increased MPO activity in the airways. The
increase in neutrophils was specific as there was no concomitant increase in
macrophage, lymphocyte or cDC recruitment. Increased neutrophilia was not
associated with changes to antiviral responses or viral loads in the lung tissue,
nor did it induce significant increases in airway hyperresponsiveness by whole
body plethysmography, but there was a suggestion of an effect on baseline lung
function in these mice.
Interestingly, although IL-17 is known to induce inflammation and neutrophil
recruitment in various tissues (McNamee et al., 2011; Witowski et al., 2000),
rIL-17 administered alone to the lungs of mice did not induce any significant
changes. This has been previously documented in other experiments using rIL-
17 in the lung (Murdoch and Lloyd, 2010), and suggests that rIL-17 increases
responses initiated by other challenges but cannot induce them alone in the
lung. Indeed, cell culture experiments also require an additional proinflammatory
stimulus, often TNFα, to generate adequate responses (Ryzhakov et al., 2011);
TNFα is also induced by rhinovirus infection in mice (Bartlett et al., 2008). The
purported mechanisms of IL-17 action, i.e. endothelial activation (Griffin et al.,
2012) and mRNA stabilisation (Hartupee et al., 2007), along with the established
anti-inflammatory environment of the lung, support this requirement.
Supplemental rIL-17 selectively increased rhinovirus-induced KC, LIX and
MIP-3α but not IL-6, IL-1β, or RANTES. Cytokine increases were seen at early
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(< 24 hours) but not late (≥ 24 hours) time points, and in some cases early
increases represented earlier induction than with rhinovirus alone. Indeed, while
LIX is induced by rhinovirus alone at 24 hours, additional rIL-17 induces a second
earlier peak, in a biphasic manner, that may even represent secretion from a
separate source. Lack of later increases in cytokines coincides with clearance
of rIL-17 from the airways of all groups after 24 hours, suggesting that later
increases would be seen with a further dose of rIL-17 at this time. rIL-17 was
only able to increase secretion of rhinovirus-induced cytokines and did not induce
production on its own (within those measured), again supporting the mechanism
of mRNA stabilisation over direct induction.
In addition, the presence of a rhinovirus infection caused the persistence of
rIL-17 in the airways. It is unlikely that this represents de novo secretion of IL-17
as no induction of IL-17+ or RORγt+ cells was seen by flow cytometry. Possible
explanations may be the release of IL-17 from rhinovirus damaged cells that have
previously taken up rIL-17 via receptor-mediated endocytosis, or physical washing
of rIL-17 back into the airways by rhinovirus-induced inflammatory infiltrate.
Further investigations using other relevant cytokines such as IL-4 or irrelevant
proteins such as BSA that can be measured by ELISA may indicate whether this
effect is IL-17–specific or a more general effect of rhinovirus infection on airway
proteins.
Transient differences in lymphocyte recruitment were seen with the addition of
rIL-17. Nevertheless, an increase in BAL lymphocytes at 24 hours and then a
decrease at 48 hours by cytospin (figure 5.1c) was associated with a trend for an
increase in NK cells at 24 hours (figure 5.6e) and a decrease in CD3+CD8+ T
cells at 48 hours (figure 5.6c) respectively. Although T cell recruitment into the
lungs was previously seen to be highest at 7 days (beyond the time frame of this
experiment), the clearance of rIL-17 from the airways by 24 hours and a lack of
significant influence on DC migration to the draining lymph nodes suggests there
is unlikely to be an effect of rIL-17 at this later time.
Recombinant IL-17 induced earlier secretion of the chemokines KC, LIX and
MIP-3α and a downstream effect of KC and LIX increases was seen by increased
neutrophil recruitment. MIP-3α is recognised by its cognate receptor CCR6,
which is known to be expressed on Th17, IL-17+γδ T cells and DC subsets.
As previously discussed, Th17 are not induced by rhinovirus infection, however
RORγt+γδ T cells were detected within the lung at baseline and are recruited in
proportion with other γδ T cells. As these cells are thought to express the CCR6
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receptor, the higher and earlier expression of MIP-3α seen with supplemental
rIL-17 may be hypothesised to increase RORγt+γδ T cell recruitment. However
this was not observed, with nearly identical numbers and kinetics of recruitment
of these cells into the airways (figure 5.9b). Nevertheless, the observed increase of
MIP-3α secretion may play an important role in IL-17 mediated diseases, whereby
a positive feedback may occur with IL-17 increasing MIP-3α expression, which
in turn recruits more CCR6+ IL-17–secreting cells to the lung, which induces
greater MIP-3α expression, and so forth. This may be more apparent in a system
that induces IL-17–secreting cells, where continued IL-17 secretion in the lung
may increase and extend later MIP-3α production.
The conventional subset of DCs (CD11c+MHC-II+) were also investigated at 6
and 24 hours, however although immature DCs express CCR6 (Ito et al., 2011),
no change in their recruitment to the lung was seen following supplemental rIL-17
(figures 5.11a and 5.11b). It may be that the high levels of MIP-3α seen with
rhinovirus alone, even though they peak later than with supplemental rIL-17,
may be maximal in terms of CCR6+ cell recruitment. It may also suggest that for
neutrophil recruitment, the effects of IL-17 on the endothelium allowing greater
transmigration are much more important than increases in chemokines in the
airways, thus a potential lack of similar effect on DC transmigration is the limiting
factor in DC recruitment. Interestingly, although UV-irradiated rhinovirus did
not induce neutrophilia or cDC recruitment to the lung, it was able to induce
trafficking of AF-OVA+ cDC to the lymph node. This is likely to occur from innate
sensing of viral products still within the UV-irradiated rhinovirus preparation
and importantly, highlights a replication-independent effect of infection.
The antiviral responses to rhinovirus were not affected by additional rIL-17, as
defined by interferon gene expression and rhinovirus clearance, even though the
numbers of neutrophils were significantly increased. However, there is conflicting
evidence whether neutrophils play a direct antiviral role (Dienz et al., 2012; Jenne
et al., 2013; Tate et al., 2009) and in many virus infections they are thought to
mediate viral pathology (Narasaraju et al., 2011; Sugamata et al., 2012; Wareing
et al., 2007). In accordance with this, the cytokine IL-17 was partly identified
by its homology to a protein (HSV13) expressed by a virus, Herpesvirus saimiri
(Yao et al., 1995), suggesting that IL-17 can assist in immune evasion by some
viruses.
A functional outcome of increased neutrophil numbers was a correlated increase
in MPO activity in the airways. The evidence for antiviral MPO activity, as with
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neutrophils, is conflicting but it is able to contribute to tissue damage through its
formation of free radicals (Grommes and Soehnlein, 2011; Klebanoff, 2005). Thus
further investigation of tissue damage and lung function would give more details
on the functional outcome of rhinovirus infection in a high IL-17 environment.
One method to examine lung damage is assessing gross ingress of fluorescent
protein into the lung tissue by histology. Additionally, the presence of total
protein and haemoglobin levels in the airways could be measured to assess leakage
into the airways. Damage to epithelial cells and tight junctions would allow faster
and deeper ingress of AF-OVA towards the sub-epithelial fibroblasts (or protein
and haemoglobin into the airways), which as well as affecting lung function would
also allow rhinovirus infection of the fibroblasts.
When present, MPO activity was seen to correlate with neutrophil numbers
in the airways; however there was no activity prior to 12 hours, even though
additional rIL-17 led to significant numbers of neutrophils in the airways by 8
hours. This suggests that while rIL-17 can enhance early neutrophil recruitment,
their activation (specifically MPO release) is an independent process that is not
affected by rIL-17.
Finally, we studied airway hyperresponsiveness (AHR) using whole body plethys-
mography (WBP) and challenge with a bronchoconstrictor. Rhinovirus infection
induces production of mucus in the airways as well as neutrophil recruitment,
and this is thought to cause the small increases in AHR seen with a rhinovirus
infection. Although the addition of rIL-17 recruited neutrophils, it did not
increase mucin gene expression and did not increase resulting AHR. However
there was a suggestion of a small increase in Penh with a rhinovirus infection and
supplemental rIL-17 at baseline and low levels of methacholine over a rhinovirus
infection alone. This may suggest the combination does have an effect on lung
function, which could be further studied using invasive measurements of lung
function such as resistance/compliance. Investigating the effect of rhinovirus in
an IL-17-driven system of AAD may give a more distinct phenotype due to the
presence of additional requirements for AHR such as Th2 cells and IL-13, in a
similar manner to our previous investigations in the systemic sensitisation model
of AAD.
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6 Exacerbation of AAD Induced
by Intranasal Sensitisation
6.1 Introduction and Rationale
We have shown that the presence of IL-17 during a rhinovirus infection significantly
and selectively increases neutrophil responses, whereas in comparison lymphocyte,
macrophage and dendritic cell responses were only minimally affected. Resultant
antiviral responses were also not affected. Other measured responses to rhinovirus
unrelated to neutrophils, such as MIP-3α, were however significantly increased by
the addition of rIL-17. As one of the main effects of IL-17 is the stabilisation of a
wide range of mRNAs (Hartupee et al., 2007), it is likely that further responses
not measured would also be increased.
We also studied the effect of rIL-17 and rhinovirus infection on lung function.
In our mouse model of primary infection, a small increase in responses to metha-
choline is observed 24 hours after rhinovirus infection. We assessed whether the
addition of rIL-17 increased the airway hyperresponsiveness to methacholine chal-
lenge following infection. Although there was a suggestion of increased responses
at baseline and low methacholine doses, these were not significant.
While neutrophils are important in host defence, especially against bacteria,
they also cause lung damage (Grommes and Soehnlein, 2011) and can mediate
changes in lung function (Nagarkar et al., 2009). In agreement, neutrophils are
associated with both severe asthma and fatal asthma exacerbations (Nakagome
et al., 2012; Sur et al., 1993). However neutrophils alone are not sufficient to
cause changes in lung function, which likely requires both specific activation of the
neutrophils and presence of other mediators, such as those provided by ongoing
allergic/Th2 inflammation (Wilson et al., 2009). IL-17 may also synergise with
these mediators to drive increased airway inflammation and hyperresponsiveness.
In our current model of exacerbated AAD, BALB/c mice sensitised to ovalbumin
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with aluminium hydroxide through the peritoneum display an exacerbated Th2
response (IL-4, IL-13, Th2 cells) following rhinovirus infection during ovalbumin
challenge, leading to increased eosinophilia and AHR (Bartlett et al., 2008). Both
Th17 cells and IL-17 protein were also detected in the lung of ovalbumin-challenged
C57BL/6 mice (figures 4.4a and 4.7a), and while these were not increased by a
rhinovirus infection, they may synergise with rhinovirus leading to the observed
increases in neutrophil response. Blocking of IL-17 in this model may show
some effect; however as IL-17 is required for aspects of ovalbumin sensitisation
and response (Schnyder-Candrian et al., 2006), as well as being only a minor
component of what is a Th2-rich model, any effect of blocking IL-17 at time of
rhinovirus challenge is likely to be small and difficult to interpret.
To better investigate the effect of the interaction of IL-17 and rhinovirus on lung
function, a more appropriate AAD model would have a significant endogenous
source of IL-17 alongside Th2 inflammation; this would also be representative of
a subset of severe asthmatics and would allow us to establish if the responses to
rhinovirus infection within IL-17–driven inflammation can exacerbate ongoing
AHR. Chronic exposure to ovalbumin in the systemic sensitisation model has been
shown to switch the inflammation from Th2 dominant to IL-17/Th17 dominant,
which is also associated with remodelling (Zhao et al., 2012). However, this is
currently an unsuitable model given the time constraints associated with this
project.
Recently AAD models involving sensitisation to allergen through the airways
have been developed, leading to a mixed Th2/Th17 inflammation with eosinophils,
neutrophils and AHR in response to allergen challenge. While the systemic
sensitisation model has been useful for exploring Th2 mediators in AAD, an
undoubtedly important pathway in many human asthmatics, sensitisation through
the airways represents a more relevant mechanism of sensitisation of susceptible
individuals to airborne allergens. Given the acute duration of the model along
with its robust IL-17 contribution, it would provide a useful model for further
investigation of IL-17 and rhinovirus interactions.
Several variants of the model have been described using either low dose LPS,
poly(I:C) or TNFα as adjuvant with ovalbumin as the experimental allergen
(Choi et al., 2010; Wilson et al., 2009; Zhao et al., 2012). As LPS is a convenient
and inexpensive reagent, we opted to develop a rhinovirus exacerbation model
using LPS as our intranasal adjuvant. While a high dose of LPS (10-100µg)
primes Th1 responses to antigen, a low dose (0.1µg) has been shown to induce
Page 148
6.2. AIMS
Th2 and Th17 responses (Eisenbarth et al., 2002). To develop our model of
rhinovirus exacerbation, we will reproduce these sensitisation and challenge
responses, before adding a rhinovirus infection to the ovalbumin challenge and
assessing any increases in neutrophil responses and changes in AHR. Investigations
in this model have used both C57BL/6 and BALB/c mouse strains, and as we only
saw a partial phenotype in response to rhinovirus in our systemic sensitisation
model in C57BL/6 mice, we will develop our rhinovirus challenge of airways-
sensitised mice in the BALB/c strain.
6.2 Aims
We aim to develop and optimise an IL-17-dominant model of AAD using intranasal
sensitisation and challenge, with investigation of exacerbation by rhinovirus at
time of challenge to:
i Show induction of Th17 in the lung, neutrophil and eosinophil recruitment
into the BAL by cytospin and AHR by WBP following intranasal ovalbumin
challenge.
ii Investigate the effect of a rhinovirus infection at the time of allergen challenge
in terms of cells by flow cytometry and cytospin, soluble mediators by ELISA
and lung function by WBP.
6.3 Hypotheses
A rhinovirus infection in an IL-17 high AAD model will lead to increased neutrophil
responses, inflammatory mediators and AHR.
6.4 Results
6.4.1 Replication of published sensitisation and challenge
protocols
Initially we looked to repeat published observations, that intranasal sensitisation to
ovalbumin with low dose LPS and subsequent challenge would induce granulocytic
Page 149
CHAPTER 6. EXACERBATION OF AAD INDUCED BY INTRANASAL SENSITISATION
inflammation in the airways and Th17 (CD4+IL-17+) cells in the lung tissue.
To do so, we dosed BALB/c mice intranasally with either 0.1µg LPS alone as a
control or 0.1µg LPS with 100µg ovalbumin on days 1 and 7. All mice were then
challenged a week later with 1% nebulised ovalbumin for one hour (figure 6.1a;
as in Wilson et al. 2009). Mice were culled 24 hours after challenge and airway
infiltrating cells were typed by cytospin (figure 6.1). While mice treated with LPS
alone showed only macrophages in the airways following ovalbumin challenge,
mice sensitised to ovalbumin had neutrophils, eosinophils and lymphocytes present
in the airways.
We also assessed T cell subtypes by flow cytometry (figure 6.2). Significantly
greater numbers of Th17 cells (CD4+IL-17+) were present in the lung tissue of
sensitised mice over those treated with LPS alone.
However, during the setup and use of the exposure box for ovalbumin nebulisa-
tion, several issues arose. Firstly, exposure lasted an hour and it was only possible
to expose a maximum of 8 mice at a time, which may be problematic for large
experiments. Secondly, the mice were seen to huddle together for warmth and to
avoid the vapour, causing varying exposure. Thirdly, the mice became sodden,
potentially chilling them and inducing a confounding factor of oral exposure as
they cleaned themselves. Attempts were made to address these problems; a raised,
perforated floor was made and placed inside to keep the mice away from the
large build up of ovalbumin solution at the bottom of the exposure box, and food
was placed in the four corners to encourage the mice to separate. While these
interventions were partially effective, continuing concerns over the time required
as well as a desire to directly make comparisons to our existing model of AAD
exacerbation led us to examine whether intranasal ovalbumin challenge would
also induce allergic responses.
6.4.2 Model development with intranasal challenge
Our published AAD model using systemic sensitisation requires three consecutive
challenges to generate substantial levels of airways inflammation. To assess the
number of intranasal challenges required in our intranasal sensitisation AAD
model to generate inflammation comparable to nebulised ovalbumin, we sensitised
all mice with LPS and ovalbumin, then challenged them for one, two or three
days (protocol figure 6.3a). Control mice were also sensitised to ovalbumin, but
challenged with PBS alone on three consecutive days. All mice were culled 24
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Figure 6.1: Granulocytes infiltrate the airways of prior sensitised mice in response to ovalbumin
challenge. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin (OVA)
on days 1 and 7, then challenged with nebulised 1% ovalbumin for one hour on day 14; protocol
in (a). Control mice were sensitised with LPS alone and then challenged with OVA. Mice were
culled 24 hours after challenge. Total leukocytes infiltrating the lung airways were counted using
a haemocytometer and indentified as neutrophils, eosinophils, lymphocytes or macrophages
from cytospins stained with QuickDiff (b). Total numbers are shown as the mean ± SEM, n =
4 mice per group.
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Figure 6.2: Th17 cells were significantly increased in prior sensitised mice 24 hours after
challenge. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin (OVA)
on days 1 and 7, then challenged with nebulised 1% ovalbumin for one hour on day 14. Control
mice were sensitised with LPS alone and then challenged with OVA. Mice were culled 24 hours
after challenge. Leukocytes from the lung tissue were stained for the surface markers CD3
and CD4 and intracellularly for the cytokines IL-17 and IFN-γ (a). Representative flow plots
are shown for LPS controls (b) and OVA sensitised mice (c). Total numbers are shown as the
mean ± SEM, n = 4 mice per group.
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hours after final challenge.
Following any number of ovalbumin challenges, similar numbers of neutrophils
were seen in the airways (figure 6.3b); increasing the number of challenges did
not increase neutrophil responses. However, a significant increase in numbers of
eosinophils was only seen following three consecutive days of ovalbumin challenge
figure 6.3c. Eosinophilia may require three challenges; yet this is potentially
the result of four days having passed since first ovalbumin challenge, as in our
systemic sensitisation model significant eosinophil recruitment has a lead time of
several days. Lymphocytes were seen in all mice, including those challenged with
PBS, and although there was an association between the number of challenges
and lymphocytes in the airways, this was not significant.
We also assessed Th17 cells within the lung tissue by flow cytometry, staining
for the transcription factor RORγt as well as the surface markers CD3, CD4,
CD8 and γδ TCR. Only low numbers of CD8+RORγt+ T cells were seen. Large
numbers of CD4+RORγt+ T cells were seen in the lung tissue of all mice, and
there was a trend for increasing numbers following two or more challenges, but
this was not significant. Additionally, RORγt+γδ T cells were observed, and
made up the majority of γδ T cells present in the lung tissue of all sensitised mice,
irrelevant of challenge (mean 82.1%, SD 3.8%; figure 6.4b). We also investigated
RORγt staining in the BAL cells, and saw both RORγt+CD4+ and RORγt+γδ+
T cells as in the lung tissue (figures 6.4c and 6.4d, respectively). However the
proportion of γδ T cells that were RORγt+ was lower in the airways than in
the lung of all mice, making up only a third of total γδ T cells, suggesting
they were prevented from trafficking into the airways. This differed from their
recruitment following a primary rhinovirus infection (figure 3.7). The proportion
of CD4+RORγt+ T cells within the airways was also lower than the lung, but
this was less pronounced.
As a single intranasal challenge was able to induce airways inflammation, further
optimisation was carried out using a single challenge. To complete this process,
the challenge dose was tested at a dose of 10, 25 or 50µg of ovalbumin. Controls
were challenged with PBS, and all mice were culled 24 hours after challenge
(protocol figure 6.5a). As before, a single challenge of 50µg recruited neutrophils
into the airways (figure 6.5). Challenge with lower doses of either 10µg and
25µg of ovalbumin caused the recruitment of similar numbers of neutrophils. A
small number of eosinophils were seen, but were not different between any groups
including PBS-challenged controls. No differences were seen in lymphocyte or
Page 153
CHAPTER 6. EXACERBATION OF AAD INDUCED BY INTRANASAL SENSITISATION
a
	
 
   
b
PBS 1 2 3
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Days of OVA i.n. challenge
To
ta
l B
AL
 
Ne
u
tr
o
ph
ils
 
x
10
4
c
PBS 1 2 3
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
*
Days of OVA i.n. challenge
To
ta
l B
AL
 
Eo
si
n
op
hi
ls
 
x
10
4
d
PBS 1 2 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Days of OVA i.n. challenge
To
ta
l B
AL
 
Ly
m
ph
o
cy
te
s
 
x
10
4
e
PBS 1 2 3
0
10
20
30
40
Days of OVA i.n. challenge
To
ta
l B
AL
 
M
a
c
ro
ph
ag
e
s
 
x
10
4
Figure 6.3: Neutrophil responses are induced by a single ovalbumin challenge and eosinophils
appear within 24 hours after three challenges. BALB/c mice were sensitised i.n. with 0.1µg of
LPS and 100µg ovalbumin on days 1 and 7, then challenged i.n. on one, two or three consecutive
days (as specified) from day 12 with 50µg ovalbumin (OVA); protocol in (a). Control mice were
sensitised and then challenged with PBS on three consecutive days from day 12. Mice were
culled 24 hours after final challenge. Total leukocytes infiltrating the lung airways were counted
using a haemocytometer and indentified as neutrophils (b), eosinophils (c), lymphocytes (d) or
macrophages (e) from cytospins stained with QuickDiff. Total numbers are shown as the mean
± SEM, n = 4 mice per group.
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Figure 6.4: Th17 are induced in BALB/c mice and show a trend for increases with two or
more challenges. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on
days 1 and 7, then challenged i.n. on one, two or three consecutive days (as specified) from day
12 with 50µg ovalbumin (OVA). Control mice were sensitised and then challenged with PBS on
three consecutive days from day 12. Mice were culled 24 hours after final challenge. Leukocytes
from the lung tissue (a, b) or from the airways (c, d) were stained for the surface markers CD3,
CD4 and γδ TCR and intranuclearly for the transcription factor RORγt. Representative plots
of flow cytometry staining for CD4+RORγt+ (e) or γδ+RORγt+ (f) lymphocytes, gated on
CD3. Total numbers are shown as the mean ± SEM, n = 4 mice per group.
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macrophage numbers.
To confirm that ovalbumin challenge induced AHR, a principle end point
in our AAD model, the mice were also assessed for lung function changes by
methacholine challenge (figure 6.6). Challenges up to 50mg/ml of methacholine
induced significant increases in Penh in all ovalbumin challenged mice versus PBS
challenge, with no differences between the doses of ovalbumin.
6.4.3 Rhinovirus infection during ovalbumin challenge
Having optimised the model in BALB/c mice and seen induction of airway
hyperresponsiveness by ovalbumin after a single challenge, we investigated the
effect of a rhinovirus infection on induced AAD. A 50µg dose of ovalbumin was
used as no difference in response was seen between this and lower doses, but there
was less variability in neutrophil induction with the higher dose.
BALB/c mice were intranasally sensitised as before and then challenged with
a single dose of ovalbumin with a concomitant rhinovirus infection. Controls
had ovalbumin, rhinovirus or both replaced with PBS. These were compared to
additional controls of un-sensitised mice given live or UV-inactivated rhinovirus.
All mice were culled 24 hours after challenge.
6.4.4 Cellular responses to rhinovirus exacerbation
Airway cell responses can be seen in figure 6.7. Unsensitised controls responded
as previously observed; at 24 hours rhinovirus had recruited neutrophils, but no
other cell type, into the airways while only macrophages were in the airways of
mice treated with UV-irradiated rhinovirus. In all sensitised groups lymphocytes
were present, in contrast to their absence in unsensitised mice, as well as a
slight increase in macrophages. PBS challenge did not induce further differences.
Sensitised mice infected with rhinovirus recruited neutrophils into the airways,
as in unsensitised mice, but to a lower level. Ovalbumin challenge also induced
neutrophil recruitment but in slightly greater numbers than rhinovirus. Small
numbers of eosinophils were also seen with ovalbumin challenge.
The final group of sensitised mice were infected with a rhinovirus during
ovalbumin challenge; infection increased neutrophil numbers recruited into the
airways greater than two-fold compared to ovalbumin alone (2.6-fold), gaining
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Figure 6.5: Airway responses to ovalbumin challenge do not vary with dose. BALB/c mice
were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on days 1 and 7, then challenged
i.n. on day 12 with the ovalbumin (OVA) dose specified; protocol in (a). Control mice were
sensitised and then challenged with PBS. Mice were culled 24 hours after final challenge. Total
leukocytes infiltrating the lung airways were counted using a haemocytometer and indentified
as neutrophils (b), eosinophils (c), lymphocytes (d) or macrophages (e) from cytospins stained
with QuickDiff. Total numbers are shown as the mean ± SEM, n = 3 mice per group, except
n = 2 for PBS control.
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Figure 6.6: A single challenge of ovalbumin induces significant lung function
changes in sensitised BALB/c mice. BALB/c mice were sensitised i.n. with 0.1µg
of LPS and 100µg ovalbumin on days 1 and 7, then challenged i.n. on day 12
with the ovalbumin (OVA) dose specified. Control mice were sensitised and then
challenged with PBS. 24 hours after infection, mice were allowed to acclimatise in
a chamber of a plethysmograph, after which they were challenged with rising doses
of methacholine and responses measured as the AUC of enhanced pause (Penh).
Mean values are shown ± SEM; significant differences between PBS controls and
each ovalbumin dose are shown (∗). n = 4 mice per group, except n = 2 for PBS
control.
significance compared to PBS challenge (figure 6.7a). This effect was synergistic,
as it was still 1.8-fold greater than the combined neutrophil responses of rhinovirus
alone and ovalbumin alone. While still low, there was also a significant recruitment
of eosinophils into the airways over PBS challenge by 24 hours. These effects were
specific to granulocytes as there is little change in lymphocyte or macrophage
numbers.
T cell subsets within the lung tissue were also analysed by flow cytometry. We
firstly investigated T cell subsets by staining for the cytokines IL-17, IL-4 and
IFN-γ and the surface markers CD3, CD4, CD8 and γδ TCR. No significant
differences or trends in cytokine staining were seen within the CD8 or γδ TCR
subsets (not shown). The CD4+ T helper subsets are shown in figure 6.8. As
seen previously, sensitisation induced greater numbers of Th17 (CD4+IL-17+;
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Figure 6.7: A rhinovirus infection exacerbates granulocyte responses to ovalbumin in an
optimised model. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on
days 1 and 7, then challenged i.n. on day 12 with 50µg ovalbumin (OVA) and infected i.n. with
rhinovirus serotype RV1B (RV). Controls had either ovalbumin, rhinovirus or both replaced
with PBS. Additionally, unsensitised mice were either challenged with UV-irradiated or live
rhinovirus. Mice were culled 24 hours after rhinovirus infection. Total leukocytes infiltrating
the lung airways were counted using a haemocytometer and indentified as neutrophils (a),
eosinophils (b), lymphocytes (c) or macrophages (d) from cytospins stained with QuickDiff.
Total numbers are shown as the mean ± SEM, n = 4 mice per group.
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figure 6.8a). Challenge with either ovalbumin, rhinovirus alone or both concomi-
tantly did not significantly increase the number of Th17 in the lung tissue by 24
hours. With Th1 (CD4+IFN-γ+; figure 6.8b) and Th2 (CD4+IL-4+; figure 6.8c)
cells, there was less of a clear difference between un-sensitised and sensitised mice,
however the highest numbers of both cell types were seen in sensitised, ovalbumin
and rhinovirus treated mice.
We investigated the expression of the Th17 transcription factor RORγt within
lung tissue T cells by flow cytometry (figure 6.9). Whereas IL-17 staining was only
seen within the CD4+ compartment, RORγt staining was seen at increased levels
following sensitisation in all three T cell subsets assessed. The greatest numbers
of RORγt+ T cells were within the CD4 subset, with RORγt+γδ T cell numbers
approximately half that of RORγt+CD4+ T cells, and RORγt+CD8+ T cell
numbers were an order of magnitude lower. Although numbers were much lower,
staining for RORγt within the airways gave a clearer picture as lymphocytes
were mostly absent in unsensitised mice figure 6.10. All sensitised mice had
RORγt+ cells within the CD4, γδ and CD8 T cell subsets present within the
airways, with RORγt+CD8+ T cells at a much lower level than RORγt+CD4+
and RORγt+γδ+ T cells, which were both recruited to similar levels. Only
with a rhinovirus infection concomitant to ovalbumin challenge was a striking
increase in the numbers of all RORγt+ cells seen; over ovalbumin alone this was
2.2-fold for RORγt+CD4+ T cells, 2.9-fold for RORγt+γδ+ T cells and 6.4-fold
for RORγt+CD8+ T cells.
6.4.5 Airway cytokine responses
Further analysis of the model was carried out by measuring protein levels in
the BALF (figure 6.11). IL-6, KC and LIX responses were seen in response to
infection in unsensitised mice, as previously seen in chapter 3. In sensitised mice,
ovalbumin challenge or infection induced some KC and LIX over PBS challenge,
with rhinovirus also inducing IL-6. However, a combined ovalbumin challenge
and rhinovirus infection induced higher levels of both KC and LIX, which reached
significance over PBS challenge. The combination also led to significant levels
of eotaxin 1 above PBS challenge, which was not seen in any other group at 24
hours.
Additionally, we measured the T cell-related cytokines IL-17, IL-23 and IL-13
(figures 6.11e, 6.11f and 6.11g, respectively). Although IL-17 is a key mediator in
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Figure 6.8: A greater number of Th17 are seen in the lung tissue of sensitised mice. BALB/c
mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on days 1 and 7, then
challenged i.n. on day 12 with 50µg ovalbumin (OVA) and infected i.n. with rhinovirus
serotype RV1B (RV). Controls had either ovalbumin, rhinovirus or both replaced with PBS.
Additionally, unsensitised mice were either challenged with UV-irradiated or live rhinovirus.
Mice were culled 24 hours after rhinovirus infection. Leukocytes from the lung tissue were
stained for the surface markers CD3 and CD4 and intracellularly for the cytokines IL-17 (a),
IFN-γ (b) and IL-4 (c). Total numbers are shown as the mean ± SEM, n = 4 mice per group.
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Figure 6.9: Sensitisation increases numbers of RORγt+ T cells in the lung tissue. BALB/c
mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on days 1 and 7, then
challenged i.n. on day 12 with 50µg ovalbumin (OVA) and infected i.n. with rhinovirus
serotype RV1B (RV). Controls had either ovalbumin, rhinovirus or both replaced with PBS.
Additionally, unsensitised mice were either challenged with UV-irradiated or live rhinovirus.
Mice were culled 24 hours after rhinovirus infection. Leukocytes from the lung tissue were
stained intranuclearly for the transcription factor RORγt and for the surface markers CD3
with CD4 (a), γδ T cell receptor (b) and CD8 (c). Total numbers are shown as the mean ±
SEM, n = 4 mice per group.
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Figure 6.10: RORγt+ T cells are seen in the airways of sensitised mice, and are further
increased with a combined ovalbumin and rhinovirus challenge. BALB/c mice were sensitised
i.n. with 0.1µg of LPS and 100µg ovalbumin on days 1 and 7, then challenged i.n. on day 12
with 50µg ovalbumin (OVA) and infected i.n. with rhinovirus serotype RV1B (RV). Controls
had either ovalbumin, rhinovirus or both replaced with PBS. Additionally, unsensitised mice
were either challenged with UV-irradiated or live rhinovirus. Mice were culled 24 hours
after rhinovirus infection. Leukocytes from the airways were stained intranuclearly for the
transcription factor RORγt and for the surface markers CD3 with CD4 (a), γδ T cell receptor
(b) and CD8 (c). Total numbers are shown as the mean ± SEM, n = 4 mice per group.
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this model, the literature suggests peak responses are seen at 4 hours (Wilson
et al., 2009) but our sampling is at 24 hours; however we still saw increased
IL-17+ and RORγt+ T cells, especially within the airways (figure 6.10). Although
IL-17 levels in most treatment groups were little above relevant controls, the
combination of ovalbumin and rhinovirus had increased IL-17 in the airways,
which was significant compared to PBS challenged controls. Both IL-23 and IL-13,
which are important in regulation of IL-17 and AHR responses respectively, were
only seen at low levels.
To investigate the activation of neutrophils within the airways, we measured
the activity of MPO. As eosinophils were present, which also secrete their own
peroxidase, we measured both peroxidation (as in figure 5.4) as well as chlorination,
which is MPO-specific. We also acquired a recombinant mouse MPO standard
so that comparisons could be made. As can be seen in figure 6.12, the only
groups with either enzymatic activity over controls were those infected with
rhinovirus. Although ovalbumin challenge alone induced similar numbers of
neutrophils to rhinovirus infection, this did not correlate with activity. Within
the responding groups, the reported concentration of MPO by chlorination was
lower than that reported by peroxidation, suggesting either other sources of
peroxidation activity (such as eosinophil peroxidase) or differential activity in
the two reactions between our recombinant MPO standard and in vivo MPO.
Although the absolute concentrations varied between the assays, the levels were
relative as they correlated for each individual mouse (r2 = 0.84; not shown).
However, unlike experiments with recombinant IL-17 (chapter 5), MPO activity
did not correlate with neutrophil numbers. Ovalbumin alone induced neutrophils,
but had no MPO activity above PBS challenged mice and although rhinovirus
exacerbated ovalbumin-induced neutrophilia, MPO activity appeared decreased,
especially by the more MPO-specific chlorination activity. Further analysis of
the MPO activity relative to neutrophil numbers present at 24 hours is shown in
figures 6.12c and 6.12d, excluding the controls where few neutrophils were present.
Again, the MPO levels seen by chlorination were lower than peroxidation, but the
trends are analogous. A rhinovirus infection in sensitised mice gave more than
twice as much activity per neutrophil than infection in un-sensitised mice (2.0 and
2.7-fold by peroxidation and chlorination respectively). Conversely, neutrophils
induced with ovalbumin challenge had little relative activity associated with them,
whether or not a rhinovirus was present.
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Figure 6.12: Ovalbumin challenge results in reduced myeloperoxidase relative to neutrophils
in the airways by 24 hours. BALB/c mice were sensitised i.n. with 0.1µg of LPS and
100µg ovalbumin on days 1 and 7, then challenged i.n. on day 12 with 50µg ovalbumin
(OVA) and infected i.n. with rhinovirus serotype RV1B (RV). Controls had either ovalbumin,
rhinovirus or both replaced with PBS. Additionally, unsensitised mice were either challenged
with UV-irradiated or live rhinovirus. Mice were culled 24 hours after rhinovirus infection.
Myeloperoxidase (MPO) activity in the BALF was assessed by measuring (a, c) the peroxidation
of Amplex Red, or (b, d) the chlorination of APF, against a standard curve of recombinant
mouse MPO. Mean concentrations are shown ± SEM, n = 4 mice per group.
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Figure 6.13: Lower levels of rhinovirus remain at 24 hours in mice with prior
sensitisation. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg
ovalbumin on days 1 and 7, then challenged i.n. on day 12 with 50µg ovalbumin
(OVA) and infected i.n. with rhinovirus serotype RV1B (RV). Controls had either
ovalbumin, rhinovirus or both replaced with PBS. Additionally, unsensitised mice
were either challenged with UV-irradiated or live rhinovirus. Mice were culled
24 hours after rhinovirus infection. RNA was purified from the apical right lung
lobe, converted to cDNA and copies of rhinovirus determined by qPCR. Mean
RNA copies per µg of total RNA are shown ± SEM, n = 4 mice per group.
6.4.6 Antiviral responses in intranasally sensitised mice
To assess the effect of sensitisation and challenge on antiviral responses we mea-
sured rhinovirus levels within the lung tissue at 24 hours (figure 6.13). Significant
levels of rhinoviral RNA persisted in unsensitised mice to 24 hours, but this was
greatly reduced in mice receiving prior sensitisation. Ovalbumin challenge, which
recruited granulocytes to the airways, did not further reduce viral load at 24
hours.
6.4.7 Lung function of intranasally sensitised mice
As mucins may play a role in AHR and are potentially induced by IL-17 (Chen
et al., 2003), their role in our model of AAD was investigated. Levels of two
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mucin genes Muc5ac and Muc5b were measured and are shown in figures 6.14a
and 6.14b, respectively. Additionally, Muc5AC protein was measured in the
airways (figure 6.14c). Overall, there was a trend for increased mucin expression
with sensitisation. While ovalbumin challenge further increased Muc5AC protein
and gene expression and rhinovirus increased Muc5b gene expression, the com-
bination of ovalbumin and rhinovirus did not increase expression of either gene
over PBS-challenged mice.
Finally, to assess the functional outcome of these exacerbated responses, we
measured lung function in response to methacholine, 24 hours after challenge,
by WBP. We have previously seen that sensitisation and subsequent ovalbumin
challenge in BALB/c mice increased responses to methacholine (figure 6.6). Shown
in figure 6.15, while rhinovirus infection alone did not induce AHR compared
to PBS in sensitised mice, in the context of an ovalbumin challenge rhinovirus
was able to significantly increase responses to methacholine challenge, giving a
response at 50mg/ml of methacholine that was nearly twice that of ovalbumin
alone.
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Figure 6.14: Mucin genes and protein show a trend for increases after sensitisation. BALB/c
mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on days 1 and 7, then
challenged i.n. on day 12 with 50µg ovalbumin (OVA) and infected i.n. with rhinovirus
serotype RV1B (RV). Controls had either ovalbumin, rhinovirus or both replaced with PBS.
Additionally, unsensitised mice were either challenged with UV-irradiated or live rhinovirus.
Mice were culled 24 hours after rhinovirus infection. RNA was purified from the apical right
lung lobe, converted to cDNA and copies of Muc5ac (a) and Muc5b (b) were determined by
qPCR. Mean RNA copies per µg of total RNA are shown ± SEM. Mucin protein concentration
in the BALF was measured using ELISA for Muc5AC (c). Mean concentrations are shown ±
SEM. n = 4 mice per group.
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Figure 6.15: A rhinovirus infection significantly exacerbates ovalbumin-induced lung function
changes. BALB/c mice were sensitised i.n. with 0.1µg of LPS and 100µg ovalbumin on
days 1 and 7, then challenged i.n. on day 12 with 50µg ovalbumin (OVA) and infected
i.n. with rhinovirus serotype RV1B (RV). Controls had either ovalbumin, rhinovirus or both
replaced with PBS. 24 hours after infection, mice were allowed to acclimatise in a chamber of
a plesthysmograph, after which they were challenged with rising doses of methacholine and
responses measured as the AUC of enhanced pause (Penh). Mean values are shown ± SEM;
significant differences between ovalbumin challenge with rhinovirus infection and PBS (∗),
rhinovirus alone (e), or ovalbumin alone (f) are shown. n = 4 mice per group.
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6.5 Summary and Discussion
While the Th2-driven model of AAD using intraperitoneal sensitisation has been
a mainstay of asthma research, it does not employ a likely route of natural
sensitisation to aeroallergen nor model more severe asthma involving IL-17 and
neutrophils. More recently, AAD models with intranasal sensitisation have been
developed which induce IL-17 responses and neutrophilia. We have previously
shown that the presence of IL-17 in the airways during rhinovirus infection
increased both the speed and magnitude of the neutrophil response to virus. To
investigate whether this interaction could exacerbate ongoing inflammation and
AHR in an IL-17-driven model, we developed a rhinovirus exacerbation model
with intranasal sensitisation and challenge.
In developing our exacerbation model, we initially demonstrated reproduction
of published observations using nebulised ovalbumin, but changed to intranasal
dosing both for practical reasons and to allow more direct comparison with our
existing systemic sensitisation AAD model. We then assessed whether a reduced
number of doses were sufficient to induce granulocyte responses, as previously
a single nebulised challenge was sufficient. A single intranasal dose induced
neutrophil responses similar to either two or three doses, and importantly also
induced changes in lung function.
Our final model, using a single intranasal challenge of BALB/c mice, showed
that rhinovirus infection at time of ovalbumin challenge was able to increase
neutrophils to significant levels and 2.6-fold over ovalbumin treatment alone.
Although eosinophils were an order of magnitude lower at 24 hours, rhinovirus
also increased their numbers over ovalbumin alone by 2.5-fold. Additionally,
rhinovirus and ovalbumin synergised to markedly increase the number of RORγt+
T cells within the airways. In association with these responses there were higher,
significant levels of LIX, KC (both neutrophil chemokines), eotaxin 1 (an eosinophil
chemokine) and IL-17 following ovalbumin and rhinovirus treatment. Finally, we
saw a significant increase in the functional outcome of AHR caused by rhinovirus
infection of ovalbumin challenged mice. This model shows that an endogenous
source of IL-17, at physiological levels may be able, in a similar manner to
exogenous recombinant IL-17, to increase neutrophil responses to rhinovirus and
with the additional presence of AHR mediators can lead to exacerbated changes
in lung function.
In chapter 5, the increases in rhinovirus-induced BALF chemokines by recom-
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binant IL-17 were seen at early time points (4 hours) for both KC and LIX, with
a secondary increase at 24 hours for LIX only (figure 5.2). In our intranasal
sensitisation AAD model, we have only currently investigated 24 hours, and in
accordance with this we see a large increase with LIX with concomitant ovalbumin
challenge. However, while recombinant IL-17 did not induce cytokines alone,
ovalbumin challenge also induced neutrophil chemokines, making analysis of these
effects more difficult; nevertheless, the highest concentration of LIX is seen after a
rhinovirus infection and ovalbumin challenge. In addition to neutrophil responses,
eosinophils are also seen to be increased in this model by a concomitant rhinovirus
infection. Currently we have only measured eotaxin 1, and while this is seen to
be induced by rhinovirus infection with ovalbumin challenge it is detected at low
levels. While we have investigated both KC and LIX for neutrophil chemotaxis,
we have only looked at eotaxin 1 for eosinophils; further investigation of other
CCR3 ligands may give more insight into eosinophil chemotaxis.
Interestingly, at 24 hours we only see an increase in IL-17 with the combination
of ovalbumin and rhinovirus. During supplementation of rhinovirus infection
with recombinant IL-17, we saw that rhinovirus caused persistence of the IL-17
within the airways. Ovalbumin challenge in this model has been shown to induce
early IL-17 secretion, and it is tempting to suggest the increased levels seen in
our experiments represent rhinovirus-induced persistence. However Th17 cells
within the lung may secrete IL-17 for longer following combined ovalbumin and
rhinovirus treatment. Comparisons between IL-17 protein and gene over time
would indicate whether secretion is ongoing.
MPO was assayed in the airways as an indirect measure of neutrophil activation.
Neutrophilia was independently induced by both rhinovirus and ovalbumin;
however mechanisms of activation may differ. With ovalbumin treatment, the
relative MPO activity per neutrophil at 24 hours is much lower than seen with
rhinovirus infection, and this low relative activity is also seen after rhinovirus
infection with ovalbumin challenge, suggesting the ovalbumin effect on MPO
release is both dominant and drastically different to rhinovirus. Combined with
the observations that other responses are exacerbated, especially AHR, this loss
of MPO activity may represent neutrophils that have been activated to the extent
they have depleted their granule contents by 24 hours. If this is the case, MPO
activity in ovalbumin challenged mice would be much higher earlier after challenge;
further investigations are needed to show whether this is the case.
The addition of rhinovirus significantly exacerbated ovalbumin-induced AHR
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and we investigated several potential mediators of this response. IL-13 alone
has been shown to induce AHR in the lung, but we were unable to detect
significant amounts in the BALF at 24 hours. We also measured mucin genes
(Muc5ac and Muc5b) and protein (Muc5AC only), increases in which cause airways
obstruction and are reported to be affected by IL-17 (Chen et al., 2003). Although
mucins were increased after sensitisation there was no further significant induction
following any challenge, suggesting mucin responses are not a major mechanism
of lung function changes in this model. The potential increase in activation of
neutrophils following ovalbumin challenge, combined with the greater number
of neutrophils with concomitant ovalbumin challenge and rhinovirus infection,
suggests that exacerbated AHR may be at least partially mediated by neutrophils.
Indeed, neutrophil depletion studies using an anti-Gr-1 antibody have shown
that neutrophils are required for AHR after intranasal sensitisation and challenge
(Wilson et al., 2009).
While many responses in rhinovirus infected and and ovalbumin challenged
mice at 24 hours were striking compared to either ovalbumin or virus alone, many
of them failed to reach significance over these controls. Although increases in the
numbers of mice as well as pooling of future results will increase the power of
these observations, the use of the non-parametric Kruskal-Wallis test and Dunn’s
post-test, appropriate for observations at a single time point, coupled with the
high number of groups (six) meant that statistical results were quite conservative
when deciding whether to reject the null hypothesis (i.e. that there were no
differences). However where differences were considered biologically relevant they
have been discussed. Future work would be along a time course, where the less
conservative test of two-way ANOVA would be appropriate and gave statistical
significance in previous chapters.
Interestingly, prior sensitisation of mice showed an attenuation of the responses
to a subsequent rhinovirus infection. The most striking difference was the large
reduction in rhinovirus load 24 hours post infection. There was also reduction of
neutrophils, the associated chemokine KC and the inflammatory cytokine IL-6 in
the airways. Conversely, there was a small eosinophilic response to rhinovirus
alone in sensitised mice in both strains, which does not occur in na¨ıve mice.
Although there were no granulocytes present in PBS challenged mice, there
was persistence of lymphocytes in the airways and induction of Th17 cells in the
lung tissue following sensitisation, which may generate a more robust antiviral
response in rhinovirus infected mice. Priming of the immune system by exposure
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to pathogens over the early life of an animal has been suggested as a way that
non-antigen-specific memory can be generated, educating the immune system
and affecting future responses to unrelated antigens. Our mice were used from
6 weeks’ old and are housed in specific pathogen free environments, limiting
their prior exposure to pathogens which may be able to generate this memory,
making LPS exposure a significant event in the immune development of these
mice. Suggested mechanisms of this immunological memory include increased
effector memory CD8+ T cells capable of antigen-independent responses (Leggat
et al., 2008) and increases in innate receptors such as TLRs (Shinya et al., 2012).
Indeed, the latter reference by Shinya et al. specifically demonstrates the ability
of prior LPS exposure in the lung to protect from subsequent lethal influenza
exposure by upregulation of TLR3. In humans, LPS can also upregulate signalling
pathways involved in alveolar macrophage recognition of bacteria and viruses
(Reynier et al., 2012).
Whilst further work, especially at earlier time points and with attenuation of
the IL-17 response, is required to better phenotype and confirm these responses,
we demonstrated that rhinovirus was able to exacerbate cellular, protein and lung
function responses to ovalbumin challenge in a Th17-dependent model of allergic
airways disease. This may allow further investigation into viral exacerbation
of severe and steroid-resistant asthma, leading to a greater comprehension of
mechanisms involved and identification of targets for treatment and prophylaxis
in patients.
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Asthma affects 300 million people worldwide, of which 250,000 die of the
disease each year. Exacerbations are the main cause of morbidity and mortality
in this population, yet treatment options are limited, and a significant number
of asthmatics continue to suffer exacerbations. Within the last few decades it
has become clear that the common cold virus, rhinovirus, is a leading cause of
asthma exacerbations.
A subset of asthmatics, typified by severe, steroid refractory disease, have a
larger involvement of neutrophils and the cytokine IL-17 than the more numerous
Th2-/eosinophil-high asthmatic population. Mechanisms of rhinovirus exacer-
bation have been studied in these milder, eosinophilic asthmatics, with little
information about how rhinovirus may exacerbate neutrophilic asthmatics. As
these patients are less well-controlled and thus suffer disproportionate numbers of
exacerbations, it is important to understand the mechanisms involved to develop
potential therapies.
Clinical studies carried out within our group have shown induction of IL-
17 following rhinovirus infection in the nasal lavage fluid of both healthy and
asthmatic subjects. To understand the mechanisms involved in this induction,
as well as any pathological outcomes in asthmatics, we have investigated the
interactions of IL-17 and rhinovirus infection in mouse models of both primary
infection and allergic airways disease. Using these models, we sought to define a
role for IL-17 in rhinovirus exacerbation of allergic asthma.
7.1 IL-17 induction by rhinovirus infection in
mouse models
In our current murine primary infection model, lymphocytes are seen to be
recruited from day two post-rhinovirus infection in both the airways and lung
tissue and have been shown to include IFN-γ– but not IL-4–secreting populations.
Page 175
CHAPTER 7. DISCUSSION
Populations of IL-17–secreting lymphocytes had not been assessed. Studies carried
out as part of this project have demonstrated a lack of IL-17 secreting cells in
the lung following primary rhinovirus infection. In support of this, we did not
detect IL-17 mRNA expression or protein in BAL cells, lung tissue or in BAL
supernatants following infection.
We also assessed the ability of rhinovirus to exacerbate IL-17 responses in our
current model of AAD. Both Th17 and IL-17+γδ T cells have been previously
shown in ovalbumin AAD models (Kudo et al., 2012; Murdoch and Lloyd, 2010),
and we confirmed their presence following ovalbumin challenges. We were also
able to detect IL-17 protein in lung homogenate. However, in both C57BL/6 and
BALB/c mice, this IL-17 response was not increased by a concomitant rhinovirus
infection, which preferentially increased Th2 responses in BALB/c mice.
7.1.1 Th17 and IL-17+γδ T cell induction and recruitment
This observed difference in IL-17 responses to rhinovirus infection between humans
and mice may be either due to a lack of de novo induction of IL-17 secreting cells
or recruitment and activation of existing populations.
As discussed in chapter 3, the initial mediators required for Th17 polarisation
have been shown to be TGF-β, IL-6, IL-1β and IL-23. Following rhinovirus
infection of mice we were able to detect IL-6 and IL-1β (figures 3.3a and 3.10) and
TGF-β has been demonstrated to be expressed in the lung (Deppong et al., 2012).
However we failed to detect IL-23 in the BAL fluid in response to rhinovirus
infection. Additionally we can detect RORγt+γδ T cells within the lung tissue
and airways after infection, but we are unable to detect IL-17+γδ T cells following
polyclonal stimulation. In human studies, IL-23 secretion from monocyte-derived
cells has been shown in response to synthetic viral ligands (R848) and Sendai
virus (Pirhonen et al., 2002; Schwarz et al., 2013). IL-23 has been detected in
the BAL fluid and lung homogenate of mice in several AAD models (Guan et al.,
2012; Moreira et al., 2011; Schnyder-Candrian et al., 2006), and Il23p19 mRNA
has also been detected in lung tissue in ovalbumin models (Newcomb et al., 2013).
As IL-23 was not a primary endpoint in this project, further work using both
ELISA and qPCR would be needed to definitively conclude that there is no
induction by rhinovirus infection. However, we did investigate the induction of
Th17 and IL-17+γδ T cells, a main functional outcome of IL-23, more fully and
did not see either of these cell types generated after rhinovirus infection alone.
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Although ovalbumin challenges induced Th17 and IL-17+γδ T cells in the lung, a
concomitant rhinovirus infection did not increase these responses, suggesting it
does not exacerbate the IL-23 response.
The published mouse model of rhinovirus infection developed within our lab
utilises the rhinovirus serotype RV1B, which is tropic for human tissues. Whilst
rhinovirus has been shown to be able to infect and replicate in murine epithelial
cells (LA-4 cells), replication is more efficient in human HeLa epithelial cell lines
(Tuthill et al., 2003). To achieve infection in mice we currently have to dose
mice with titres much higher than required for successful infection of an adult
human, and while significant increases in viral load are seen in experimentally
infected humans peaking around day three post infection (DeMore et al., 2009;
Jackson et al., manuscript submitted), in mice rhinovirus is mostly cleared by day
three (figure 3.2). Significant increases in viral load from baseline are not seen in
mice, though it is possible to measure the replicative strand (-ve strand ssRNA)
to better assess replication in the mouse, as we have done previously using in
situ hybridisation and others have by qPCR (Bartlett et al., 2008; Newcomb
et al., 2008). Additionally, it has been suggested that rhinovirus may infect
macrophages in humans (Gern et al., 1996; Laza-Stanca et al., 2006) and this
may be a required trigger for IL-23 production from these cells. Taken together,
although we are able to effectively model many aspects of human rhinovirus
disease in mice, the infection could be considered less robust than seen in humans
in terms of infectious dose required, virus replication and persistence. Thus, a
reason why IL-17 responses are not seen in mice may be that it is a feature of a
stronger or more persistent infection, capable of inducing IL-23.
The chemokine receptor CCR6, in addition to being expressed on dendritic cells,
has been shown to be expressed on the IL-17–producing cells Th17 and IL-17+γδ
T cells (Haas et al., 2009). It recognises a single ligand, MIP-3α, though other
ligands have been suggested (Hoover et al., 2002). We have shown that rhinovirus
induces MIP-3α within 8 hours following infection in mice (figure 3.11a) with
parallel observations being made in our human studies (Jackson, unpublished).
Additionally, MIP-3α is induced after ovalbumin challenge in sensitised mice
(figure 4.5). This chemokine has the potential to recruit IL-17–producing cells to
the lung in response to infection.
In mice kept in specific pathogen free environments, only low levels of Th17
are seen in the circulation (Lexberg et al., 2008), thought to be generated by the
presence of bacteria in the gut (Ivanov et al., 2006). However, humans are exposed
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to a much greater bacterial burden in the gut and, possibly more importantly, are
also exposed to frequent respiratory pathogens, with adults typically contracting
2-4 colds a year (Myint et al., 1996). In consequence of this exposure to pathogens,
in healthy adults approximately ∼2% of circulating CD4+ T cells are IL-17+ (Wu
et al., 2010b; Zhao et al., 2010).
Although we screen our human subjects for antibodies against our experimental
serotype (RV16), this does not discount the presence of RV16-specific Th17 or
cross-reactive Th17 generated after exposure to related rhinovirus serotypes. In
support of this, the existence of rhinovirus-specific T cells has been shown in
peripheral blood (Gern et al., 1997b). Induction of AAD in mice increases the
numbers of both IL-17+γδ and CD4+ T cells in the lung, and in agreement with
this, asthmatics have been shown to have both higher circulating Th17 (Zhao
et al., 2010) as well as more IL-17 positive cells in the lung (Al-Ramli et al., 2009;
Doe et al., 2010).
Taken together, in contrast to mice, human subjects have a sizeable pool of
Th17 capable of responding to MIP-3α secretion following rhinovirus infection,
and in asthmatics this pool is significantly increased.
7.1.2 Other sources of IL-17
Other cells have been suggested to be able to secrete IL-17 including LTi cells,
NK cells, NKT cells (Raifer et al., 2012), macrophages (Kasahara et al., 2012),
neutrophils (Wozniak et al., 2011) and the newly described innate lymphoid cells
type 3 (ILC3) (Spits et al., 2013). During this project we did not specifically
investigate most of these other sources of IL-17; however no IL-17 staining
was seen in NK1.1+ cells during rhinovirus infection, nor RORγt staining in
NK1.1+ cells or Gr-1+ neutrophils. Gross live cell staining was also investigated
for IL-17 and RORγt in our experiments, and no positive cells, outside of T
cell populations, were seen (data not shown). However, further investigation
using lineage specific markers are required to exclude the presence of additional
IL-17–secreting populations in our models.
7.1.3 Myeloid-derived suppressor cells (MDSCs)
We also observed the generation of myeloid-derived suppressor cells (MDSCs)
following rhinovirus infection (figures 3.14 and 3.15). MDSCs were initially
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discovered as a mechanism of immune suppression within tumours in both humans
and mice (Almand et al., 2000; Bunt et al., 2006), but have since been found in
other diseases such as autoimmunity, infection and allergy (Arora et al., 2010;
Delano et al., 2007; Zhu et al., 2007). MDSCs have been shown to mediate
LPS-induced suppression of allergic inflammation (Arora et al., 2010) and are
involved in the regulation of immune responses to viral infections (Fortin et al.,
2012; Qin et al., 2013). Intriguingly, there is also literature suggesting that MDSC
can support the generation of Th17 cells, mainly through their production of
IL-1β, in a model of experimental autoimmune encephalomyelitis (EAE) (Yi
et al., 2012).
MDSCs are a heterogeneous population, but appear to be a group of partially
differentiated myeloid cells with the ability to suppress T cell responses; most
papers identify MDSC as being CD11b+Gr+/int. While we have not assessed
suppressive capacity, we have identified a clear population with these markers,
distinct from neutrophils, within the lung. Further investigation, such as staining
for F4/80 or cell sorting for subsequent functional assays, would allow us to
further characterise these cells and assess whether they play an important role in
rhinovirus infection and AAD exacerbation.
7.2 IL-17 exacerbation of rhinovirus responses
Although rhinovirus-induced IL-17 secretion was not demonstrated in existing
models of primary infection and rhinovirus-exacerbated AAD, we were interested
in the interaction between IL-17 and rhinovirus in the lung. IL-17 is detected at
higher levels in the lung of asthmatics compared to healthy controls by qPCR
(Al-Ramli et al., 2009) and histology (Al-Ramli et al., 2009; Doe et al., 2010). To
explore the effects on a rhinovirus infection of increased IL-17 in the lung, we
investigated two models of rhinovirus and IL-17 interaction; supplementation of
an infection with rIL-17 and rhinovirus infection during Th17-driven AAD.
Rhinovirus induces secretion of the neutrophil chemotactic cytokines KC, MIP-
2α and LIX within 8 hours of infection (figure 3.3), which leads to significant
neutrophil recruitment by 12-24 hours (figure 3.1). Rhinovirus infection in
the presence of IL-17, either exogenous rIL-17 or endogenous activated Th17,
led to further significant increases in KC and LIX and subsequent increases
in neutrophil recruitment, in both models to over twice that with virus alone.
This effect was specific for neutrophils as other cells recruited by rhinovirus
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(lymphocytes, macrophages, DCs) were not increased by the presence of IL-17.
Additional effects of IL-17, such as endothelial activation, may also play a role
in this cell-specific recruitment. These neutrophil increases are associated with
significant increases in airway obstruction in our Th17-driven model of AAD.
To date, the effects of IL-17 on virus infections have mostly been studied in
cell culture experiments. One paper has shown increases in IL-8 secretion (the
human orthologue of KC) by rIL-17 supplementation of rhinovirus infection of
human cell cultures (Wiehler and Proud, 2007); others have shown increases
in IL-6 and IL-8 following supplementation of RSV infection with rIL-17 in
culture (Ryzhakov et al., 2011). However, in mouse models of respiratory viral
infections, RSV or influenza alone have been shown to induce IL-17 (Hamada
et al., 2009; Mukherjee et al., 2011). IL-17 induction by these viruses in vivo
makes supplementation experiments difficult to design and interpret. However,
the lack of IL-17 induction by rhinovirus in our mouse models has allowed us to
take these in vitro observations further and show functional outcomes of IL-17
supplementation of a respiratory viral infection in mice.
7.2.1 Role of neutrophils in virus infection
The most striking effect of IL-17 on a rhinovirus infection was increased neutrophil
recruitment. Neutrophilia is a common response to infection with bacteria and
viruses, as well as sterile challenges such as LPS and injuries (reviewed in Amulic
et al. 2012). However, while there are clear anti-bacterial roles for recruited
neutrophils, the evidence for an anti-viral role is less clear. Activated neutrophils
release multiple enzymes such as elastase and MPO, which can cause unwanted
pathology in the lung (Grommes and Soehnlein, 2011). Thus the balance of
anti-viral and pathological responses is important in the ultimate outcome of an
infection.
IL-17 driven increases in neutrophils will only be of benefit if they assist in
rhinovirus clearance, which in our model of rIL-17 supplementation does not
appear to be the case, as there was no increase in innate interferon induction nor
reduction of rhinovirus load with the addition of rIL-17 (figures 5.12 and 5.13).
Several papers have shown direct antiviral activity of MPO or degranulated
neutrophil supernatant in culture against respiratory viruses such as influenza
and RSV, as well as other viruses such as HIV-1 (Klebanoff, 2005; Widegren
et al., 2011; Yamamoto et al., 1991). However the relevance of these experiments
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to a natural infection in a host is unclear as viruses spend most of their life
cycle within host cells and myeloperoxidase activity has been demonstrated to
be rapidly inhibited in tissues including the lung (Dawra et al., 2008). The
role of neutrophils has been investigated in influenza mouse models, and has
been attributed with both pathogenic and protective effects. Several papers
suggest neutrophils can reduce viral load (Dienz et al., 2012; Jenne et al., 2013;
Tate et al., 2011) in experimental infection, potentially by capture of free virus
in neutrophil extracellular traps (NETs; Jenne et al. 2013) or phagocytosis of
infected cells (Hashimoto et al., 2007), and in neutrophil depletion studies mice
become more sensitive to fatal influenza infection (Tate et al., 2009). However
other investigators have found that MPO can mediate acute respiratory distress
syndrome (ARDS) following influenza infection and that MPO knockout mice
were more capable of reducing viral load (Sugamata et al., 2012). Additionally,
mice lacking neutrophil responses either by CXCR2 gene knockout or antibody
depletion showed attenuation of pathology following influenza infection with no
change on viral clearance (Narasaraju et al., 2011; Wareing et al., 2007). More
relevant to our models, CXCR2 knockout mice infected with rhinovirus showed
significantly reduced neutrophils following infection with rhinovirus, and showed
a trend for lower viral load 24 hours after infection (Nagarkar et al., 2009).
In humans, patients with chronic granulomatous disease (CGD), who have a
poor ability to form reactive oxygen species and are susceptible to bacterial and
fungal infections (Forehand and Johnston, 1994) or those with MPO deficiencies
(Kutter et al., 2000; Lanza, 1998) do not appear to have an increased risk of viral
infection. However there is documentation of fever in patients with neutropenia
being commonly associated with the presence of respiratory viruses (Ohrmalm
et al., 2012). In subjects experimentally infected with rhinovirus, subsequent
treatment with LTB4 (which has been shown to activate neutrophils) induced
significant increases in MPO and a trend for reduction in viral loads, but it
did not affect cold symptom scores (Widegren et al., 2011). In addition to
destructive enzymes, neutrophils also secrete cytokines and chemokines, which
can enable them to communicate with other leukocytes and orchestrate the
adaptive response (Mantovani et al., 2011; Scapini et al., 2000). There are
suggestions that neutrophils consist of several different subtypes and, contrary
to their role as aggressive first lines of defence, some of these appear to have
anti-inflammatory and repair functions (Kolaczkowska and Kubes, 2013; Pillay
et al., 2013; Tosello Boari et al., 2012). Neutrophils may even be precursors of
the suppressive MDSCs (Brandau et al., 2013).
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The signals required for neutrophil degranulation in vivo (as distinct from
signals for chemotaxis and tissue invasion) are incompletely understood, although
this is clearer for bacteria where the bacterial products LPS and fMLP are known
to induce degranulation (Liu et al., 2005). In our studies we have measured
degranulation of neutrophils by the levels of MPO activity in the BAL fluid.
Following a primary rhinovirus infection, we saw MPO activity induced within
24 hours. The addition of rIL-17 to an infection led to further increases in MPO
activity (figure 5.4), and this correlated with the observed increase in neutrophil
numbers. However, while rIL-17 also caused more rapid neutrophil recruitment,
reaching significance four hours earlier than with rhinovirus alone, there was no
earlier induction of MPO activity, which was induced at 24 hours with or without
rIL-17. This observation suggests that while IL-17 is able to influence neutrophil
recruitment kinetics it does not affect their degranulation, which may be reliant
on viral signals.
The delayed secretion of MPO following neutrophil recruitment by rhinovirus
is surprising, given that rhinovirus load and many mediators peak around 8
hours. Mechanisms of virus activation of neutrophils include ligation of TLRs,
of which neutrophils have been shown to express most except TLR3 and TLR7,
as well as expressing other internal pathogen receptors such as RIG-I (Prince
et al., 2011). Several studies have investigated direct RSV-induced neutrophil
activation in mice and demonstrate neutrophil secretion of IL-8 and MPO in
response to RSV (Jaovisidha et al., 1999); however direct sensing of virus is
unlikely to be a major mechanism in our model given neutrophil activation at
24 hours when viral loads are greatly reduced. However, neutrophils can also
respond to indirect viral signals, and RSV has been shown to indirectly activate
neutrophils by production of the DAMP Hsp72 from infected cells, which can
be recognised by TLR4 (Wheeler et al., 2009). Additionally some rhinovirus
responses do peak at 24 hours, notably the neutrophil chemokine LIX, which may
have a role in neutrophil activation.
7.2.2 Role of neutrophils in virus-induced AAD
Rhinovirus infection induced significant MPO activity at 24 hours in both pri-
mary infection and a Th17-driven model of AAD, and this was associated with
significant neutrophil recruitment. However, while ovalbumin challenge in the
same AAD model induced similar numbers of neutrophils, there was no associated
MPO activity (figure 6.12). It is likely that although both rhinovirus infection
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and ovalbumin challenge recruits neutrophils, their mechanisms of neutrophil
activation are different. Rhinovirus may well be inducing maximal MPO secretion
by 24 hours, as in a primary infection, however ovalbumin challenge is either not
inducing activation, or is inducing much earlier MPO release which has either
ceased or depleted neutrophil granules by 24 hours, with secreted MPO being in-
activated or removed from the system. As ovalbumin challenge is associated with
AHR, and it has been shown in this model AHR is dependent on neutrophils by
depletion with anti–Gr-1 and use of CXCL2 knockout mice (Wilson et al., 2009),
it is likely that ovalbumin challenge activates these neutrophils. The published
literature also shows that responses in this model are rapid, which is unsurprising
as responder T cells are within the lung tissue and airways at time of challenge,
so a rapid recruitment and degranulation of neutrophils is possible. With the
addition of a rhinovirus, the greater numbers of neutrophils may cause MPO
persistence by overwhelming clearance mechanisms, providing greater amounts of
neutrophils to degranulate over an extended period, or rhinovirus may cause a
second wave of degranulation at 24 hours, but on a partially depleted population.
Further investigations at earlier time points would be required to unravel these
mechanisms.
The mechanism of neutrophil degranulation to ovalbumin is unknown, but
will either be by direct recognition or indirect signalling. Ovalbumin is an inert
experimental allergen, which causes minimal immunological responses in the
airways of unsensitised mice. While LPS contamination is common in ovalbumin
preparations, and LPS is known to be able to degranulate neutrophils, our stock
is considered low in LPS, as assessed by limulus amebocyte lysate (LAL) assay
(<1U/ml). Sensitisation in the Th17-dependent AAD model has been shown to
induce T cells capable of responding to ovalbumin, however the humoral response
has not been investigated. It is quite possible that ovalbumin-specific antibodies
are generated; neutrophils have been shown to express FcγRI, FcαRI and FcRI
which, when aggregated by binding to antibodies grouped in immune complexes,
leads to cell activation and degranulation (Jo¨nsson et al., 2013; Otten et al., 2007;
Porcherie et al., 2011). Allergen-specific antibodies, especially of the IgE class,
are a common finding in asthma patients (Tan and Corren, 2011), and have been
shown to promote asthma pathology by degranulating mast cells and causing
histamine release. AHR in our Th17-driven model may also, in part, rely on IgE
and mast cell responses, as well as potential interactions with neutrophils.
Indirect methods of neutrophil degranulation may also occur through effector
molecules released from ovalbumin-specific T cells. The intranasal sensitisation
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paper by Wilson et al. (2009) shows a rapid induction of LIX following ovalbumin
challenge, initially peaking at 4 hours. This is in comparison to our rhinovirus
infection models showing LIX peaking around 24 hours. However there is little in
the literature demonstrating LIX-mediated degranulation, and as there are some
suggestions of neutrophils themselves secreting LIX/IL-8 (Scapini et al., 2000)
these observations may also be the result of activation.
In humans, increased neutrophils are seen in the airways of severe asthmatics
in both induced sputum and BAL at baseline (Nakagome et al., 2012; Wenzel
et al., 1997). Neutrophils are also seen to be increased in asthma exacerbations,
especially those induced by viral infections (Wark et al., 2001), and large numbers
are seen in the lungs of asthmatics following fatal exacerbations (Carroll et al.,
2002; Sur et al., 1993). The presence of neutrophils is associated with insensitivity
to steroids (Choi et al., 2012). In association, MPO has been shown to be
increased in the airways of asthmatics, especially during exacerbation (Norzila
et al., 2000), and correlates with reduction in PEF and increases in symptom
scores (Louis et al., 2000). Recognition of the heterogeneity of asthma and
the defining of asthma subtypes with respect to the granulocytic inflammation
present has led to clinical trials of subtype-specific therapies, including a trial of a
CXCR2 antagonist in severe asthmatics (Nair et al., 2012). However, the precise
contributions of neutrophils to the asthmatic phenotype are yet to be established.
7.2.3 Other effects of IL-17
Although exacerbation of neutrophil responses is one of the main consequences of
IL-17 secretion, and is also one of our most striking observations, it is not the only
response to IL-17. As discussed, IL-17 stabilises a range of mRNAs. We have
only assayed a small number of cytokines, including those involved in neutrophil
recruitment (KC, LIX) which we saw increased with rIL-17 supplementation of
rhinovirus infection, as previously reported in cell culture experiments (Wiehler
and Proud, 2007).
We also measured other chemokines, and notably MIP-3α was significantly
increased at earlier time points, as has previously been shown with IL-17 (Kao
et al., 2005). MIP-3α is chemotactic for CCR6+ cells, which includes dendritic
cells and cells associated with IL-17 secretion such as Th17 and IL-17+γδ T cells.
We assessed the recruitment of dendritic cells to the lung following rhinovirus
infection, and saw no effect of the addition of rIL-17. We did however see a
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trend for decreased trafficking of antigen loaded (fluorescent ovalbumin) dendritic
cells to the lymph node, possibly retained in the lung by additional MIP-3α
(though mature DC may lose CCR6 expression; Ito et al. 2011). No significant
numbers of Th17 or IL-17+γδ T cells were seen in rhinovirus-infected mice, so we
cannot investigate their recruitment in this model, however it suggests a possible
positive feedback in inflamed tissues, where continued secretion of IL-17 recruits
further numbers of IL-17+ cells into the tissue. Additionally, the IL-17 family
cytokine IL-17C has recently been described as being produced by structural cells
and signalling through the IL-17RA and IL-17RE receptor proteins (Ramirez-
Carrozzi et al., 2011), inducing similar responses to IL-17. Increasing MIP-3α
and recruiting professional IL-17 secreting cells to the tissue may be a mechanism
by which IL-17C could drive Th17 inflammation, in a similar manner to the way
that IL-25 and IL-33 secretion can drive Th2 responses.
IL-17 has also been shown to activate the endothelium, causing expression of
receptors specific for neutrophil tethering and migration into the tissue (Griffin
et al., 2012). Although this study showed that this effect was specific for neu-
trophils as IL-17 did not increase lymphocyte transmigration (but IFN-γ did),
specific lymphocyte subtypes were not investigated so this does not exclude other
cell types (including Th17) also increasing their transmigration.
We have only investigated a few chemokines and it is likely that others are
increased by the presence of IL-17, thus a wider analysis of cytokines would
provide more understanding of IL-17–induced mRNA stabilisation. We also do
not know what mechanism activates neutrophils in IL-17–mediated disease, but it
appears from our experiments that IL-17 is unable to do so directly. However it
may be under the control of ovalbumin-specific Th17 in our model of Th17-driven
AAD.
IL-17 is known as being pro-inflammatory; however it has also been shown to
accelerate resolution of inflammation in the lung (Murdoch and Lloyd, 2010). As
it does not induce responses alone in the lung, but only stabilises mRNAs that
are induced by other responses, it may be that the main role of IL-17 is as a
‘multiplier’ of existing responses, whether they are pro- or anti-inflammatory. Thus
the increase of IL-17 seen in the lung of all asthmatics may increase responses to
both allergen and viruses leading to exacerbation, even though these two separate
responses may be different.
Increased mucin production is seen following rhinovirus infection (Bartlett et al.,
2008; Hewson et al., 2010) as well as in the airways of asthmatics, and mucus
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plugs are seen after fatal asthma exacerbations (Carroll et al., 2002). There are
suggestions in the literature that IL-17 may be able to drive mucus production
(Chen et al., 2003) and overexpression of IL-17A or F in the lung leads to mucus
hypersecretion (Kawaguchi et al., 2009; Yang et al., 2008). However, we did not
see increases in mucins with either supplemental rIL-17 or during Th17-driven
AAD (figures 5.3 and 6.14).
7.3 Summary of conclusions
• Unlike in human subjects, rhinovirus infection in mice does not induce IL-17
secretion, nor does it generate Th17 or IL-17+γδ T cells in the lung.
• In a classical systemic sensitisation model of AAD, rhinovirus selectively
exacerbates Th2 responses but not Th17 or IL-17 responses.
• Exogenous IL-17 delivered to the airways selectively increases neutrophil
responses to rhinovirus, both in terms of speed and magnitude, which is
preceded by increases in the neutrophil chemokines KC and LIX.
• Exogenous IL-17 delivered to the airways increased MPO release in response
to rhinovirus, correlating with neutrophil numbers, but was not anti-viral.
• In a Th17-dominant nasal sensitisation model of AAD, rhinovirus was able
to exacerbate the neutrophil response to allergen and significantly increased
airways hyperresponsiveness (AHR).
• These observations add to published data showing IL-17 in the lungs of
asthmatics, and suggest that IL-17 antagonists may be a therapeutic target
for reducing asthma exacerbations in response to rhinovirus infection.
7.4 Future work
7.4.1 Modelling IL-17 responses to rhinovirus infection
Although we were unable to detect the IL-17 responses to rhinovirus in a mouse
model as observed in human subjects, this does give an opportunity to investigate
the signals required for IL-17 responses to viruses in the lung. IL-23 assays were
not a primary endpoint in this project, but further work would allow us to confirm
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or discount IL-23 as the main cause of the differences seen in IL-17 induction
between human and mouse following rhinovirus infection. Firstly, although we
have seen IL-17 protein after rhinovirus infection of human subjects, we do not
know the cellular source. Flow cytometry in future clinical studies or dual staining
of stored bronchial biopsies for IL-17 and T cell markers such as CD4 or γδ TCR
would allow us to focus mouse studies on the most likely candidates. We also
have not measured IL-23 levels in our human samples; no antibodies for flow
currently exist; however again biopsy staining or detection of protein or mRNA in
existing samples would support the study of IL-23 supplementation of a rhinovirus
infection in a primary mouse infection. These investigations would add to the
work into an IL-23 vaccine that has been used to reduce responses in mouse model
of AAD as a potential therapeutic for asthmatic patients (Guan et al., 2012).
For IL-23 to have an effect on development of IL-17 responses in the mouse
following rhinovirus infection, the polarising cytokines would have to initiate the
early stages of Th17 polarisation, leading to IL-23R expression, or the RORγt+γδ
T cells seen would also need to be expressing IL-23R. Flow cytometry could be
used to assess the expression of IL-23R on ‘proto’-Th17 cells following rhinovirus
infection and the general responsiveness of the system to IL-23. These are likely
to be transient, so detailed, early time courses would be necessary. Additionally,
IL-23R expression is under the control of STAT3; several studies suggest STAT3
signalling is upstream of RORγt (Hirahara et al., 2010) and thus analysis of its
expression by Western or flow (for phosphorylated STAT3) would add to these
investigations.
To assess how MIP-3α may recruit Th17 to the lung, adoptive transfer of
polarised, labelled Th17 (generated either by in vitro culture or sorting of
CD4+CCR6+ cells from mice after LPS and ovalbumin sensitisation) to mice
prior to primary rhinovirus infection would show whether rhinovirus was capable
of recruiting existing populations of Th17 by assessing the numbers of labelled
cells trafficking to the lung following a rhinovirus infection. In support of this,
we see development of Th17 in the lungs of Tbet knockout mice (unpublished
observations) which may be due to an increase in numbers of Th17 in mice lacking
the repression on Th17 generation by Th1 cells, either during development or
following rhinovirus infection. In the literature, it has been shown that Tbet
knockout mice have increased Th17 responses in several models (Lazarevic et al.,
2011; Villarino et al., 2010). Additionally, in a model of RSV infection following
sepsis, increased Th17 in the spleen led to greater IL-17 responses to subsequent
RSV infection (Mukherjee et al., 2012).
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It may be possible, by modification of existing models, to develop a mouse
model of rhinovirus-induced IL-17. To show a deficiency of IL-23 as a key factor
in the mouse, a rhinovirus infection could be supplemented with recombinant
IL-23 with subsequent Th17 polarisation and induction of IL-17 secretion from
Th17 and IL-17+γδ T cells being assessed. Additionally, the presence of Th17
in Tbet knockout mice suggests a potential suppression mechanism by Th1 cells
in mice. Further investigation of this response may inform us why Th17 are not
generated in wild-type mice.
As discussed above, the lack of IL-17 responses may be a consequence of the
lower level of virus replication observed in mice, or a lack of macrophage infection,
failing to generate IL-23 responses. Host adaptation of the virus may address
this potential problem. Several studies have shown alternate passage in human
and mouse cell lines generates point mutations in rhinovirus leading to more
efficient replication in mouse cell lines alone (Harris and Racaniello, 2003, 2005;
Rasmussen and Racaniello, 2011). It may be possible by this technique to generate
a mouse trophic rhinovirus which would efficiently replicate in mice and induce
more robust responses, such as IL-23, and more accurately model the human
situation. In addition it may be possible to greatly reduce the dose required to
infect mice and achieve responses (to a similar level as for humans), allowing
sequential experiments to use the same virus batch (reducing variability), as well
as lower doses containing lower concentrations of cell culture contaminants (such
as BSA), along with the associated savings in labour and costs of virus production.
Alternatively the use of a related picornavirus, Mengovirus, has also been shown
to generate responses in mice similar to those after rhinovirus infection in humans,
including induction of Il17a mRNA (Rosenthal et al., 2012).
7.4.2 Further investigating the effects of IL-17
Although IL-17 responses are not significantly exacerbated in our working model
of Th2-driven AAD, IL-17 protein and IL-17+ cells are induced by ovalbumin
challenge. Neutrophil responses to rhinovirus are also exacerbated in this model,
and as work with rIL-17 has indicated, this can be IL-17–driven. Blocking IL-17
with an anti–IL-17 antibody at the time of rhinovirus infection would be predicted
to reduce this neutrophilia and may have additional effects on AHR. Defining
the cellular source of this IL-17 could also point to sources within our human
asthmatics. Flow cytometry shows early induction of IL-17+γδ T cells, making
them a good candidate. Previous work in this model has investigated γδ T cell
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activation and subsets (Glanville, 2010; Glanville et al., 2013), showing increased
CD69 expression after challenge, and that the Vγ4 subset is recruited into the
airways but in proportion to other γδ T cell subsets. The literature suggests
that there is a large overlap between Vγ4+ and RORγt+γδ T cells (Murdoch and
Lloyd, 2010; Zhao et al., 2011), and further staining for these markers as well as
IL-23R, CD69 and IL-17 may better define cells responding with IL-17 in this
model.
Although we have developed a model of rhinovirus exacerbation of Th17-driven
AAD, we have only been able to examine a single time point at 24 hours within the
timeframe of this project. Initially, investigation of earlier time points is needed
to answer the questions posed regarding differential neutrophil activation with
ovalbumin and rhinovirus as well as more fully characterising other responses. The
presence of ovalbumin-specific antibodies has yet to be explored, but their presence
and class may help understand mechanisms of neutrophil degranulation and other
mechanisms of AHR such as mast cell degranulation. Additionally, assessing the
the activation of T cells (e.g. by staining for CD69) within the lung tissue and
airways in response to either ovalbumin or rhinovirus may give more clues to
neutrophil activation and AHR responses. In support of studies into neutrophil
degranulation, resulting lung pathology could be assessed by measurement of total
protein and haemoglobin in the airways showing disruption of airway integrity.
Histological analysis of lungs after administration of fluorescent ovalbumin in this
Th17-driven AAD model would also show if there was increased penetration of
allergen into the lung tissue.
To confirm that the secretion of IL-17 from Th17 cells is the driving factor
behind increased neutrophilia following rhinovirus infection, rhinovirus exacerba-
tion could also be investigated in a model of ovalbumin-specific Th17 transfer, as
described in McKinley et al. (2008) and similar to a Th2 adoptive transfer model
within our department. Th17 were generated by in vitro culture of spleen cells
from DO11.10 mice, transferred into recipient mice who were then challenged
intratracheally with ovalbumin. This resulted in recruitment of Th17 cells and
IL-17 secretion in the lung, neutrophil chemokine and cell responses and increases
in AHR. Rhinovirus infection in this model and assessment of any increase in
neutrophil recruitment and AHR would allow us to confirm the interactions
between Th17 and rhinovirus in vivo. Conversely, depletion of IL-17 following
ovalbumin challenge or use of Il17 knockout mice in our Th17-driven AAD model
would also show whether increased neutrophilia is dependent on IL-17.
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Further work on signalling interactions between IL-17 and rhinovirus could be
undertaken using our rIL-17 supplementation model. Intriguingly, it has been
suggested that the IL-17 receptor adaptor protein Act1 is also involved in the
interferon response to RNA viruses (Ryzhakov et al., 2012). Investigation of this
protein in response to rhinovirus and rIL-17 could yield further insight into this
pathway. IL-17 is thought to act by mRNA stabilisation, however the signalling
pathways in response to IL-17 and rhinovirus may overlap at other points.
7.4.3 Other work
In this project we have mainly investigated IL-17A, however the IL-17 family
consists of the related proteins IL-17A to IL-17F. We have shown IL-17F secretion
in our Th2-driven AAD model (figure 4.4b), and other work within our lab has
investigated IL-17E (Beale, 2013), also known as IL-25 and involved in Th2
responses. The other family members are less well known, however IL-17C has
recently been shown to be produced by the epithelium, in a similar manner
to IL-25, and has similar effects to the proteins IL-17A and IL-17F in that it
recruits neutrophils, though it signals through a different receptor consisting of
IL-17RE paired with the common IL-17RA chain. As we see induction of IL-25
following rhinovirus infection, it is possible that IL-17C may also be induced in
the epithelium. qPCR with Il17c-specific primers and probe as well as IL-17C
ELISA would show whether rhinovirus infection induces this protein.
The presence of MDSC following rhinovirus infection, detected by flow cytome-
try, suggests the inflammatory population is more diverse than can be assessed
by cytospin. We currently type airway cells using a light microscope based on
differential staining, and characterise them as either neutrophils, eosinophils,
lymphocytes or macrophages. We already investigate lymphocyte subsets by flow
cytometry, but as some MDSC populations resemble neutrophils, as well as there
being suggestions of neutrophil subsets, flow cytometry analysis of these may
help further work on granulocytes. Neutrophils can be identified by expression
of Ly6C (using either a specific antibody or anti-Gr-1) and CD11b, eosinophils
are siglec-F+CD11c-, and MDSC cells express F4/80 as well as being Gr-1int and
CD11b+. With other markers such as MHC-II and CD103, subsets of dendritic
cells and macrophages can also be investigated with one staining panel. This
would greatly expand our knowledge of the inflammatory cell response.
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